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Resumé (dansk) 
Immunforsvaret arbejder konstant på at beskytte kroppen imod invaderende stoffer og 
sygdomsfremkaldende organismer som bakterier og virus (antigener). Antistoffer er vigtige 
molekyler, som immunforsvaret bruger til at genkende disse fremmedstoffer. Gennem den 
specifikke binding til antigener genkendes disse af effektorceller, som derefter kan eliminere det 
indtrængende antigen. Antistofmolekylets ene ende består af en konstant del, som ikke varierer 
meget imellem forskellige antistoffer, og som bruges til at kommunikere med kroppens 
immunceller. Den anden ende af antistoffet er meget forskellig imellem antistoffer, og det er denne 
del, som binder til de fremmede stoffer. Herved rammer dette sofistikerede system nærmest alt 
fremmed, der kommer ind i kroppen, ved at danne et repertoire af forskellige antistoffer. Når 
kroppen møder det samme antigen flere gange, modnes responset og antistoffernes bindingsstyrke 
til antigenet øges, hvilket resulterer i et mere effektivt respons..  
Symplex-teknologien er den eneste metode, der kan isolere humane antistofrepertoirer. I løbet af 
mit ph.d.-arbejde har vi brugt denne teknologi til at isolere tre repertoirer imod stivkrampe fra hver 
af to frivillige donorer med mellem 1,5 til 4,5 års mellemrum. Desuden har vi isoleret et 
antistofrepertoire fra en donor, som for første gang modtog en stivkrampevaccination for at kunne 
sammenligne tidlige og sene repertoirer. Disse syv repertoirer er de mest omfattende specifikke 
antistofrepertoirer, der er rapporteret til dato, og det er det eneste studie, der følger udviklingen i 
antistofrepertoirer efter flere vaccinationer af de samme mennesker. Baseret på dette store antal 
antistoffer har vi rapporteret det første estimat af størrelsen på specifikke antistofrepertoirer. Vi har 
også – som de første – rapporteret, at antistofrepertoirer når et loft i bindingsstyrke efter flere 
vaccinationer. Desuden har vi fundet, at det antistofrespons, vi danner første gang, vi møder et 
bestemt antigen, ligner senere responser mere end hidtil antaget. Dog opnås det omtalte loft i 
bindingsstyrke først efter flere vaccinationer. 
Forståelsen, der er opnået gennem dette projekt, vil være brugbar ved design af fremtidige vacciner 
og ved antistofbaserede lægemidler, der efterligner et naturligt immunrespons og som derfor er 
effektive med få bivirkninger. Resultaterne er desuden af fundamental immunologisk interesse, da 
konklusionerne fra dette projekt formentlig vil kunne overføres til en generel forståelse af 
sammensætningen og udviklingen af specifikke antistofrepertoirer. 
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Abstract 
The human immune system is constantly working to protect the body against potentially harmful 
invading substances and organisms such as virus or bacteria (antigens). Antibodies are important 
molecules which are used by the immune system to recognize these invaders. Through the specific 
binding of antibodies to antigens, these are recognized as foreign and can then be eliminated by 
effector cells of the immune system. The antibody molecule consists of two parts. One is similar for 
most antibodies and is used to signal to the cells of the immune system to take action. The other 
part differs much between different antibodies. This is the part that binds to foreign antigens. In this 
fashion, the immune system targets almost anything foreign in the body by the generation of a 
diverse antibody repertoire. When the antigen is recognized repeatedly, the antibody repertoire 
matures and the binding strengths of the antibodies to antigens are increased facilitating a more 
efficient elimination.   
The Symplex™ technology is the only means of isolating specific human antibody repertoires. 
During my PhD work, we have utilized this technology to isolate three consecutive antibody 
repertoires against tetanus from two donors with 1.5 to 4.5 year intervals. Additionally, we have 
isolated an antibody repertoire from a donor after receiving the very first tetanus vaccination in 
order to compare early and late repertoires. These seven repertoires are the most comprehensive 
specific antibody repertoires reported to date. Further, it is the only study that follows the 
development of antibody repertoires after several vaccinations of the same donors. Based on this 
large panel of antibodies, we have reported the first estimate on the size of specific antibody 
repertoires in humans. We have also – as the first – reported that antibody repertoires reach a 
ceiling in binding strength after several vaccinations. Additionally, we have found that the antibody 
response after the first encounter with antigen is similar to later responses. The ceiling in binding 
strength is, however, reached only after several vaccinations. 
The understanding gained through this project will be of use in design of future vaccines and 
antibody therapeutics that mimic natural immune responses and hence are efficient with limited side 
effects. The results are of fundamental immunological interest as well since the conclusions 
regarding repertoire size and functional maturation limits of tetanus specific repertoires may well be 
applicable to antibody repertoires of other specificities than tetanus. 
 
     
6 
 
7 
Contents 
 
Resumé (dansk) ....................................................................................................................................3 
Abstract ................................................................................................................................................5 
Contents................................................................................................................................................7 
Original Papers.....................................................................................................................................9 
Abbreviations .....................................................................................................................................10 
1. Introduction ....................................................................................................................................13 
2. Antibody structure..........................................................................................................................17 
2.1 Affinity of antibodies ...............................................................................................................19 
3. The Symplex™ Technology ..........................................................................................................21 
4. Antibody generation and diversification of antibody repertories ..................................................25 
4.1 V(D)J recombination................................................................................................................25 
4.2 Further diversification of antibodies ........................................................................................26 
4.2.1 Somatic hypermutation .....................................................................................................27 
4.2.3 Class switch recombination (CSR) ...................................................................................30 
4.2.4 Receptor editing ................................................................................................................30 
5. Antibody repertoires.......................................................................................................................33 
5.1 Germline gene repertoire..........................................................................................................33 
5.2 Specific antibody repertoires....................................................................................................35 
6. Affinity maturation.........................................................................................................................41 
7. Concluding remarks .......................................................................................................................45 
7.1 Suggestions for further work....................................................................................................47 
Acknowledgements ............................................................................................................................51 
Reference List ....................................................................................................................................53 
 
8 
9 
Original Papers 
 
This thesis is based on the following papers which are referred to in the text by their numbers (1-3). 
The papers are appended at the end of the thesis. 
 
 
Paper 1: 
Poulsen, T. R., Meijer, P.-J., Jensen, A., Nielsen, L. S., Andersen, P. S. 
Kinetic, Affinity, and Diversity Limits of Human Polyclonal Antibody Responses against 
Tetanus Toxoid  
J. Immunol. 2007, 179: 3841–3850 
 
 
Paper 2: 
Poulsen, T. R., Jensen, A., Haurum, J., Andersen, P. S. 
Limits for affinity maturation and repertoire diversification in developing human antibody 
responses  
2009 (Manuscript) 
 
 
Paper 3: 
Poulsen, T. R., Andersen, P. S.  
The role of genetic diversification mechanisms in antigen-induced antibody repertoires 
2009 (Manuscript in preparation) 
10 
Abbreviations 
 
 
A adenine 
aa amino acid 
Ab antibody 
Ag antigen 
AID activation-induced cytidine deaminase 
BCR B cell receptor 
C constant domain 
C cytosine 
CH constant, heavy chain 
Cκ constant, kappa chain 
CDR complementarity determining region 
CMV cytomegalovirus 
CSR class switch recombination 
D diversity 
dsDNA double-stranded DNA 
Fab fragment, antigen binding 
FACS fluorescence activated cell sorting 
FW framework  
G guanine 
GC germinal center 
H heavy 
HC heavy chain 
HCMV human cytomegalovirus 
HIV human immunodeficiency virus  
Ig immunoglobulin 
IGHV immunoglobulin heavy chain variable 
IGKV immunoglobulin kappa chain variable 
IMGT the international immunogenetics information system 
J joining 
κ kappa 
KD affinity – dissociation constant (M) 
koff off-rate (s-1) 
kon on-rate (M-1*s-1) 
L light 
LC light chain 
mAb monoclonal antibody 
pAb polyclonal antibody 
RA rheumatoid arthritis 
RAG1 recombination activating gene/protein 1 
RAG2 recombination activating gene/protein 2 
rpAb recombinant polyclonal antibody 
RSS recombination signal sequence 
RT-PCR  reverse transcription polymerase chain reaction 
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1. Introduction 
The immune system is a versatile defense system that has evolved to protect us from invading 
pathogenic bacteria and virus, and from toxins and cancer. It is able to generate an enormous 
variety of cells and molecules capable of specifically recognizing and eliminating an apparently 
limitless variety of foreign invaders. The system has a remarkable specificity and is able to 
distinguish different pathogens. Once the foreign molecule has been recognized, a variety of cells 
and molecules are recruited to mount an effector response. In humans and other higher vertebrates, 
adaptive immunity ensures that later exposures to the same pathogen triggers a memory response 
characterized by a more rapid and heightened immune reaction than the first encounter. An 
important feature of immunity is the discrimination between the body’s own cells and molecules 
and foreign molecules (self and non-self). Antibodies are some of the mediators of the specificity of 
the immune system since they are generated to bind specifically to a certain target. All the 
antibodies targeting one antigen make up a repertoire which can be altered and improved with 
multiple challenges by the process of affinity maturation in conjunction with selection mechanisms. 
With their dual function, antibodies act as powerful adapter molecules by binding specifically to 
foreign molecules with one end and then triggering immunological effector systems by the 
subsequent binding to receptors on cells or to other effector molecules. By the specific binding to 
e.g. viruses, toxins or bacteria the antibodies thus facilitate elimination of the foreign molecule from 
the host. However, recognition of a massive amount of different cells and molecules (antigens) 
requires a tight regulation of antibody recognition since the generation of widely recognizing 
antibodies also produces antibodies that bind to self. If not removed, these self-binding antibodies 
can result in numerous autoimmune diseases (e.g. systemic lupus erythematosus and rheumatoid 
arthritis) (Meffre et al. 2008). However, the amazing ability to generate both specificity and 
diversity is one of the hallmarks of adaptive immunity.  
Owing to their great specificity, antibodies have been utilized in a wide variety of diagnostic 
applications for a long time, e.g. in pregnancy tests, blood type tests, as medical diagnostic tools 
etc. Also in the clinic, antibodies are widely used. They have been used for many years as 
therapeutics as plasma from individuals who have been challenged with different antigens naturally 
or by immunization. Since these preparations contain plasma from over 1000 individuals, they 
contain large amounts of polyclonal antibodies against many different antigens. Previously, these 
so-called gammaglobulin injections were usually given in an attempt to temporarily boost a 
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patient's immunity against certain diseases. In Europe it was common practice to recommend 
healthy people traveling to high risk countries in e.g. Africa and Asia these injections to protect 
against e.g. hepatitis A by passive immunization. However, this practice has largely been replaced 
by specific vaccines against the diseases in question, e.g. Havrix against hepatitis A. Nevertheless, 
immunoglobulins (Ig) from human donors are still used in the clinic as both gammaglobulin (bolus 
injections) and intravenous immunoglobulin (IVIg) to treat a number of acute and chronic 
infectious diseases, inflammatory and autoimmune disorders and to prepare patients for 
transplantations. Further, larger animals such as horses, goats and rabbits are used for raising 
antibodies against several toxins for passive immunization with so-called antiserum or antivenin.  
In 1975, Cesar Milstein and Georges Köhler developed the hybridoma technology for recombinant 
production of monoclonal antibodies for specific targets (Köhler and Milstein 1975). This allowed 
for production of large quantities of antibodies targeting specific diseases. In the beginning, these 
antibodies were of murine origin; however when used in the clinic, there were problems because 
murine antibodies are recognized as foreign when administered in the human body resulting in less 
efficacy and unwanted immune or allergic reactions. Later, the recombinant antibodies were 
engineered to resemble human antibodies more. The so-called chimeric antibodies – antibody 
hybrids with human constant regions and mouse variable regions – were engineered in an attempt to 
overcome this problem. The chimeric antibodies were further improved by grafting only the 
antigen-contacting regions of the murine antibody into a human antibody which became known as 
humanized antibodies. Recent advancement in antibody technologies has enabled the isolation and 
recombinant production of truly human antibodies. The Symplex technology developed at 
Symphogen A/S is one technique that allows for the isolation of large repertoires of fully human 
antibodies from human donors. These antibodies can be combined into polyclonal compositions 
targeting several molecules simultaneously. This creates a higher antibody density on target 
molecules which enhances biological effector functions. In addition, polyclonal preparations are 
less sensitive to mutation of the antigen and can target several bacterial or virus strains in one 
preparation. In this way, recombinant polyclonal antibodies (rpAb) resemble plasma derived 
immunoglobulins. The big difference is that rpAb do not contain a large fraction of irrelevant 
antibodies, they can be produced in essentially unlimited quantities and importantly, the risk of 
transferring infections between individuals is eliminated.     
The Symplex technology facilitates the isolation of extensive antibody repertoires against specific 
antigens while conserving the natural pairing of heavy and light chains in each antibody clone. This 
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unique feature ensures that the native affinity and specificity of each antibody is conserved. Further, 
the technology has a very high throughput compared to other antibody isolation techniques. The 
molecular and cellular basis for development of diverse and effective antibody repertoires remains 
only partly elucidated due to different limitations of previous antibody isolation techniques. The 
unique features of Symplex make the technology an excellent tool for studying diversity and 
development of specific human antibody repertoires. In the current study, we have utilized the 
ability of the Symplex technology to isolate large repertoires of antibodies against tetanus toxoid 
from human donors. This has allowed us to explore the field of specific human antibody repertoires 
from healthy donors in a fashion that has not been possible until recently. 
During this project, we have studied comprehensive tetanus specific antibody repertories from two 
hyperimmune adults after each of three tetanus vaccinations. The isolation of these repertoires has 
allowed us to investigate the genetic and functional diversity of mature specific antibody repertoires 
(paper 1-3) and follow the development after several antigen encounters (paper 2 + 3). Further, we 
have isolated a primary repertoire from a naïve donor after receiving the very first vaccination 
(paper 3). This has allowed for a genetic study of antibodies generated in the early response. These 
seven specific antibody repertoires collected before and during my PhD work, comprise a total of 
605 unique antibodies. This is by far the most comprehensive panel reported to this date of specific 
and naturally selected antibodies isolated directly from single human donors. Further, it is the only 
study that follows the development of specific antibody repertoires in the same donors. We have 
selected a subset of the antibodies for functional characterization by surface plasmon resonance 
(SPR). In total, affinities have been determined for 157 tetanus specific antibodies. This has 
allowed for the establishment of an experimentally determined affinity ceiling for antibodies 
selected naturally (paper 2). It has also allowed for a study on the influence of antibody 
diversification on antigen binding (paper 1+ 3). Tetanus toxoid was chosen as antigen for these 
studies because it is one of the most potent vaccines in clinical use and it is safe. Further, it is a 
structurally complex antigen ensuring that the studied antibody repertoires are not restricted by the 
antigen itself rather than in vivo selection mechanisms. We anticipate that the results concentrating 
on antibody repertoires against tetanus toxoid can be transferred to a more general understanding of 
antibody affinity ceilings and antibody repertoire development.  
In the following, antibody structure and generation will be described. Further, antibody 
diversification mechanisms will be described as well as the generation and selection of specific 
antibody repertoires and affinity maturation. These subjects will be related to our own findings 
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during my PhD project. These include antibody affinity limits, genetic development of antibody 
repertoires and diversification of antibodies by e.g. somatic hypermutations and deletions of 
codons. Finally, further work that builds on the project results will be suggested.   
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2. Antibody structure1 
Antibodies are glycoproteins consisting of four immunoglobulin polypeptide chains with a basic 
composition of two identical light chains of molecular weights of about 25 kDa each and two 
identical heavy chains, weighing about 50 kDa each. Each light chain is linked to one heavy chain 
by a disulfide bond and the two heavy chains are further connected to each other by disulfide bonds. 
The overall structure of an antibody resembles the letter Y or T (see figure 1).  
  
Figure 1. General structure of an antibody molecule.  
The identical heavy chains are shown in red and blue while identical light chains are shown in green and 
yellow (modified from http://en.wikipedia.org/wiki/Antibody). 
 
The light chains each consists of two globular domains – immunoglobulin folds constituted by two 
β sheets stabilized by hydrophobic interactions and disulfide bonds. Each heavy chain contains 4-5 
of these globular domains (depending on heavy chain isotype). Each chain has an amino-terminal 
variable (V) region, which differs significantly for different antibodies whereas the rest of the 
                                                
1 This section is written based on sections from “Immunology” by Richard A. Goldsby et al. 5th edition and 
”Immunobiology” by Charles A. Janeway et al. 5th edition 
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molecule consists of so-called constant (C) regions. It is the genetic variability of the V gene that 
determines the antigen recognition diversity (Honjo and Habu 1985). The V domain contacts the 
antigen while the C regions mediate physiological/effector functions like e.g. interaction with 
effector cells or complement. The greatest sequence variation of the V domains is concentrated in a 
few discrete regions which are the parts of the sequence that correspond to the loops that join the β 
strands. These regions are called complementarity determining regions (CDRs) because they form 
the antigen binding site – or paratope – of the antibody. The paratope contacts the antibody-binding 
site – or epitope – on the antigen. Depending on the structure and size of the antigen, it is contacted 
by one or several CDRs. There are three CDRs in the V domain of each heavy and each light chain 
(termed CDR1, CDR2, and CDR3) and the CDR3 regions exhibit more variation than CDR1 and 
CDR2 (Padlan 1994, Davies and Cohen 1996). The CDR3 of the heavy chain is generally regarded 
as the major contributor to the antigen-specificity. The parts of the variable domains that display 
less variation are called framework regions (FWs) and serve as scaffolds for the CDR loops.  
There are five antibody isotypes which are determined by the heavy chain class: immunoglobulin A 
(IgA, α), IgD (δ), IgE (ε), IgG (γ), and IgM (µ). Furthermore, there are two subtypes of the IgA 
class (IgA1 and IgA2) and four subtypes of the IgG class (IgG1-4) in humans. The different 
isotypes are structurally distinct and exert different biological functions. For example, IgG – the 
most abundant class in serum – is secreted as a monomer while IgM is secreted as a pentamer and 
hence exert a high avidity for antigen. Of differences in biological functions can be mentioned that 
for instance IgG2a is a potent activator of the complement system (Benhnia 2009).  
In contrast to the many heavy chain isotypes, there are only two light chain types; lambda, λ, and 
kappa, κ, with a frequency of 40% and 60%, respectively, in humans (de Wildt 1999a). One B cell 
clone can express one heavy chain subclass at one time point but the subclass can be changed over 
time (class switching). Similarly, each B cell clone can only express one type of light chain (either 
κ or λ) at one time point. The class of light chain can however be changed by the process of 
receptor editing (only from κ to λ). 
When monomeric antibodies are digested with papain (an experiment first conducted by Rodney 
Porter), the heavy chains are cleaved in the hinge region producing a fragment with receptor-
binding activity – the Fc fragment – and two identical Fab fragments with preserved antigen-
binding activity (see figure 1) (Porter 1991s). In many assays, only this antigen-binding part 
consisting of the variable domain and the first constant globular domain of each heavy (CH1) and 
light chain (Cк) of the antibody is used in order to have a monovalent binder. For example, when 
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measuring binding affinity of the antibody-antigen complex by surface plasmon resonance (SPR), it 
is very convenient to use Fab fragments in solution since multivalent molecules “wander” on the 
antigen surface resulting in a higher measured affinity. 
Antibodies can either be expressed as membrane-bound antibody which is transported to the B cell 
membrane and functions as a B cell receptor (BCR) or they can be secreted in a soluble form. While 
the latter has a hydrophilic amino acid (aa) sequence at the C-terminal end, the BCR is expressed 
with a hydrophiobic transmembrane sequence and a short cytoplasmic tail. Whilst the secreted 
antibodies can exert different effector functions by binding of their Fc ends, the BCR plays a role in 
signaling to the B cell, e.g. when detecting antigen. 
 
2.1 Affinity of antibodies 
The affinity of an antibody is a measurement of how well the epitope fits in the antigen binding site 
of the antibody; in other words, the affinity is the binding strength of the antibody-antigen 
interaction. The affinity is measured as the steady state of the association and dissociation of 
antibody and the antigen it binds to:   
Ag + Ab ↔  Ag-Ab 
The affinity is defined by the rate at which the Fab fragment and antigen dissociate divided by the 
rate at which they associate:  
 
 
Affinities can be measured by either measuring the concentrations of bound and unbound Fab 
fragment and antigen (Ag) at different time points, or the association and dissociation rates can be 
measured in real time. 
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3. The Symplex™ Technology 
During the last couple of decades, many technologies have been developed for the cloning of 
antibodies from humans or mice to be able to study the immune system or to isolate monoclonal 
antibodies. For many years, larger panels of antibodies were isolated successfully by different 
combinatorial library technologies such as phage and yeast display (Smith 1985, McCafferty et al. 
1990, Clackson et al. 1991, Boder and Wittrup 1997), and recently mammalian display (Beerli et al. 
2008). These technologies have allowed for isolation of antibodies against virtually any antigen 
(Marks et al. 1991). Moreover, smaller panels of antibodies with cognate pairing of heavy and light 
chain have been isolated by the elaborate hybridoma technology (Kohler and Milstein 1975). 
However, these techniques have low efficiency or scramble heavy and light chains of single 
antibodies and are thus not suited for the isolation of larger repertoires of antibodies of defined 
specificities selected in vivo (Stahli et al. 1980, Babcook et al. 1996). In recent years, a number of 
technologies have been developed that are efficient with cognate pairing of the heavy and light 
chains of each antibody (Tiller et al. 2008, Wardemann et al. 2003, Traggiai et al. 2004, 
Lanzavecchia et al. 2007, Jiang et al. 2006, Wrammert et al. 2008, Love et al. 2006).  
The Symplex technology is a proprietary technology developed at Symphogen A/S which facilitates 
rapid isolation and cloning of extensive antibody repertoires from human blood samples. This 
allows for capture of original antibody repertoires against specific antigens such as viruses, toxins, 
or bacteria. The technology conserves the natural pairing of heavy and light chains in each antibody 
clone. This unique feature ensures that the native affinity and specificity of each antibody is 
conserved. Further, the technology has a very high throughput compared to most antibody isolation 
techniques. These features make the Symplex technology ideal for studying human antibody 
repertoires in detail and for isolation of therapeutic antibodies. The technology is currently being 
used in the development of fully human recombinant polyclonal treatments and has been used for 
the isolation of antibody repertoires against complex antigens including influenza virus, tetanus, 
respiratory syncytial virus (RSV), cancer, Vaccinia virus (smallpox), hepatitis B virus and some 
non-disclosed bacterial targets.  
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Figure 2. Symplex technology overview. Printed with permission from Symphogen A/S. 
 
Figure 2 shows an overview of the steps in the Symplex technology. In short, the technology is 
carried out by recovering the lymphocyte fraction from blood from a donor who has been 
challenged with an antigen either naturally or by immunization within the last 5-9 days (preferably 
on day 6) (Meijer et al. 2006). This allows for the capture of recently activated plasma blasts 
migrating to secondary lymphoid tissues (Odendahl et al. 2005). The plasma blasts are then isolated 
from the B cell fraction by fluorescence activated cell sorting (FACS). The plasma blasts are single 
cell sorted into 384 well plates containing buffer and primers and a reverse transcription polymerase 
chain reaction (RT-PCR) is performed directly in the plates. The RT-PCR is designed to link CH1-
VH genes to κ light chain encoding genes (Cκ); see figure 3: Symplex PCR. Hereafter, the pool of 
CH-VH-Cκ gene products is inserted into an expression vector. The linker sequence is replaced by a 
bidirectional promoter to allow Fab or antibody expression (depending on the expression vector) 
followed by the insertion of the vector into E. coli or mammal cells such as CHO or HEK. Finally, 
the clones are screened for specificity against the antigen in question. 
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Figure 3. Symplex PCR overview. 
The Symplex polymerase chain reaction takes place in two steps: First, a reverse transcription polymerase 
chain reaction (RT-PCR) is performed which links CH1-VH genes to κ light chain encoding genes (Cκ). 
Second,a nested PCR is performed to amplify the heavy chain variable regions linked to kappa light chain 
genes. The two consecutive PCR reactions result in DNA pieces of ~1070 bp which can be checked by 
agarose gel electrophoresis. Printed with permission from Symphogen A/S. 
 
The Symplex technology offers a unique opportunity to study the development of human antibody 
repertoires which has not been possible until recently. During this project we have used the 
technology for the isolation and characterization of human antibody repertoires against tetanus 
toxoid from two hyperimmune donors and a tetanus-naïve donor (paper 1, 2 and 3). Each of the two 
hyperimmune donors were boosted with the tetanus vaccine 3 times separated by 3,5 years for the 
first and second boost and by 1.5 years for the second and third boost. Antibody repertoires were 
isolated after each boost and screened for tetanus binding. A number of positive hits were 
sequenced (see paper 1, 2 and 3 for details) resulting in 6 tetanus specific repertoires each 
consisting of 82-176 antibodies from each of the two hyperimmune donors. A repertoire of 11 
antibodies was isolated from the previously naïve donor.       
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4. Antibody generation and diversification of antibody repertories 
Antibody genes are generated during the development of B lymphocytes. The massive diversity of 
the antibody repertoire is generated by two mechanisms. The first mechanism being recombination 
of immunoglobulin gene variable (V), diversity (D), and joining (J) gene segments (V(D)J 
recombination) during the early stages of B cell development in the bone marrow. Heavy chains are 
generated by combination of a V, D and J segment, whereas light chains only have recombined V 
and J segments (Joho et al. 1980, Cook and Tomlinson 1995, Matsuda and Honjo 1996). The 
second mechanism that occurs within secondary lymphoid organs is somatic hypermutation (SHM) 
of functional immunoglobulin genes from antigen-activated B cells. The diversity generated by 
these two mechanisms not only provides protective humoral immunity but also generates 
potentially harmful clones expressing antibodies that bind to self-molecules (autoantibodies) 
(Clarke et al. 1985, Jacob and Kelsoe 1991). Therefore developing B lymphocytes undergo both 
positive and negative selection. These processes ensure that the antibody producing B cells produce 
functional immunoglobulin and remove autoreactive B cells at central and peripheral B cell 
tolerance checkpoints (Meffre and Wardemann 2008). Apart from clonal deletion, autoreacting B 
cells can maintain tolerance to self antigens by the mechanisms of receptor editing and anergy 
(Casellas et al. 2001).  
4.1 V(D)J recombination 
The process of V(D)J recombination combines and assembles antibody genes from a pool of gene 
segments (germline genes) in developing B lymphocytes (Tonegawa 1983). These gene segments 
can not be transcribed and translated into complete protein chains until they are rearranged into 
functional genes. The site-specific rearrangement process creates an immense diversity of 
antibodies at the molecular level. Although, the Ig genes are generated by a relatively small number 
of gene segments, the pre-immune diversity based on these combinatorial reactions alone can 
generate over 107 different antibody specificities (in theory) (Papavasiliou and Schatz 2002). The 
genes encoding the sequence-specific DNA endonuclease initiating V(D)J recombination (McBlane 
et al. 1995, van et al. 1995) are recombination activating gene 1 and 2, or simply RAG1 and RAG2. 
These two genes were discovered by David Schatz, Marjorie Oettinger, and David Baltimore at 
MIT during the late 1980’s. They also discovered that these two genes reside only a few kilobases 
from each other (Schatz et al. 1989, Oettinger et al. 1990). Further experiments demonstrated that 
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RAG1 and RAG2 are almost invariably expressed together and that their coexpression results in 
potent activation of V(D)J recombination (Oettinger et al. 1990). Both genes are required for the 
introduction of double-strand breaks initiating the recombination process (Oettinger et al. 1990). 
The breaks are introduced between V, D, and J coding segments and their flanking recombination 
signal sequences (RSSs) consisting of conserved heptameric (consensus, 5’-CACAGTG) and 
nonameric (consensus, 5’-ACAAAAACC) motifs connected by 23 or 12 bp variable sequence 
(Max and Leder 1979, Sakano et al. 1979). The cleavage occurs in two steps in ordered sequence: 
nicking and hairpin formation (McBlane et al. 1995, Lewis 1994). A nick is first introduced in the 
top strand 5’ of the RSS heptamer at the junction between the heptamer and the V, D or J coding 
segment. This exposes a 3’ hydroxyl group at the end of the coding flank and a 5’ phosphate group 
attached to the heptamer end. The 3’ hydroxyl group attacks the antiparallel strand and cleaves the 
DNA which is followed by the formation of a hairpin coding end and a blunt 5’ phosphorylated 
signal end (van Gent et al. 1996). When both participating DNA substrates have been cleaved, the 
RSS ends are precisely joined and excised as a circular product. Simultaneously, the coding ends 
are modified and joined imprecisely in a process involving non-templated (N) and templated (P) 
nucleotide addition in the non-homologous end-joining DNA repair pathway (reviewed in 
references (Bassing et al. 2002, Gellert 2002, Fugmann et al. 2000)). This junctional flexibility 
leads to both productive and non-productive rearrangements by e.g. out of frame sequences 
resulting in stop codons or the introduction of amino acids that “disturb” proper folding of the 
antibody.  
 
4.2 Further diversification of antibodies 
After B lymphocytes leave the bone marrow following successful generation of functional 
antibodies, they undergo two further receptor diversification processes upon encounter with 
antigen: somatic hypermutation (Berek and Milstein 1988) and class switch recombination (CSR) 
(Sakano et al. 1980, Stavnezer 1996). The first process is initiated by the binding of antigen and 
introduces point mutations in the variable region of immunoglobulin genes while the latter changes 
the constant region to other constant regions (isotypes) producing antibodies of the same specificity 
but with other effector functions (Besmer et al. 2004). Both of these processes are executed by the 
enzyme activation-induced cytidine deaminase (AID) (Besmer et al. 2004) and are generally tightly 
controlled to occur in germinal centers (GCs) only (Odegard and Schatz 2006). 
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4.2.1 Somatic hypermutation 
Somatic hypermutation introduces additional diversity to that introduced by combinatorial 
rearrangement of V(D)J gene segments and by the association of different heavy and light chains. 
Somatic hypermutation is initiated by the binding of the B cell receptor to antigen and introduces 
point mutations into the variable region of immunoglobulin genes (Besmer et al. 2004). AID is 
required for the generation of somatic mutations together with some co-factors (Muramatsu et al. 
2000, Odegard and Schatz 2006, Wilson et al. 2005, Neuberger et al. 2003). Naturally, effects of 
this protein have been studied intensively during the last few years (Odegard and Schatz 2006, 
Besmer et al. 2004, Muramatsu et al. 2000). The expression of AID is generally confined to GC B 
cells (Odegard and Schatz 2006) and is tightly regulated. The protein deaminates single-stranded 
DNA (ssDNA), but not RNA or double-stranded DNA (dsDNA). And it has a preference for 
deaminating cytidines in SHM hotspot motifs (such as (A/G/T)G(C/T)(A/T) or 
(A/T)(A/G)C(T/C/A)) (reviewed by (Odegard and Schatz 2006)). The deamination happens during 
transcription when AID can act on small regions of ssDNA on the non-transcribed strand. AID 
initiates SHM by deamination of C nucleotides, and the resulting U-G (uridine-guanosine) 
mismatch can lead to mutation in several ways (Neuberger et al. 2003). If the mismatch is not 
repaired before DNA replication, DNA polymerases insert A nucleotides opposite U which lead to 
transition mutations. However, if uracil-DNA glycosylase (UNG) removes the U, replication can 
give rise to both transitions and transversions through an error-prone mismatch repair machinery 
(Wilson et al. 2005, Odegard and Schatz 2006). This machinery is also thought to create mutations 
at A-T sites near the initial mismatch (Neuberger et al. 2003).  
SHM are introduced at a rate of app. 10–3 mutations per base pair per cell division, which is 106-
fold higher than the spontaneous mutation rate in somatic cells (Odegard and Schatz 2006). Hence, 
SHM are tightly controlled and targeted specifically at variable regions of Ig genes. As described 
above, the mutations exhibit preferences for transitions and are not distributed randomly over the 
entire length of the variable regions of antibodies. The hotspots where mutations are often found are 
generally structurally situated at the edge of a loop in the antibody structure (Sale et al. 2001) 
probably because this is where they are best tolerated. Further, SHM decrease exponentially with 
distance from the transcription start site (Rada and Milstein 2001). By studying hapten responses, it 
has been demonstrated that the average number of somatic hypermutation per antibody increases 
with several antigenic challenges (Berek and Milstein 1987). In paper 2, we demonstrate that the 
number of SHM per antibody varies between 0 and 40 on amino acid levels for hyperimmune 
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responses against tetanus toxoid with 50% of the antibodies having between 16 and 25 SHM. We 
further demonstrate that the number of hypermutations in specific mature and saturated antibody 
repertoires is rather constant after several immunizations but can differ slightly between individuals. 
This feature might reflect that antibodies lose the typical Ig structure when too many SHM are 
introduced and hence it cannot bind the antigen or initiate proper effector functions. In paper 2, we 
also demonstrate that somatic hypermutations in mature specific antibody repertoires follow a 
normal distribution in agreement with a random system. It follows from the stochastic nature of 
single somatic hypermutations that they can be deleterious to the cell (either by the creation of a 
non-functional or self-recognizing immunoglobulin), increase or decrease binding affinity or be 
neutral depending on the type and the location of the substitution. Hence, it is conceivable that there 
is a general maximum to the number of tolerated SHM.  
In order to investigate the level of hypermutation in early responses, in paper 3, we isolated a 
primary anti-tetanus repertoire. Surprisingly, the 11 antibodies isolated from this previously naïve 
donor on day 6 after the first tetanus vaccination displayed an average of 15 SHM per heavy and 
light (H+L) chain pair. The antibodies each had between 6-22 SHM, indicating that hypermutations 
can occur relatively fast in primary repertoires and much faster than what has been observed in 
hapten responses (Berek and Milstein 1987).        
It is known that the quality of the antibody response decreases with age, with a lower level of 
specific antibodies and an increased level of non-specific antibodies generated in response to 
vaccination (Howard et al. 2006). Lately, it has been demonstrated that the average number of 
somatic hypermutations per antibody is significantly raised in the elderly (>75 years) compared to 
non-elderly (Gibson et al. 2009, Chong et al. 2003). Banerjee et al. (Banerjee et al. 2002) have 
shown that the somatic hypermutation process occurs at the same rate in young and old humans. 
Therefore, it is suggested that the observed increase might be the result of an immense 
accumulation in SHM over many years in combination with a waning amount of bone marrow and 
it could be partly responsible for a less effective immune system in the elderly (Banerjee et al. 
2002). Another possibility could be a less tight selection on antibodies with age.   
There are several opinions about the importance of somatic hypermutation for the in vivo generation 
of a high-affinity antibody response. Manivel et al. (Manivel et al. 2000) have proposed that non-
mutated antibodies are more flexible and hence cross-reactive whereas those that have introduced 
mutations are more rigid. So combined with selection, somatic mutations yield antibodies of high 
specificity and high affinity (a lock and key mechanism) compared to germline antibodies.  
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A perhaps more controversial theory for the role of SHM has been proposed by Andersson et al. 
(Andersson et al. 1998). They argue that the SHM apparatus originated in the Peyers patches in the 
GI tract in response to gut bacteria where it is important because of antigen-independent antibody 
production. The apparatus was then introduced into GCs as these developed. Because of the 
selection of B cell clones by T cells, the SHM apparatus is not essential in GCs but does not hurt 
either as long as B cell clones are actively selected based on affinity. It is, however, discussable 
whether such an “expensive” feature on the cellular level as somatic hypermutations would exist if 
it were expendable. In paper 3, we argue that SHM are not directly correlated to affinity or binding 
kinetics although they do yield antibodies of higher affinity and better binding kinetics compared to 
germline “ancestor” antibody clones on two occasions. Thus, somatic hypermutation in itself does 
not ensure higher affinity clones but combined with selection for these it is an indispensible feature 
in the generation of efficient and diverse antibody repertoires of high quality.   
 
4.2.2 Insertions and deletions  
In addition to the structural diversity introduced by the recombination of different gene segments 
and the generation of somatic hypermutations, entire codons can be inserted or deleted in 
rearranged antibody genes. These insertions and deletions are clustered at hot-spots in the antigen 
binding site and they often result in the generation of new combinations of canonical loop structures 
or entirely new loops creating an expanded antibody structure space (de Wildt et al. 1999b). The 
insertions and deletions involve repetitive sequence motifs in the antibody-encoding genes, and it 
has been suggested that they occur through polymerase slippage (Lantto and Ohlin 2002). 1.5–9.7% 
of normal B cells have been reported to carry insertions or deletions in their hypermutated antibody-
encoding genes (de Wildt et al. 1999b, Goossens et al. 1998, Ohlin and Borrebaeck 1998, Wilson et 
al. 1998, Reason and Zhou 2006). The actual frequency may be even higher, since insertions and 
deletions in the CDR3 of the heavy chain and at the end of the CDR3 of the light chain are usually 
unidentifiable due to the unknown length of the primary transcripts (Lantto and Ohlin 2002). It has 
been demonstrated that IGHV genes specifically carry repetitive trinucleotide motifs in CDR1 and 
CDR2, thus making these parts of the genes that encode highly flexible structures particularly prone 
to functional deletions (Lantto and Ohlin 2002). Like the hypermutations, many of the 
modifications result in an inability of the antibody gene to encode a functional protein, either 
because the deletions and insertions produce an out-of-frame gene, or because the modification 
alters the protein so dramatically that it cannot fold properly. Recently, Reason and Zhou (Reason 
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and Zhou 2006) have demonstrated by clonal lineage analysis that insertion and deletion events 
occur throughout the course of the somatic maturation of individual antibody clones. The co-
occurrence of these modifications with base-pair substitutions that appear to have arisen from SHM 
suggests that insertions and deletions may be a normal consequence of the somatic maturation of 
antibody responses. Hence, it also suggests that these processes contribute to diversification of 
antibody repertoires (Ohlin and Borrebaeck 1998). 
In paper 3, we demonstrate that deletions are found in mature specific antibody repertoires against 
tetanus. We found that the process had occurred in 6.4% of the clonotypes isolated (based on 
analysis of V segments only) with 3 in 5 found in heavy chains. No insertions were observed in our 
rather large data sets. Most of the deletions were found close to CDR1s or CDR2s in both heavy 
and light chains supporting the findings by de Wildt et al. (de Wildt et al. 1999b) that they often 
result in the generation of new combinations of canonical loop structures or entirely new loops 
which are then likely to contact the antigen directly. The frequencies of insertions and deletions 
may, however, be underestimated since insertions and deletions in CDR3 regions are difficult to 
assign. Nevertheless, our results demonstrate that deletions are indeed found in mature specific 
antibody repertoires against tetanus. However, the small frequency by which they occur – and the 
lack of insertions – suggest that they are not a dominant means of diversification.    
4.2.3 Class switch recombination (CSR) 
After activation of a mature B cell that has recognized antigen, certain cytokines can stimulate the B 
cell to switch heavy chain class while keeping the antigenic specificity by the process of class-
switch recombination (CSR) or isotype switching (Sakano et al. 1980, Stavnezer 1996). This can 
alter the antibody’s effector function. It is done by recombination of the already joined V-D-J 
segment of the variable domain of the heavy chain with a CH gene segment of another heavy chain 
class, e.g. the µ heavy chain can be switched to γ (IgM⇒IgG). The B cell switches the isotype in a 
certain sequence (µ, δ, γ, ε, α) and can never go back to a previously used isotype since the used 
gene segments are excised from the genome during recombination. The enzyme AID is required for 
CSR as well as for somatic hypermutation (Revy et al. 2000). 
4.2.4 Receptor editing 
Receptor editing (sometimes referred to as receptor revision) is thought to be a process by which 
self-reacting antibodies escape deletion and it has been described as a dominant mechanism 
controlling central B cell tolerance in addition to clonal deletion and anergy (Pelanda and Torres 
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2006, Ait-Azzouzene et al. 2005). The mechanism was identified by two groups in the early 1990’s 
(Gay et al. 1993, Tiegs et al. 1993) who noticed that a small proportion of immature B cells 
expressing auto-reactive immunoglobulin were not submitted to clonal deletion. Rather, the auto-
reactivity of the B cell clone was eliminated through secondary V(D)J recombination. Hence, when 
the immature B cell binds a self-antigen, maturation can be arrested while the cell upregulates 
expression of RAG1 and RAG2. This in turn initiates further rearrangement of the V(D)J gene 
segment DNA that has not already been excised from the genome resulting in antibodies with new 
specificities. The process is relatively fast and has been shown to occur within about 6 hours in 
transgenic mice (Hippen et al. 2005). Hence, the B cell gets a second chance (or more) to produce a 
functional, non-self-binding antibody. In addition to rescuing self-reactive B cells, the process is 
thought to rescue some B cells with non-productive V(D)J rearrangements (Reth et al. 1986b, Reth 
et al. 1986a).  
The process has been demonstrated to work on both immunoglobulin heavy and light chains (Gay 
et al. 1993, Tiegs et al. 1993, Papavasiliou et al. 1997, Nemazee and Weigert 2000). However, it 
has later been suggested that receptor editing of the heavy chain is an infrequent event, leaving light 
chain editing as the main mode of avoiding autoreactive specificities in vivo (Nadel et al. 1998b). In 
addition to rescuing self-reactive or non-functional B cells from deletion, receptor editing has been 
proposed as a process which serves to further diversify antibody repertoires (Radic and Zouali 
1996, Pelanda et al. 1997, Ohlin and Zouali 2003). Groups at Rockefeller University, University of 
Cologne, and Scripps Research Institute have found that about 25% of all antibody molecules are 
produced by gene replacement (receptor editing). They thereby suggest that receptor editing 
actually represents a major force in shaping the antibody repertoire (Casellas et al. 2001). By 
contributing to the diversity of a given antibody repertoire, receptor editing may not only be a 
means of ensuring central tolerance but it may also contribute to affinity maturation by generation 
of clones with potentially higher affinity for antigen. This is also suggested by de Wildt et al. who 
have demonstrated that receptor editing occurs in the periphery as well as centrally, and that the 
same antibody lineage can be subjected to both receptor editing and somatic mutation (de Wildt et 
al. 1999a). In paper 3, we report that we do not observe cases of receptor editing in our relatively 
large data sets of tetanus specific antibodies. This suggests that receptor editing is not a major 
contributor to diversification of “normal” (non-autoimmune) antibody repertoires.  
Although, receptor editing may be a dominant mechanism controlling central B cell tolerance and 
may be involved in affinity maturation (de Wildt et al. 1999a), the process itself needs to be tightly 
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controlled. This is supported by a study in patients suffering from rheumatic autoimmune diseases 
by Zouali (Zouali 2008). The study demonstrates that receptor editing is either impaired or 
accelerated in these patients. Notably, both alterations can result in pathogenesis since impaired 
secondary rearrangements might result in ineffective silencing of B cells, while exacerbation of 
receptor editing can give rise to autoreactive receptors from B cell clones that were initially devoid 
of autoreactivity (Zouali 2008). 
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5. Antibody repertoires 
The study of antibody repertoires provides insights into the generation of antibody diversity as well 
as selection mechanisms or selection criteria. Therefore antibody repertoire characterization may 
help reveal the rules guarding antibody selection.  
The imprecise joining of V(D)J segments can be estimated to generate a potential naïve repertoire 
of up to 1010 possibilities. However, since the available number of B cells is well below the number 
of variants that can be generated and some cells might generate the same recombination by chance, 
the available repertoire is several orders smaller – likely to be well below 108 (Berek and Milstein 
1988).  This also follows from the estimate that there are a total of about 108 B cells per person 
(Gibson et al. 2009). 
In 1951, Jerne stated that the quantity and quality of antibodies changed during the course of the 
primary antibody response. He further explained that later during the primary response, antigen-
specific antibodies exhibit improved affinity for the antigen and have switched isotype from IgM to 
IgG, IgE, or IgA (Jerne 1955). The statement was elaborated in the clonal selection theory which 
was proposed by Burnet in 1957. This theory states that initial antigen challenge is anticipated to 
lead to clonal expansion of the B cells that produce a cognate antibody specificity (M.F.Burnet 
1959). The same theory anticipated that the random collection of Igs would include the generation 
of auto-reactive specificities, which would require silencing by the immune system.   
The point mutations that are introduced into the Ig genes upon binding to antigen result in some of 
the altered antibodies having a higher affinity for the antigen in question. Because of the active 
selection during affinity maturation, cells containing these higher affinity antibodies will proliferate 
and survive preferentially. This is the background for selection of antibodies into specific 
repertoires from the non-specific and for the development of specific repertoires after several 
antigenic challenges.   
5.1 Germline gene repertoire 
During the past 30 years several groups have worked on the mapping and sequencing of the human 
antibody gene repertoire (Cook and Tomlinson 1995, Corbett et al. 1997, Matsuda et al. 1998, 
Ravetch et al. 1981, Schable and Zachau 1993, Tomlinson et al. 1992, Williams et al. 1996, Hieter 
et al. 1982, Kawasaki et al. 1997). The recombination of these gene segments generates antibodies 
that constitute the so-called naïve repertoire until they are hypermutated upon encounter with 
34 
antigen (Berek and Milstein 1988). All the information on antibody gene segments has been 
compiled by Lefranc and Lefranc, is available online where it is continually updated (IMGT Home 
Page 2009).  
The heavy chain genes are located on chromosome 14. There are 53 functional VH gene segments2 
(and 4 non-functional gene segments) divided into 7 families or subgroups (IGVH1-7) based on 
sequence homology. Each family shares at least 75% identity at the nucleotide level. The different 
families vary in size with the largest group being IGVH3 with 24 functional members (and 3 non-
functional) while the smallest families IGVH2, IGVH5, IGVH6 and IGVH7 have between 1 and 3 
members each. Located downstream from the VH gene segments are 32 D gene segments belonging 
to 7 families (IGHD1-7), followed by 6 JH gene segments which constitute one family each (IGHJ1-
6). The light chain genes loci, encoding kappa (κ) and lambda (λ), are located on chromosome 2 
and 22, respectively. There are 46 Vκ gene segments divided into 5 (IGKV1-5) families and 40 Vλ 
gene segments have been classified into 11 subgroups (IGLV1-11). IGKV1 and IGLV3 are the 
largest families with 22 and 11 members, respectively. There are 5 Jκ and 7 Jλ gene segments each 
representing one family. Normal human antibody repertoires usually consist of 60% antibodies with 
κ- light chains and 40% with λ-light chains (a 3:2 ratio) (de Wildt et al. 1999a). Besides the number 
of functional gene segments, there are also a number of non-functional genes or pseudogenes. Some 
of the structures generated by recombination of gene segments are deleterious to the cell because of 
frame shifts resulting in stop codons or the presence of non-tolerated amino acids in certain 
positions.  
The sizes of the different gene segment families are roughly reflected in the usage of each family in 
specific antibody repertoires which leads to differences in the overall representation of the different 
genes (Brezinschek et al. 1995, Brezinschek et al. 1997, Huang et al. 1996, Brezinschek et al. 1998, 
Poulsen et al. 2007). Yet, within the families there are biases for usage of certain members. Skewed 
usage of gene segments and heavy-light chain combinations have been reported in non-specific 
antibody repertoires by several groups (Demaison et al. 1995, Tian et al. 2007, Cox et al. 1994, 
Stewart et al. 1993, Brezinschek et al. 1997, Foster et al. 1997). However, diverse germline 
repertoires are important in particularly primary infections since the initial binding of antigen to the 
B cell receptor – although it might be of low affinity – triggers further affinity maturation. 
Therefore, these biases might be the result of affinity maturation in combination with intrinsic 
                                                
2 All gene segment numbers are from IMGT®, the international ImMunoGeneTics information system® 
http://www.imgt.org (founder and director: Marie-Paule Lefranc, Montpellier, France).  
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genetic features causing preferential usage of certain segments such as chromosomal location 
(Williams et al. 2001) or variations in RSS (Nadel et al. 1998a).  
Some groups have observed that germline antibodies (non-hypermutated antibodies) have more 
flexible paratopes than their hypermutated variants (Manivel et al. 2000, Brooks et al. 2008, 
Thomson et al. 2008). They hence exhibit a high degree of cross-reactivity (especially at 
physiological temperature) and the binding of germline and mutated antibodies to antigen have been 
found to be differentially affected by temperature increases (Manivel et al. 2000). Manivel et al. 
find that both types have increased dissociation at higher temperatures (Manivel et al. 2000). 
However, they find that primary repertoire antibodies have a decrease in association at higher 
temperatures while secondary repertoire antibodies increase association rates facilitating a 
qualitative distinction in on-rates. Zhou et al. actually suggest that polyreactive antibodies are a 
major contributor to the broad antibacterial activity of the natural (germline or non-hypermutated 
antibodies) antibody repertoire (Zhou et al. 2007).  
5.2 Specific antibody repertoires 
Many of the first studies on antibody repertoires were done on antibodies against different haptens 
(e.g. 2-phenyloxazolone, oxazolone, and nitrophenyl) in mice or rabbits. These repertoires turned 
out to be very restricted in terms of gene segment usage and were shown to be converging against 
very few clonotypes – especially after several challenges (Kaartinen et al. 1983, Takahashi et al. 
1998, Berek and Milstein 1988). Berek and Milstein (Berek and Milstein 1988) have reported that 
the secondary and later responses to oxazolone in mice are dominated by a certain combination of 
gene segments and antibodies have certain hypermutations which are rarely found in the primary 
repertoire. They refer to this as a repertoire shift. However, the relevance of anti-hapten repertoires 
compared to challenges with more “natural” antigens is discussable. Hapten binding studies may 
not be relevant to microbial protein responses because the small size of haptens allows for high-
affinity interactions with only a limited portion of the antibody-contacting surface (Persson and 
Ohlin 2007). Few studies have sought to determine how naturally occurring somatic mutations in 
human antibody genes affect the response to an important biologically relevant protein (Kallewaard 
et al. 2008). Nevertheless, more natural antigens have indeed proved to induce specific antibody 
repertoires dominated by a few clones (mono- or oligoclonal repertoires) such as antibody 
responses against Rhesus D (Andersen et al. 2006), human cytomegalovirus (HCMV) (Thomson et 
al. 2008), influenza virus (vaccine) (Wrammert et al. 2008), rotavirus (Kallewaard et al. 2008) and 
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Haemophilus influenzae type B (Hib) (Barington et al. 1996, Insel et al. 1985, Silverman and Lucas 
1991). Interestingly, certain ethnic groups such as Navajos, Apaches and Alaskan Eskimos show an 
increased susceptibility for the latter where antibody responses are normally pauciclonal and 
dominated by antibodies using the Vκ A2 gene. Feeney et al. (Feeney et al. 1996) have 
demonstrated that these ethnic groups have a high frequency of polymorphisms in the Vκ A2 gene 
leading to defective rearrangements of this gene segment. Thus, the germline gene segments play an 
important role in the immunological control of certain pathogens especially where “normal” 
specific repertoires are dominated by a few clones.     
In contrast to the restricted specific repertoires described above, antibody repertoires against other 
pathogens have been shown to be very diverse in terms of both number of clonotypes and 
hypermutations. These repertoires include responses against viruses and bacteria such as Vaccinia 
(Benhnia et al. 2009), cytomegalovirus (CMV) (Speckner et al. 1999, Ohlin et al. 1993), vesicular 
stomatitis virus (VSV) (Roost et al. 1995, Kalinke et al. 1996) (VSV in mice), tetanus as described 
by us in paper 1-3 and by others (Poulsen et al. 2007, de Kruif et al. 2009, Volk et al. 1984), and 
interestingly, HIV (Scheid et al. 2009) although this recent report contradicts the work by Köhler et 
al. (Kohler and Milstein 1992).  
In several cases of pathogens, one specific antibody (or even Fab fragment) has been shown to be 
sufficient for clearance of the disease e.g. P. aeruginosa (Baer et al. 2009). In other cases, the 
binding of several antibodies is clearly necessary for neutralization, as has been shown for 
botulinum toxin neutralization (Marks 2004) and one could easily imagine this being true for other 
lethal toxins and complex or quickly mutating viruses. Hence, different antigenic targets require 
different numbers of antibodies for neutralization. Further, some viruses have been shown to require 
certain antibody isotypes for neutralization since complement activation is sometimes necessary 
(Benhnia et al. 2009).   
The gene segment usage of specific antibody repertoires against several antigens has been shown to 
be highly biased just as the usage in naïve repertoires (Poulsen et al. 2007, Corbett et al. 1997, 
Souto-Carneiro et al. 2004, Yamada et al. 1991, Cox et al. 1994, Klein et al. 1993, Ohlin and 
Borrebaeck 1996). In paper 1 and 3, we report that our anti-tetanus repertoires exert a skewed gene 
segment usage. However, as we show in paper 1, they reflect natural skewing of non-specific 
repertoires. The skewing in both, VH, JH, Vκ and Jκ is quite similar for both donors and also between 
the different repertoires for the same donor. Interestingly, we found that our small primary 
repertoire actually displayed the same skewing as the mature responses. These findings indicate that 
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tetanus specific antibody repertoires do not converge against a certain type of rearrangement but 
keep reflecting the naïve repertoire bias and hence keep being diverse in terms of gene segment 
usage even after repeated exposure.  
It is widely believed that the heavy chain CDR3 is the major contributor to the antigen-specificity 
for many antibodies (Xu and Davis 2000). Several groups have observed that some repertoire 
specificities require certain lengths of CDR3+FW4 for binding. These include antibody repertoires 
against dextran (19 residues),  β-1,6 galactan (20 residues), and oxazolone (16 residues) (reviewed 
by (Berek and Milstein 1988)). However, as we show in paper 1, our anti-tetanus repertoires do not 
seem to require certain lengths of heavy chain CDR3 although there does seem to be a slight 
preference for lengths of 15 and 21 amino acids. Nevertheless, general skewing against longer 
heavy chain CDR3 loops has been observed in specific antibody repertoires (Ohlin and Borrebaeck 
1996) such as west nile virus (Throsby et al. 2006), rabies virus (Kramer et al. 2005), tetanus toxoid 
(Poulsen et al. 2007) compared to unselected repertoires. Ohlin and Borrebaeck (Ohlin and 
Borrebaeck 1996) suggest that this might be due to potentially higher affinities for antibodies with 
longer heavy chain CDR3 loops because they allow for more contact points in the binding site than 
shorter CDR3s. However, Searle et al. have found that there is not a strict correlation between the 
number of contact points at the contact site and affinity of the antibody for the antigen (Searle 1995) 
so the significance of biases for longer CDR3s is not fully understood.   
Based on phage display libraries with only one type of light chain but with heavy chains isolated 
from immunized donors, de Kruif et al. (de Kruif et al. 2009) argue that in tetanus repertoires, 
specificity is predominantly defined by the heavy chain CDR3s. Nevertheless, studies in other 
systems are contradictory. For example, Ohlin et al. (Ohlin and Borrebaeck 1996) have 
demonstrated that the reactivity of a high- affinity virus-neutralizing  human antibody against the 
AD-2 epitope of cytomegalovirus gB can be modified by combining the original heavy chain with 
other light chains by phage display.  
Some groups have speculated about the question of the absence of an equitable relationship 
between the number of antigen receptors and antigenic determinants (the paradox of infinite ligands 
for finite receptors) (Manivel et al. 2000, Joyce 1997, Mason 1998). It has been suggested that high 
flexibility of germline (primary) antibody paratopes in part compensate by cross-reacting with a 
large number of antigens (Manivel et al. 2000, Sethi et al. 2006, Brooks et al. 2008).  This is in 
essence an amplification of the functional recognition repertoire beyond that prescribed by the BCR 
repertoire alone. The antibody paratopes are thought to be rendered more rigid by SHM in 
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conjunction with antigen-selection to ensure specific antigenic binding in conjunction with 
increased affinity (another role of somatic hypermutation) (Zimmermann et al. 2006). It has been 
discussed whether certain germline gene segments have undergone evolutionary selection for the 
generation of binding sites for certain dangerous pathogens that have frequently infected humans 
through evolution (Roost et al. 1995). Recently, Thomson et al. (Thomson et al. 2008) have argued 
that this is indeed the case for the antibodies expressed by repertoire dominating clones against 
HCMV (the segment being IGHV3). They observed that the contacts between the antigen and 
antibody did not change by the introduction of somatic hypermutations. Instead, the selected 
hypermutations stabilized and enhanced the germline encoded interaction with the antigen. They 
thus support the theories described above of germline antibodies being more flexible and hence 
more promiscuous than hypermutated antibodies. However, it does not seem highly likely that 
humans should be able to select for genes that counteract certain pathogens when almost all known 
pathogens mutate much faster than humans (our life cycle is much longer than most pathogens’). 
Further, with all the potential foreign antigens, it would be highly unlikely that one or several gene 
segments would specifically bind to certain targets although the suggested flexibility of germline 
antibodies could increase the number of targets. In paper 1 and 3 we report a broad usage of 
different V and J genes in all of the tetanus specific repertoires indicating that human antibody 
segments have not evolved to bind tetanus. Further, in paper 2 we report a constant addition of new 
antibodies to older repertoires and we find non-hypermutated antibodies of intermediate and high-
affinity in paper 1 and 3. This suggests that the large potential of diversification of antibodies 
results in some antibodies having high affinity by chance rather than certain segments have evolved 
to specifically bind certain targets.  
 
Peak antibody responses decline during the first year after vaccination, but antibody titers then 
stabilize and remain nearly constant for up to 75 years after immunization (Hammarlund et al. 2003, 
Crotty and Ahmed 2004, Slifka 2004, Crotty et al. 2003). Höfer et al. (Hofer et al. 2006) have 
calculated that tetanus as a model antigen produces a number of antibody producing tetanus-specific 
plasma cells which drops to 50% 173 years after immunization. Indeed, a recent study by Yu et al. 
(Yu et al. 2008) on survivors of the 1918 H1N1 influenza virus pandemic confirms the prolonged 
presence of specific antibodies. The study demonstrates that even nearly 90 years after exposure to 
this particularly virulent virus, 7 out of 8 tested blood samples from survivors still contained B cells 
secreting antibodies that bound the 1918 hemagglutinin (HA). Strikingly, all 32 individuals tested 
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showed seroreactivity with the 1918 virus strain. Out of five isolated monoclonal antibodies from 
these individuals, none cross-reacted with more contemporary human influenza viruses. This 
demonstrates that for some antigenic targets (and maybe particularly viruses), circulating memory B 
cells can be found for nearly a hundred years – or rather throughout the person’s lifetime. Similar 
findings have been reported by Crotty et al. (Crotty et al. 2003) who find that Vaccinia-specific 
serum titers are kept constant up to at least 60 years after immunization.  
 
In paper 1, we demonstrate that the specific kappa antibody repertoire against tetanus consists of in 
the order of 100 clonotypes and hypermutated variants thereof based on the first antibody repertoire 
from each of the two hyperimmune donors. The finding is confirmed in paper 2, where the two 
consecutive repertoires from each donor verify the primary estimates on repertoire sizes. Further, 
we demonstrate in paper 2 that the influx of new clonotypes into existing tetanus repertoires upon a 
new challenge is relatively large and may compose over half of the “base” repertoire. This suggests 
that the composition of specific antibody repertoires is relatively dynamic while repertoire sizes (at 
least against tetanus) seem to remain about the same. The size of the total B cell repertoire only 
allows the expression of a fraction of the genetic repertoire at any given time, thus only a random 
sample of the total potential is available (Berek and Milstein 1988). It therefore seems likely that 
only relatively small numbers of clonotypes are specific for each target and the specific numbers 
could be even smaller in the case of structurally restricted antigens such as e.g. Rhesus D (Andersen 
et al. 2007). 
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6. Affinity maturation 
The concept of affinity maturation was introduced by Siskind and Benacerraf (Siskind and 
Benacerraf 1969). The development of the concept followed the 1965 demonstration by Siskind and 
Eisen that there was a gradual increase in affinity of specific serum antibodies after small amounts 
of antigen were repeatedly injected in rabbits (Siskind and Eisen 1965). Parts of the affinity 
maturation process still need to be uncovered. However, there is a general agreement that affinity 
maturation of B cells is initiated by encounter with antigen which in turn triggers initiation of 
somatic hypermutation of the Ig genes. B cells are then competitively selected for high affinity to 
specific antigen by the signaling to certain clones to proliferate faster as they acquire advantageous 
mutations compared to other clones as explained by the clonal selection theory (Burnet 1959). 
Clones whose hypermutations result in either non-functional or self-binding antibodies are deleted 
during this process or undergo further rearrangement processes (e.g. receptor editing). Therefore, 
maturation is the result of selection and specific expansion of B cell clones expressing high-affinity 
antibodies (Berek and Milstein 1987). Later it has been demonstrated, that the process of affinity 
maturation takes place in the germinal centers of secondary lymphoid tissues and is indeed 
characterized by somatic hypermutation of Ig genes and subsequent selection of the clones with 
genes encoding the best antibodies (MacLennan 1994). 
The end-goal of the affinity maturation process is to maximize (or in praxis, optimize) for 
complementarity between epitope and paratope (Manivel et al. 2000). Nevertheless, an affinity 
threshold has been suggested for B cell triggering (Sale et al. 2001, Batista and Neuberger 1998). It 
has been argued that if the threshold is set too high, the B cell repertoire might not cover widely 
enough, while a too low threshold might be associated with excessive B cell activation and 
difficulties in discrimination between self and non-self (Batista and Neuberger 1998). Sale et al. 
have even speculated that there might be a difference in this triggering threshold during the 
development of B cells (immature B cells) and for mature B cells.    
In 1995, Foote & Eisen proposed that in vivo selection of antibodies must have an affinity ceiling 
(Foote and Eisen 1995). This proposal was based on assumptions on association and dissociation 
rates. Maximum selection on on-rates (kon) was predicted to be 105-106M-1s-1 based on diffusion 
coefficients of antigens which had been verified experimentally (Northrup and Erickson 1992, 
Raman et al. 1992). Limiting dissociation rates (koff) of 10-3-10-4s-1 were estimated by multiplying 
the rate of receptor internalization upon antigen binding by a factor 2-3 (Foote and Eisen 1995) 
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where half-life for internalization was estimated to 8.5 minutes based on endocytosis (Watts and 
Davidson 1988). Thus, the predicted maximum kon values of 105-106M-1s-1 and lower koff limits of 
10-3-10-4s-1 lead to an affinity ceiling having equilibrium dissociation constants (KD) in the range of 
10-8-10-10 M. This does not mean that antibodies of higher affinity do not arise as both we (Poulsen 
et al. 2007) and others have demonstrated (Roost et al. 1995, Wrammert et al. 2008, Rathanaswami 
et al. 2005). Rather antibodies with affinities above the ceiling have no further advantage in antigen 
selection during normal responses. Although, Batista and Neuberger (Batista and Neuberger 1998) 
have demonstrated in vitro that these theoretical boundaries seem to exist, the boundaries have been 
difficult to address experimentally in vivo. This has mainly been due to the inability of existing 
antibody cloning techniques to generate a sufficient number of antibody clones from single antigen 
repertoires of animal or human origin. Recent advance in techniques for isolation and analysis of 
single antibody producing B cells has lifted this limitation and thereby allowed for detailed studies 
of the composition and functionality of antigen-driven antibody repertoires at single time points 
(Poulsen et al. 2007, Love et al. 2006, Yu et al. 2008, Lanzavecchia et al. 2007, Wrammert et al. 
2008, Scheid et al. 2009). In paper 1, we show that affinities of in vivo selected antibodies cover a 
span of a million fold. We further demonstrate that both affinities and binding kinetics (on- and off-
rates) follow log-normal distributions reflecting the intrinsic properties of random somatic 
diversification. In paper 2, we report for the very first time, that affinities for in vivo selected 
antibodies binding to tetanus toxoid peak at 1x10-9 M at physiological temperature (37°C). Further, 
we are able to demonstrate that kinetic rate constants are maturated separately with constants 
peaking at 1.6x105 M-1s-1 and 1.7x10-4 s-1 at physiological temperature for on- and off-rates, 
respectively. The observed limits are in agreement with the theoretical limits proposed by Foote and 
Eisen (Foote and Eisen 1995).  
Because relatively short time passed between the second and third vaccinations in our study, there 
is a slight possibility that the observed ceiling is a bit lower (higher KD) than what is actually 
possible due to much available antigen. If antigen persists in the system for a longer period of time 
it does not allow for maximum competition which leads to a case where the very high affinity 
clones do not have the extreme selective advantage they would have at low amounts of available 
antigen. However, we do not expect this feature to be able to displace the ceiling by several orders 
of magnitude. 
In paper 2 we reported that on-rates peak before off-rates since they did not improve with several 
challenges whereas the off-rates were significantly slower (and hence better) in the second and third 
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repertoires compared to the first. However, the off-rates may be under a more tight control since 
they are less dispersed than on-rates. The observed separate maturation of kinetic rate constants 
supports that maturation of antibody responses is kinetically rather than thermodynamically 
controlled (Foote and Milstein 1991, Furukawa et al. 1999, Roost et al. 1995). 
The antibody affinity ceiling we observe is not only consistent to theoretical limits under certain 
assumptions. Batista and Neuberger (Batista and Neuberger 2000) have shown in vitro that the 
amount of antigen needed to trigger a B cell response is discriminated by the cell over a range in 
affinities of 10-6-10-10 M. With greater affinities (lower KD), there was no discrimination for B cells 
recognizing soluble antigen. However, they found that the form in which the antigen was displayed 
to the B cell affected the ceiling. They demonstrated that particulate antigen or antigen tightly 
tethered to a non-internalizable surface displayed lower affinity ceiling values (higher KD) – as low 
as 10-6 M – possibly driven by higher avidity. Our findings in paper 2, that the affinity ceiling of 10-
9 M for in vivo selected tetanus specific antibodies suggest that most of the tetanus toxoid is 
displayed in a soluble form or that other mechanisms have influence on in vivo selection of 
antibodies.   
As described, we have observed that affinities cover a span of a million-fold which was confirmed 
by data presented in paper 2. This large span can be explained by the observation that 
hypermutation occurs locally in distinct germinal centers, allowing for local competition of B cell 
clones but that there is no competition between distinct germinal centers (Dal Porto et al. 1998, 
Jacob et al. 1991, Jacob and Kelsoe 1992, Kelsoe and Zheng 1993). Further, Jacob & Kelsoe 
demonstrate that both focus and germinal center populations are pauciclonal, founded, on average, 
by three or fewer B lymphocytes (Jacob and Kelsoe 1992). These very small numbers of cells 
forming the basis of a GC offer a nice explanation for a large span in affinities as a result of limited 
local competition. Further, the explanation is supported by our observation in paper 2 that a 
relatively large part of the anti-tetanus repertoire consists of new clones entering the repertoire – 
these new clones may even compose over half of the “base” repertoire. Naturally, these clones 
contribute to the large span in affinities but as we have shown in paper 1 even newly formed 
antibodies can be of high affinity. Therefore, they might even contribute to affinities in the full span 
and not only in the lower end.  
The large span in affinities and the large influx of new clonotypes into existing tetanus repertoires 
upon a new challenge combined with the finding that the primary repertoire is relatively diverse and 
can include high-affinity binders, suggest that each subsequent repertoire consists of a memory 
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repertoire and a primary repertoire. In other words, it seems that a part of the mature repertoire 
consists of specific antibodies from newly activated and differentiated naïve B cells. The 
pauciclonality of GCs may easily make room for expansion of these newcomers. The theory is 
supported by the fact that the span in affinities is approximately the same for antibody repertoires 
that seem to have reached an affinity ceiling as repertoires that have not (data in paper 2). Further, 
the fact that we are able to isolate a number of tetanus specific non-hypermutated antibodies in 
mature antibody repertoires is in favor of this theory as well. 
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7. Concluding remarks 
In this thesis, different aspects of antibody repertoires are addressed with the overall goal to 
increase the understanding of genetic and functional development of in vivo selected specific human 
antibody repertoires. We anticipate that these results concentrating on antibody repertoires against 
tetanus toxoid can be transferred to a more general understanding.  
 
In paper 1, we characterized the composition of antigen-specific polyclonal antibody responses. 
Using the Symplex technology, we isolated antibody repertoires from two healthy donors after 
receiving a tetanus vaccination. We argued that the observed genetic diversity among the tetanus 
toxoid specific plasma cells indicated that human polyclonal repertoires are limited to the order of 
100 B cell clones and hypermutated variants thereof. Further, we found that affinity and kinetic 
binding constants were log-normally distributed and that antibody affinities varied a million-fold. 
We also identified antibodies of high affinity without hypermutations indicating that antibodies 
selected from the naive repertoire are not only of low affinity. 
In paper 2, we isolated further two consecutive tetanus specific repertoires from each of the two 
donors from paper 1. We demonstrated that maturation of on- and off-rates occurred independently 
which indicated a kinetically controlled affinity maturation process. The repertoires developed 
functionally from the first to the second vaccination while the third vaccination of each donor 
induced no significant changes in the distribution of somatic mutations and binding rate constants. 
This implied that the limits for affinity maturation and repertoire diversification had been reached. 
The fully matured antibody repertoires remained similar in size to earlier isolated repertoires and 
also remained genetically diverse and dynamic. Somatic mutations showed normal distribution 
profiles while kinetic rate constants confirmed the log-normal distributions demonstrated in paper 
1. The fully matured antibody repertoires allowed us to report for the first time an experimental 
determination of the biological limits for antigen-driven affinity maturation and repertoire 
diversification. The clear distribution profiles of somatic hypermutations, on- and off-rates, and 
affinities indicated that mean values could be considered as biological constants defining the 
observed boundaries. The mean level of somatic mutations was 14 and 7 amino acid transitions per 
VH and Vκ gene segment, respectively. At physiological temperature, affinity maturation peaked at 
on-rates of 1.6x104M-1s-1 and off-rates of 1.7x10-4s-1 leading to maximum mean affinity of 1.0x10-
9M. 
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In paper 3, we investigate the role of diversification mechanisms in developing antibody repertoires. 
In addition to the hyperimmune repertoires from paper 1 and 2, we isolated an antibody repertoire 
from a tetanus naïve donor after receiving the first tetanus vaccination. We demonstrated that the 
diversity of tetanus specific antibody repertoires was evident after a single vaccination and did not 
change with many antigenic challenges. Also, we demonstrated that as early as day 6 after the first 
vaccination, the level of mutations of each specific antibody was surprisingly high with an average 
of 15 amino acid mutations per antibody. In our large data sets, we did not observe any instances of 
receptor editing suggesting that this is not an important mechanism for antibody diversification. 
Further, we identified few antibodies with deletions and none with insertions – indicative of a minor 
contribution by these processes to antibody diversification.  
The number of hypermutations for each antibody did not correlate to affinity or on- rates 
confirming our previous results. However, off-rates were improved when mutations were 
introduced to germline antibodies. Based on these observations we concluded that somatic 
hypermutations are important for improvements in off-rates of germline antibodies. This was 
supported by our finding that somatic hypermutations occur very fast in the primary tetanus 
repertoire. Our findings indicated that the quality of the primary antibody repertoire against 
physiologically relevant antigens is better than predicted from hapten studies.  
Together, the results of this project have increased the understanding of compositions and 
development of specific human antibody repertoires following immunization. Therefore, the results 
may be of use in the development of future antibody therapeutics and in vaccine design. Further, the 
findings are of general immunological interest since the conclusions regarding repertoire size and 
functional maturation limits of tetanus specific repertoires may well be applicable to antibody 
repertoires of other specificities. 
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7.1 Suggestions for further work 
The results of this project have opened up for many further questions that could be sought answered 
by treatment of the existing or new Symplex antibody repertoires: 
 
1. Does the specific repertoire cover the antigen or are there certain dominant epitopes? 
 
2. How do human antibody repertoires change on the molecular level with multiple exposures 
to the same antigen – and are there differences between individuals? 
 
3. Is the diversity of the mouse antibody repertoire comparable to that of humans on genetic 
and functional levels? 
 
4. What is the starting point for selection of antibodies from a naïve repertoire?  
 
5. What is the size of the naïve antibody repertoire at any given time in humans? 
 
Question 1 could be sought answered simply by using the previously expressed and purified human 
Fab fragments to test how well the repertoire covers the antigen by epitope mapping. The 
experiments would be conducted on SPR equipment and would reveal if the functional diversity of 
a repertoire works by full coverage of the antigen or whether it only covers a few immuno-
dominant epitopes. In addition, it would reveal how many antibodies from a given repertoire that 
can bind to the antigen simultaneously. The results of these studies would be of fundamental 
immunologic interest as well as supportive to future vaccine design. 
Regarding question 2, a further genetic analysis of the seven existing antibody repertoires from the 
two hyperimmune donors could aid in characterizing the development of antibody repertoires 
during several immunizations with a single antigen. This study could employ bioinformatics to 
analyze the genetic details of developing antibody repertoires and to characterize selection 
mechanisms shaping human antibody repertoires. The data could further be analyzed to show 
whether there is a difference between individuals. The results would help reveal rules guarding the 
generation and expansion of antibody diversity in human B cells and the optimization of antibody 
structures that bind microbial antigens. This knowledge would help to better understand the 
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influence of affinity maturation in the maintenance, expansion, or narrowing of antigen-specific 
repertoires in the B cell compartment. It could be very supportive in the future design of vaccines. 
A further investigation of human antibody responses would also assist the development of 
recombinant mono- or polyclonal antibody-based treatments since it would aid in the selection of 
antibodies for more potent and efficient treatments. 
Since the Symplex technology has already been employed in the isolation of anti-tetanus mouse 
repertoires, these could be used in the answering of question 3. By analyzing the genetic and 
functional differences between human and mouse repertoires, important knowledge on the 
comparability between human and mouse antibody repertoires could be obtained. The results could 
be of importance to the interpretation of the many studies within immunology that are conducted in 
mice for practical and ethical reasons. Hence, the study would help elucidate how transferable 
mouse study results are to humans.      
To answer question 4 and investigate where humoral immunity begins in humans could be done by 
characterizing more antibody repertoires upon the first tetanus vaccination in donors and antibody 
repertoires upon the second tetanus vaccination of these donors. The study could also include the 
characterization of a panel of tetanus specific antibodies in germline configuration. This study 
would reveal important information about initial selection mechanisms of antibodies. This could be 
done by choosing a panel of ~25 antibodies, which we have previously characterized functionally, 
and remove all hypermutations by gene synthesis. The antibodies should be functionally 
characterized (affinities) and compared them to their original antibody counterparts. This would 
further address the issues of whether antibodies start out as low affinity antibodies that only get 
better affinities by the process of affinity maturation since results from our previous studies on a 
few non-mutated antibodies show that some antibodies actually have a high affinity before somatic 
hypermutations are introduced (see papers 1-3). The generation of a non-hypermutated version of 
an antibody repertoire selected in vivo would be an important and unique opportunity to study a 
snapshot of the same antibody repertoire before and after somatic hypermutation and affinity 
maturation. Further, it could be valuable in investigating further whether certain antibody gene 
segments have been developed through evolution to specifically target tetanus. Therefore this study 
could give insights into the basis on which antibody-producing cells are chosen for expansion and 
differentiation in the initial phase.  
Question 5 could be sought answered by the development of mathematical and statistical methods 
for predictions on the size of the naïve antibody repertoire based on the specific repertoires 
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characterized. Thus, these studies could reveal important fundamental knowledge about selection 
mechanisms that take effect upon the first encounter with antigen as well as the pool of cells that 
are the basis for selection. This knowledge could help determine whether people who have been 
exposed to dangerous microbial agents only once (and which we cannot vaccinate against) can be 
used for isolation of antibody repertoires that can form the basis for the development of a successful 
drug against the harmful agent in question.  
It would be of great value to be able to compare these repertoires: the “non-hypermutated”, the 
initial and second natural repertoires and analyze them statistically. Additionally, it would be 
valuable to compare the affinities of the naturally hypermutated repertoires from the 
multichallenged and hence hyperimmune donors. 
The studies presented above could generate information which would be valuable for the 
development of new drugs such as vaccines and antibody therapeutics - both by a better prediction 
of B cell epitopes and by a better understanding of the development of protecting antibody 
repertoires. Additionally, the results would contribute to the field of fundamental immunology by a 
better understanding of B cell epitopes and by elucidation of principles guarding antibody selection 
and development of antibody repertoires. The results of these suggested studies may therefore be of 
both fundamental immunological interest and of industrial and societal relevance. 
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Paper 1 
 
Kinetic, Affinity, and Diversity Limits of Human Polyclonal
Antibody Responses against Tetanus Toxoid
Tine Rugh Poulsen, Per-Johan Meijer, Allan Jensen, Lars S. Nielsen, and Peter S. Andersen1
Due to technical limitations, little knowledge exists on the composition of Ag-specific polyclonal Ab responses. Hence, we here
present a molecular analysis of two representative human Ab repertoires isolated by using a novel single-cell cloning approach.
The observed genetic diversity among tetanus toxoid-specific plasma cells indicate that human polyclonal repertoires are limited
to the order of 100 B cell clones and hypermutated variants thereof. Affinity and kinetic binding constants are log-normally
distributed, and median values are close to the proposed affinity ceilings for positive selection. Abs varied a million-fold in affinity
but were restricted in their off-rates with an upper limit of 2  103 s1. Identification of Abs of high affinity without hyper-
mutations in combination with a modest effect of hypermutations on observed affinity increases indicate that Abs selected from
the naive repertoire are not only of low affinity but cover a relatively large span in affinity, reaching into the subnanomolar
range. The Journal of Immunology, 2007, 179: 3841–3850.
A ntibodies are produced by B cells in response to anti-genic challenge. The primary repertoire of B cells ismade by a random rearrangement of five gene segments,
including V, D, and J gene segments for the H chain and V and J
gene segments for the L chain. In addition, junctional diversity is
introduced by nontemplate insertion and deletion of nucleotides in
the joining regions during the rearrangement process. B cell clones
from the primary repertoire are selected by Ag and subjected to a
clonal expansion/selection process in which hypermutation occurs,
thereby increasing the affinity of the Ab/Ag interactions (1). Con-
sequently, the humoral immune response consists of a polyclonal
repertoire of B cells generally characterized by a diverse genetic
profile and the production of high affinity Abs. However, the un-
derstanding regarding the development and composition of poly-
clonal Ab repertoires in response to Ag challenge is modest,
mainly due to the limitations of current techniques.
The functional development of Ag-selected polyclonal Ab rep-
ertoires has mainly been studied by making mAbs from mice pro-
gressively exposed to Ag. By studying anti-hapten responses it has
been concluded that primary responses are of low affinity, which
increases as a consequence of somatic mutations upon multiple
challenges with Ag (2–4). However, anti-hapten responses are
known to be genetically restricted and involve only a limited set of
V gene segments (discussed below), implying that the Ag has a
significant role in shaping such Ab repertoires. In contrast, high-
affinity Abs have been observed early in mice in response to a viral
infection (5) and to hen egg lysozyme (6), implying that primary
Ab responses toward more complex Ags are less restricted in terms
of affinity. Foote and Eisen (7) proposed a theoretical limit for Ab
affinities in developing B cell responses based on the consideration
that the selection based on the off-rate must be limited by the rate
of Ag endocytosis, leading to maximal off-rates in the range of
103 to 104 s1 and that the on-rates cannot exceed the maximal
rate of diffusion in the range of 105 to 106 M1 s1. Thus, the
immune system should not be able to select for affinity constants
(KD) beyond 0.1 nM, although such Abs might arise by chance.
Genetic diversity of Ag-selected polyclonal Ab repertoires to-
ward complex Ags has mainly been studied by using phage display
technology because of its ability to screen massive numbers of V
gene sequences. As a recent example, 55 uniquely rearranged H
chain variable domain (VH)2 sequences were isolated by phage
display from two human donors immunized with a rabies vaccine
(8). However, phage display involves the random pairing of H and
L chain genes, which often leads to a drop in affinity. Conse-
quently, only about one-third of the anti-rabies Abs appear to be of
high affinity. In addition, phage display preferentially selects for
promiscuous VH domains, which further reduces the diversity of
the Ag-specific repertoires isolated by phage display (9, 10). Thus,
although it is currently the preferred method for studying the com-
position of Ag-specific repertoires, phage display is likely to un-
derestimate the actual VH diversity generated by the immune sys-
tem and, further, provides no information regarding cognate L
chain usage and, hence, native affinities.
We have recently reported a novel strategy, the Symplex Technol-
ogy, for the isolation of comprehensive repertoires of cognate pairs of
Ab V genes directly from human plasma cells (10). The screening of
such V gene repertoires allows for simultaneous analysis of the clonal
and functional diversity of the Ag-selected human Ab repertoire. In
this study we examine the genetic diversity and binding characteristics
of two comprehensive panels of distinct mAbs obtained from single
individuals immunized with a tetanus toxoid (TT) vaccine. Our results
have implications for the understanding of the mechanisms that lead
to a polyclonal response and for the limits of the selective forces
responsible for affinity maturation.
Materials and Methods
Donors and vaccination
Two healthy volunteers were boosted with a TT vaccine (Statens Serum
Institut, Copenhagen, Denmark) in the musculus deltoideus. Both donorsDepartment for Antibody Discovery, Symphogen A/S, Lyngby, Denmark
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were Caucasian adults (designated TT01, a male, and TT02, a female)
residing in Denmark and both had been challenged with TT several times
before this study. Six days after the vaccination, blood (200 ml) was col-
lected in anticoagulant. The project was approved by the Regional Ethical
Review Board in Copenhagen, Denmark, and informed consent was ob-
tained from each donor.
Ab libraries were constructed according to Meijer et al. (10) from
plasma blasts isolated on a FACSAria cell-sorting system (BD Bio-
sciences) from freshly drawn blood. Shortly, PBMC were isolated using
Lymphoprep (Axis-Shield) and enriched for B cells by a CD19 MACS
procedure. B cells that stained positive for CD19, highly positive for CD38,
and intermediately positive for CD45 were single cell-sorted directly into
wells of 96-well PCR plates and designated plasma cells. H chain and  L
chain variable region genes were linked and amplified by RT-PCR. Am-
plified genes were pooled and inserted into a bacterial Fab expression vec-
tor and transformed into Escherichia coli. Fabs were expressed and
screened for activity against TT by ELISA. All positive clones were se-
quenced and the VH-V sequences were aligned to group clones according
to sequence homology. For each group, the V-D-J usage and location of
somatic mutations were determined by alignment with germline sequences
using the ImMunoGeneTics sequence directory (www.ebi.ac.uk; http://
imgt.cines.fr). The phylogenetic trees were generated using ClustalW
(www.ebi.ac.uk).
Construction of deduced germline Fabs
Protein sequences of two Fabs without hypermutations were constructed by
aligning mutated Ab sequences from common rearrangements in the two
donor repertoires (VH1–69-JH6 V1–27-J3 and VH3–21-JH6 V1–39-J1;
where JH is H chain joining region) to germline protein sequences of V and
J segments (http://imgt.cines.fr). The more common CDR3 sequence mo-
tifs of each H and L chain rearrangement were inserted in each synthetic
protein sequence (underlined in Figs. 2 and 3). Each protein sequence was
back translated and AscI and XhoI restriction sites were added to the ends
of VH sequences. Furthermore, an L chain  constant domain was added to
each L chain variable region and NheI and NotI restriction sites were added
to the ends of L chain genes. Finally, the genes were optimized for ex-
pression in E. coli and synthesized (GeneArt). Each synthesized gene was
cloned into a vector and plasmid DNA was purified from transformed E.
coli (GeneArt). Each gene was released from its vector with the appropriate
combination of restriction enzymes, and fragments were subsequently pu-
rified by preparative 1% (w/v) agarose gel electrophoresis. L chain genes
were subcloned into pJSK301. Subsequently, VH regions were subcloned
into the L chain gene-containing vectors. Plasmid DNA was sequenced
(AGOWA) and verified. Expression of TT-specific Fab expression was
verified by ELISA.
Multiple alignments
A genetic phylogeny analysis was conducted to assess the homology of all
206 Abs from donors TT01 and TT02. A phylogenetic cladogram (data not
shown) was generated by submitting FASTA formats of variable region
amino acid sequences (combined H and L chain sequences) of all Abs to
the European Molecular Biology Laboratory-European Bioinformatics In-
stitute online phylogeny analysis program, ClustalW (http://www.ebi.
ac.uk/clustalw/) (11), using default settings. The cladogram containing
only affinity-measured Abs (see Fig. 5) was generated similarly.
Statistical calculations of repertoire sizes
According to Behlke et al. (12) the probability of observing exactly d
distinct gene rearrangements among a total number of r examined se-
quences for a fixed number n of distinct gene rearrangements is shown in
Equation 1,
FIGURE 1. V and J gene segment
usage and distributions of H chain
CDR3 lengths. Distribution of H
chain gene segment usage, VH (A) and
JH (B), and L chain gene segment us-
age, V (C) and J (D) in the Ab rep-
ertoires of TT01 (gray bars; n 122),
TT02 (open bars; n  84), and a pre-
viously described naive peripheral
IgM B cell repertoire (13, 14) (filled
bars, nVH  350, nJH  206, nVK,JK 
321). H chain CDR3 lengths (E) of
the present set of sequences from do-
nor TT01 (green bars; n  122) and
TT02 (red bars; n  84) in compari-
son to a set of randomly selected H
chain CDR3 lengths (black bars; n 
177) (18) as well as a set of CDR3
lengths of highly restricted
anti-rhesus D Abs (yellow bars,
n  68) (15).
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Pd  Sr,dndd!nr (1)
where S(r,d) are Stirling’s numbers of the second kind. The analysis as-
sumes that no significant skewing of the data set by nonrandom gene seg-
ment usage has occurred.
For donor TT01 the maximum likelihood estimate of n was n  29 for
d and r fixed at d  29 and r  122, whereas the maximum likelihood
estimate for donor TT02 was n  48 for d  40 and r  84. A 95%
one-sided confidence of the estimates were calculated by determining the
smallest value of n for which the probability of observing d distinct gene
rearrangements among r examined sequences was 5%. This returned a
value of n  31 for donor TT01, whereas the 95% confidence for donor
TT02 was bound at n  57.
Surface plasmon resonance (SPR)
Fabs were expressed in culture volumes of 100–300 ml depending on
expression levels. Bacteria were grown at 37°C in 2 YT broth supple-
mented with 100 g/ml carbenicillin and 0.1% glucose until the A600 value
reached1.3, after which isopropyl--D-thiogalactopyranoside was added
to a final concentration of 0.1 mM and the culture was continued overnight
at 30°C. Bacteria were pelleted by centrifugation and the periplasmic frac-
tion was extracted by resuspending the pellet in 1–3 ml (depending on
FIGURE 2. Alignment of cluster 1 VH and V gene amino acid sequences. The CDR3 consensus motif of each H and L chain cluster is indicated
below each group of sequences. Dots represent amino acids similar to the germline sequence or the CDR3 consensus motif. Amino acids that differ
from those found at the same position in the germline/consensus sequence are indicated by the letter of the replaced amino acid. A deletion is
indicated by a dash (-). Each clone is denoted by the donor number (1 or 2, corresponding to donor TT01 and TT02, respectively) followed by the
clone name (e.g., 60D04).
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culture volume) of ice-cold PBS containing 0.94 M NaCl and 0.8 mM
EDTA. Fabs were further purified on protein L spin columns according to
the manufacturer’s instructions (Pierce). The concentration of Fab was de-
termined by an indirect immunoassay using a purified Fab as standard. SPR
analysis was performed using a Biacore 2000 apparatus (Biacore AB). TT
was immobilized on a CM5 chip surface using standard amine coupling
chemistry to a level resulting in a maximum response unit (RU) value of
100 RU or less. Purified Ab Fab were diluted serially in HBS-EP
running-buffer (10 mM HEPES (pH 7.4), 0.15 M NaCl, 3 mM EDTA,
0.005% surfactant P20; Biacore) and passed over the chip at 50 l/min.
All measurements were conducted at 25°C. In most cases, association
was measured for 5 min and dissociation for 20 min. However, for Fab
with very slow off-rates (below 1  104 s1), dissociation was mea-
sured for longer periods of time, up to 16 h, depending on the off-rate.
Rate constants (kon and koff) and affinity constants (KD) were determined
using the BIAevaluation software (Biacore) by the global fitting of 4 – 6
different concentrations passed over the same sensor surface. Global fits
of kon and koff simultaneously gave average 2 values of 1.8 and 0.8,
respectively.
Results
Isolation of Ab repertoires
Ab repertoires were, as reported previously (10), made from
plasma cells obtained from blood of two healthy volunteers (do-
nors TT01 and TT02) after a boost with TT. Using the Symplex
Technology, which involves high throughput single-cell sorting,
single-cell RT-PCR, and bulk cloning of the isolated IgG H chain
and  L chain variable region gene pairs (VH-V), repertoires were
generated with preservation of the cognate H and L chain pairing.
These repertoires were subsequently expressed in bacteria and
screened for Ag reactivity. This led to the isolation of 122 and 84
unique tetanus-specific VH-V gene products from donor TT01 and
TT02, respectively.
Statistical analysis of repertoire sizes
Based on V and J gene segment usage and CDR3 sequence ho-
mology, we estimated the numbers of rearrangement events in the
isolated Ab repertoires to be 29 and 40 events for donor TT01 and
TT02, respectively. Because the number of isolated sequences for
each donor is much larger than the number of rearrangements (four
and two times larger for TT01 and TT02, respectively), it appears
reasonable to make statistical predictions of actual repertoire sizes
based on the isolated libraries. The analysis is based on the as-
sumption that no significant skewing of the data set by nonrandom
gene segment usage occurred (12). It calculates the statistical num-
ber of distinct rearrangements (the statistical/theoretical repertoire
size) from the number of examined sequences and the number of
rearrangements in the data set. This analysis returned statistical
maximum likelihood estimates of the repertoire size of 29 and 48
distinct rearrangement events for donor TT01 and TT02, respec-
tively. Ninety-five percent one-sided confidences were calculated
as the smallest number of rearrangements for which the probability
of observing the distinct number of gene rearrangements among
the number of examined sequences was 5%. These confidences
returned values of 31 and 57 rearrangement events for donors
TT01 and TT02, respectively.
Distribution of variable gene fragment usage in human anti-TT
Ab repertoires
Major structural restrictions of an Ab response can be identified by
a genetic analysis of the variable region gene segment usage.
Hence, the distributions of V gene segments and J gene segments
for the VH and V genes of donor TT01 and TT02 were analyzed
and compared with a naive repertoire from peripheral IgM B
cells (13, 14) (Fig. 1). Both TT repertoires showed extensive di-
versity in their V gene segment usage. The five most prevalent H
chain V gene segment families were found with only minor dif-
ferences relative to the naive repertoire (Fig. 1A). The H chain J
gene segment usage also followed the naive repertoire except for
the JH5 gene segments, which were less frequently used (Fig. 1B).
The distribution of -chain V gene families followed the naive
repertoire dominated by the V1 and V3 families, although the
V2 gene family was less prevalent in the TT repertoires (Fig. 1C).
Similarly, -chain J gene segment usage showed a similar distri-
bution between the repertoires except for J5 which was less fre-
quent in the TT01 repertoire (Fig. 1D). Thus, the TT repertoires
showed extensive diversity without any major biases in V and J
gene segment usage.
Distribution of H chain CDR3 lengths
Binding site topology is highly dependent on the length and com-
position of the CDR3 of the H chain. Hence, restricted Ab re-
sponses have been shown to select for CDR3 loops of particular
lengths (15–17). Fig. 1E shows the distributions of the CDR3
lengths of donor TT01 and TT02 in comparison to a randomly
selected set of Abs with different specificities (18) and a highly
restricted anti-rhesus D Ab repertoire (15). The distribution of the
randomly selected Ab repertoire is relatively broad, going from 3
to 27 aa with an average CDR3 length of 14. In marked contrast,
FIGURE 3. Alignment of cluster 2 VH and V gene amino acid sequences. Sequences are represented as in Fig. 2.
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the highly restricted rhesus D Ab repertoire shows a narrow dis-
tribution ranging from 14 to 30 aa with a prominent peak of 18
aa. The CDR3 length distributions of donor TT01 and TT02 are
both broad, ranging from 8 to 26 aa, indicative of an unrestricted
response. However, both TT repertoires showed an increased pref-
erence for longer CDR3 lengths of 15 or 16 aa, leading to av-
erages of 17 and 16 aa, respectively, which was higher than the
unselected repertoire. Thus, although the TT responses were di-
verse in their requirement for CDR3 lengths, there was a bias
toward more extensive contact regions.
Sequence homology among Abs within and between
anti-TT repertoires
Structurally restricted Ab responses are known to lead to almost
identical Abs from different individuals (15, 16). To investigate
whether any of the V gene diversity was shared between the two
donors, a multiple alignment was performed on the combined set
of 206 VH and V sequences (data not shown). V gene sequences
of the two donors were evenly distributed throughout the cla-
dogram. This indicates that both donor repertoires possessed ex-
tensive diversity with no dominating preferences for particular V
genes in agreement with the previous analyses. However, two clus-
ters of homology contained V gene sequences from both the TT01
and TT02 repertoires. The VH and V sequences were aligned sep-
arately for each of the two clusters. Abs belonging to cluster 1
(Fig. 2) all had H chain CDR3 lengths of 15 aa containing the
LGGTR consensus motif or single amino acid variants thereof.
There was an exclusive usage of the JH6 gene segment and the V
gene alleles VH1-69 or VH3-21. The -chain V gene usage was
restricted to the alleles V1-27 and V3-20, whereas CDR3 length
varied from 9 to 10 aa and -chain J usage involved J1, J2, and
J3. In total, the different H and L chain rearrangements made up
FIGURE 4. Binding constant distributions. A–C, Distributions of on-rates (A), off-rates (B), and affinity constants (C) of anti-TT Fab. Data originating
from donor TT01 (n  28) are indicated by gray dots whereas data from donor TT02 (n  21) are indicated by black dots. The black bars show the median
of each data set. Arrows indicate that the dissociation of this particular Ab Fab (clone 60F01) was too slow to measure accurately using SPR, hence only
giving an upper limit for off-rate and affinity. Dashed gray lines indicate theoretical limits proposed by Foote and Eisen (7). D–F, Normal fractile plots of
on-rates, off-rates, and affinity. The horizontal axis presents kinetic values (xi) whereas the vertical axis indicates normal fractiles (Ui). Clone 60F01 was
left out of the distribution analyses of koff (E) and KD (F).
Table I. Kinetics and affinity constants of Abs with deduced germline variable region genes and their hypermutated variants and the influence of
hypermutations on Ab binding
Rearrangement
clustera Clone
On-Rate
(M1 s1)
Off-Rate
(s1)
t1/2
(min1)
Affinity
(M)
No. of Hypermutations
(VH  V)
1 Germline VH1–69-JH6 V1–27-J3 3.0  106 3.3  104 35 1.1  1010 0  0
60D05 (VH1–69-JH6 V1–27-J3) 6.4  106 1.7  105 670 2.7  1012 13  6
62D09 (VH1–69-JH6 V1–27-J3) 2.7  106 5.6  105 210 2.1  1011 10  6
63B12 (VH1–69-JH6 V1–27-J3) 4.6  106 7.4  105 160 1.6  1011 10  4
2 Germline VH3–21-JH6 V1–39-J1 6.8  105 1.7  101 0.1 2.5  107 0  0
63D10 (VH3–21-JH6 V1–39-J1) 1.0  105 4.2  104 28 4.0  109 14  13
60A02 (VH3–21-JH3 V1–27-J2) 9.1  103 1.3  104 90 1.4  108 0  0
a Related to cluster numbers in Figs. 2 and 3.
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five different assemblies of Ab germline genes. Competitive bind-
ing studies among Abs belonging to cluster 1 by SPR revealed that
they all recognized overlapping epitopes (data not shown). Abs
using the VH1-69 all originated from the TT01 repertoire and could
therefore potentially be of common clonal origin, and their differ-
ential usage of three different V genes could be explained by
receptor revision (19). However, the Abs appeared to be the result
of independent rearrangement events because only few somatic
mutations were shared among the VH genes, which contrasts with
previous examples of receptor revision of Ab L chains (20), and
because differences within CDR3 were mainly located in the H
chain V-D and D-J joining regions, which are encoded by random
insertion/deletion of nucleic acids and thus typically unique for
each clonal rearrangement. An analysis of silent mutations confirmed
FIGURE 5. Relationship between
genetic and functional diversity. Left-
hand column shows H chain CDR3
sequences ordered by a cladogram
(red, TT01; green, TT02). Middle col-
umn presents the affinity in nanomo-
lar measured for each Fab. Clonally
related Abs are marked by blue
boxes. The affinity of the Ab marked
by an asterisk (; belonging to clone
60F01) could not be measured pre-
cisely because it has a very slow off-
rate that is beyond the detection limits
of SPR. The affinity was estimated to
be 1 pM. Difference in variance of
affinities was tested by a two-sided F
test on variance in affinities within
each of the eight groups of clonally
related Abs against the variance of all
measured affinities. p values returned
by the test are shown in the right-
hand column for each of the eight
groups.
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these observations (not shown). Selection of such highly homologous
albeit clonally independent Abs was further demonstrated by the
remaining Abs belonging to cluster 1, which were isolated from both
the TT01 and the TT02 repertoires. Thus, it appeared that Abs from
TT01 belonging to cluster 1 were the result of four independent re-
arrangement events rather than being the result of receptor revision of
a single B cell progenitor. Cluster 2 (Fig. 3) consisted of Abs from the
TT01 and TT02 repertoire characterized by having H chain CDR3
lengths of 8 aa containing the (S/T)SG(S/T)L motif and L chain
CDR3 lengths of 9 aa containing a central QTYS consensus motif.
There was an exclusive usage of the VH3-21 allele together with JH6
paired with a L chain having the V1-39 allele joined to J3. Fur-
thermore, several somatic mutations were shared between the Abs
independently of donor origin. This further demonstrated the selection
of highly homologous albeit clonally independent Abs. Together,
these observations indicated that structural restrictions were indeed
shaping parts of the Ab repertoire against TT despite the extensive
overall diversity of the TT01 and TT02 repertoires and the vast com-
plexity of the antigenic surface.
Binding characteristics of Abs in germline configuration
To investigate whether the Abs of cluster 1 and 2 originated from
germline Abs of particularly high affinity, Fab genes were con-
structed in their deduced germline configuration and their binding
constants were determined by SPR (Table I). Cluster 1 appeared to
originate from a germline Ab of fast association and slow disso-
ciation leading to high affinity, whereas cluster 2 originated from
an Ab of fast association and fast disassociation leading to a rel-
atively modest affinity. One Ab, 60A02, isolated from TT01, was
without any identifiable hypermutations and had a modest on-rate
and a slow off-rate leading to high affinity, although not as high as
that seen for cluster 1. These observations indicate that Abs of the
primary repertoire can be of high affinity and have interactions of
relatively high stability. Further, comparison of the binding con-
stants of the hypermutated Abs with their deduced germline coun-
terparts revealed that the positive effects of hypermutations were
mainly acting by lowering the off-rates whereas the on-rates were
both positively and negatively affected by the hypermutations.
Moreover, in both cluster 1 and 2 hypermutations lead to an100-
fold increase in affinity.
Distribution of affinity and binding rate constants
To address the proposed limits for Ab affinity and kinetics, we
determined the binding rate constants of representative sets of Abs
from the TT01 and TT02 repertoires. The association rate (kon),
dissociation rate (koff), and affinity constant (KD) values of 28
TT01 and 21 TT02 Fabs were determined by SPR (Fig. 4, A–C).
Association rates showed a wide range of distributions covering
almost 5 orders of magnitude. The medians for the TT01 and TT02
repertoires were of similar magnitude at 1.77  105 M1 s1 and
1.10  105 M1 s1, respectively. The dissociation rates of TT01
ranged	2 orders of magnitude with a median value of 1.6 104
s1 whereas the TT02 repertoire was more restricted covering, 1.5
orders of magnitude with a median value of 3.6  104 s1. Af-
finity constants showed the widest range covering up to 6 orders of
magnitude with median values of 9.3  10 10 M and 3.6  109
M for the TT01 and TT02 repertoires, respectively. Thus, affinities
ranged from micromolar to picomolar values and the median af-
finity of the TT01 repertoire was 4-fold higher than the median of
the TT02 repertoire due to a 2-fold difference in both kon and koff
rate medians. To examine whether binding constants were ran-
domly distributed, data sets were plotted as logarithmic normal
fractile diagrams (Fig. 4, D–F). All data sets fitted well to linear
regressions, with R2 ranging from 0.91 to 0.99 as expected for a
log-normal distribution. Hence, no obvious biases were apparent
and the data sets seemed evenly distributed around the median as
expected for a random distribution.
The relationship between V gene homology
and affinity
To investigate the relations between genetic homology and affinity,
VH and V sequences of Abs with known affinity were combined
into one single continuous sequence for each Ab and aligned ac-
cording to homology. The affinity constants were evenly distrib-
uted throughout the cladogram (Fig. 5), indicating no general cor-
relation between affinity and V gene composition. However, the
affinity between clonally related Abs varied in the order of 10- to
100-fold, which was significantly less than the 106-fold variation
observed for the whole set.
Relationship between number of somatic mutations, affinity, and
kinetics
The relationship between somatic amino acid replacements and
binding constants was investigated by plotting for each TT reper-
toire the combined number of replacements in the VH and V genes
against kon, koff, and KD (Fig. 6, A–C). The average number of
replacements for the full data set was 21 per V gene pair, whereas
the average number for donor TT01 and donor TT02 separately
FIGURE 6. Correlation between number of somatic mutations and binding constants in terms of on-rate (A), off-rate (B), and binding affinity (C). Gray
diamonds represent Abs from donor TT01 (n  28 for kon and n  27 for koff and KD) whereas filled squares represent those from donor TT02 (n  21).
Clonally related Abs (marked by blue boxes in Fig. 5) are connected by lines. The punctured horizontal line indicates the average number of hypermutations
per VH-V gene pair.
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were 23 and 19, respectively. The scattered distributions of the
data points on all plots indicated that within each repertoire there
was no correlation between the number of amino acid replace-
ments and the binding strength. This was also the case among
clonally related Abs. Plotting replacement frequencies of VH and
V separately did not change the appearance of the data (not
shown). Hence, somatic mutations had multiple effects on Ag
binding, reflecting the intrinsic properties of random somatic di-
versification. Regardless, the higher replacement average of TT01
relative to TT02 correlated with the increased average in binding
strength, supporting the notion that somatic mutations, together
with Ag selection, lead to enhancement of the overall affinity of Ab
repertoires.
Discussion
To determine the diversity, affinity, and kinetic limits for the hu-
man polyclonal Ab response we have examined the genetic diver-
sity and binding characteristics of comprehensive panels of mAbs
obtained from two individuals immunized with TT. The Ab rep-
ertoires were generated using a novel technique for the efficient
cloning of cognate pairs of human Ab V genes from single plasma
cells, the Symplex Technology (10). These repertoires consisted of
122 and 84 unique tetanus-specific V gene pairs and can thus be
considered the most authentic Ag-specific Ab repertoires of single
individuals reported to date.
The two TT repertoires showed extensive diversity in their V
gene family and J gene segment usage for the VH and V genes
without any major biases toward certain gene segments. The extent
of the diversity was similar to a naive repertoire from peripheral
IgM B cells (13, 14) and thus matched the extensive structural
complexity of the TT surface, which creates a vast number of
putative Ab epitopes. The TT responses were also diverse in their
requirement for VH-CDR3 lengths, although there was a bias to-
ward a more extensive CDR3 relative to a randomly selected rep-
ertoire of different specificities (18). This concurs with a previous
report, which showed that secondary response repertoires on av-
erage use longer CDR3 than primary repertoires (21), leading to
the hypothesis that large Ags may skew the VH repertoire toward
longer CDR3 loops by allowing more contact points and, hence,
higher affinity for the Ab combining site.
Despite the extensive genetic diversity found within each rep-
ertoire, we found two shared clusters of highly homologous V
genes. Within each cluster, members were characterized by CDR3
consensus motifs, restricted V and J gene segment usage, and char-
acteristic amino acid replacements. Further, within the TT01 rep-
ertoire it appeared that highly homologous albeit clonally unre-
lated Abs were selected from the naive repertoire. Thus, despite
the vast complexity of the antigenic surface of TT there was a
common preference for certain V gene configurations. To test
whether this was caused by high native affinity of these particular
rearrangement events, V gene pairs of each cluster were synthe-
sized in their proposed germline configuration and expressed as
functional proteins. The affinity constants (KD) of cluster 1 and 2
germline Ab Fabs were 1.1  10 10 M and 2.7  107 M, i.e.,
of high and intermediate affinity, respectively (Table I). Thus, se-
lection of these highly homologous V gene sequences appears to be
caused by their relatively high native affinity for TT. Further, we
found one Ab without somatic mutations in the TT01 repertoire
with a KD of 1.4  108 M. Although this Ab did not belong to
any of the shared clusters, it confirmed the possibility of naive Abs
of high affinity from primary repertoires. This raises the question
of whether such naive high affinity Abs are due to the evolutionary
selection of certain innate V genes matching common pathogens
(in this case tetanus toxin) or whether it simply reflects a random
occurrence of rare high-affinity B cell clones within the naive rep-
ertoire. The latter possibility appears the most likely, because high-
affinity Abs without hypermutations have also been observed in
human responses against the rhesus D Ag (15), in short term re-
sponses in mice toward lysozyme (6, 22), and in mice responding
toward a nonpathological viral infection (5).
Selection of high-affinity Abs in vitro from naive phage display
libraries of 1010 clones or greater has resulted in Ab affinities in the
subnanomolar range (23). Considering that the total number of
naive B lymphocytes in the human organism is 	1010, it appears
reasonable to expect a similar selection of such high affinity Abs
from the primary repertoire in vivo. Further considering the oc-
currence of naive high-affinity Abs a purely statistical event, it
follows that structurally complex Ags harboring an exhaustive set
of epitopes are more likely to select for early high-affinity Abs
relative to less complex Ags harboring only a few epitopes. Such
an argument would explain the lack of early high-affinity Abs in
the first reports on anti-hapten responses in mice that contrasts the
later observations on structurally more complex protein Ags. Al-
ternatively, the absence of early high-affinity Abs in responses
against haptens can be explained by the multivalency of the Ag
when coupled to the carrier protein, which contrasts the monova-
lency of the protein Ags mentioned above. Hence, anti-hapten re-
sponses would be dominated by avidity effects favoring the selec-
tion of low-affinity Abs in the primary response (24).
Based on V gene sequence homology, we have estimated the
number of clonal selection events creating the two isolated anti-TT
IgG/ Ab repertoires to be 29 and 40 events, respectively. These
repertoires can be considered representative of the native Ag-se-
lected repertoires from the two donors for several reasons. Firstly,
the isolation of clonally related Abs within a repertoire indicated
good sampling of the existing repertoire. Secondly, the isolation of
highly homologous albeit clonally unrelated Abs within a reper-
toire as well as between repertoires further indicated good sam-
pling of the actual repertoires. Third, phage display on combina-
torial libraries that was made using total RNA from TT01 blood
cells (our unpublished data) gave, in 95% of the cases, VH rear-
rangements identical to those identified with Symplex. Statistical
analysis of the data set of each donor returned 95% confidences at
31 and 57 rearrangement events for the IgG/ Ab repertoires of
donor TT01 and TT02, respectively. However, actual repertoire
sizes are likely to be somewhat larger than estimated by pure sta-
tistics because the statistical analysis is based on the assumption
that all clones are equally represented within the repertoire. Thus,
further assuming that the V repertoire, which typically constitutes
40% of a human Ab response, is of equal complexity, the Ag-
selected repertoires against TT is estimated to be in the order of
100 clonally unique Abs in addition to hypermutated variants
thereof.
Dissociation and association rate constants of biologically active
molecules are normally in the range of 100 to 105 M1 s1 and
102 to 107 M1 s1, respectively. Low affinity receptors are
characterized by having slow on-rates in the range of 102 to 104
M1 s1 and/or fast off-rates in the range of 100 to 102 s1,
whereas high affinity receptors are characterized by having fast
on-rates in the range of 105 to 107 M1 s1 and/or slow off-rates
in the range of 103 to 105 s1. Both TT repertoires essentially
cover the entire biological range of kon values, indicating no spe-
cial preference for a particular kon. In contrast, the koff range of
both repertoires had a lower limit of 2  103 s1, which is well
beyond what is generally found for low-affinity ligands. Even
though we found examples of unmutated Abs of high intrinsic
affinity, it must be assumed that most of the Abs were initially of
relatively low affinity (and fast dissociation) as exemplified by the
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fast dissociation rate of cluster 2 in germline configuration. Fur-
ther, the ELISA used for the screening and selection of clones for
this study were able to identify TT Abs with fast dissociation ki-
netics from phage display libraries (our unpublished results), ver-
ifying that the observed lower limit for dissociation is not a con-
sequence of technical limitations. Thus, it appears that the off-rate
is subjected to more stringent requirements for efficient clonal ex-
pansion and selection than the corresponding on-rate. Differential
effects of the two kinetic parameters on clonal selection have pre-
viously been observed (2, 24, 25) and are also the rationale behind
the proposed affinity limits for the maturing Ab response (7). Al-
though studies using B and T cell hybridomas have demonstrated
that Ab-mediated Ag presentation requires an off-rate of at least
0.5 M s1 (25), our findings suggest that this limit is moved a
further 250-fold to 2  103 s1 in order for efficient clonal ex-
pansion and selection in a developing Ab response in vivo. Inter-
estingly, this minimum half-life of Ab/Ag interactions of 5.7 min
corresponds to the estimated half-life of 8 min for membrane-
bound IgG, which offers an explanation for the requirement for
high affinity for the Ab-mediated internalization of monovalent
and soluble Ag by specific B cells for presentation to T cells at the
beginning of a T cell-dependent humoral response (24). Further
emphasizing the importance of off-rates on clonal selection, we
found that the affinity maturation due to somatic mutations within
cluster 1 and 2 mainly affected dissociation with little or even
negative effect on association.
The even distribution of affinities and kinetic rate constants
around their medians follows a log-normal distribution. This con-
curs with the random nature of somatic rearrangement and hyper-
mutation events and is in agreement with clonal selection being
based solely on ligand binding characteristics. Median values were
all close to the proposed theoretical limits, which further supports
the existence of an affinity ceiling based on positive selection.
Because both repertoires yielded similar median values and
showed extensive diversification by somatic mutation as expected
for highly matured Ab repertoires, it appears reasonable to make
predictions regarding the kinetic and affinity limits for positive
selection of B lymphocytes: association rates accumulated at 105
and dissociation rates at 104, leading to an affinity ceiling of
109 M. These predictions are supported by a previous report
finding a similar affinity ceiling of 0.5  109 M in Ab repertoires
from mice responding to a viral infection (5). However, the affinity
ceiling does not appear discrete, because evidence for affinity mat-
uration beyond 10 10 M was observed within cluster 1. Thus, the
possibility remains that the ceiling is at an even higher affinity than
suggested. One such additional factor that could push the affinity
ceiling even further into the lower picomolar range could be in-
terclonal competition for limited amounts of Ag (25).
Both repertoires were extensively mutated, indicative of a
highly matured response. Within each repertoire it was not possi-
ble to observe any correlation between binding strength and level
of amino acid replacements, even among clusters of Abs of iden-
tical clonal origin, indicating that the repertoire was saturated in
terms of somatic alterations. The only positive correlation between
the level of hypermutation and affinity was between the two rep-
ertoires. TT01 had a median affinity 4-fold above that of TT02,
which correlated to the averages of 23 and 21 aa transitions per V
gene pair, respectively. Thus, even though both repertoires were
saturated with hypermutations, the overall effect on affinity was
still positive.
The observation that for germline Abs of clusters 1 and 2 affinity
maturation led to maximally a 100-fold increase in affinity and the
observation that Ab affinity was generally restricted to vary 10- to
100-fold among clonally related Abs point to the possibility that
each rearrangement carries a limited potential in regard to affinity
maturation. This is in agreement with previous observations in
which secondary responses of enhanced affinity involved changes
in V gene usage (2) and also in agreement with the limitations on
affinity maturation imposed by particular amino acid replacements
in developing anti-hapten Ab responses in mice (26). It further
implies that the large affinity range spanning six logarithmic units,
observed for both TT repertoires, is mainly due to differences in
native affinity among the Abs selected from the primary repertoire.
An extensive range of affinities in the primary repertoire would
also explain the observation of early high affinity Abs as discussed
above.
We here present a molecular analysis of two human Ab re-
sponses against TT. Each repertoire is composed of extensive
genetic diversity involving most V gene families and J gene seg-
ments. The repertoires appear unrestricted and representative, and
the human polyclonal repertoire can thus be estimated to be in the
order of 100 clonal selection events. Affinity and association con-
stants are evenly distributed over a relatively large range, whereas
dissociation rates cover a more restricted range of relatively slow
dissociation. Further, we find evidence that affinity maturation
mainly favors reduction in dissociation rates. Hence, the dissoci-
ation and association rates have a differential effect on the devel-
oping Ab response, with more strict requirements for the dissoci-
ation rates. Finally, identification of high-affinity Abs without
hypermutations in combination with a relatively modest effect of
hypermutations on affinity increases indicates that the primary rep-
ertoire has a relatively large affinity span into the subnanomolar
range. Taken together, our results have implications for the under-
standing of the development of human Ab responses and for the
understanding of polyclonality in an immunological context.
Acknowledgments
We thank Johan Lantto and Klaus Karjalainen for careful reading of the
manuscript.
Disclosures
All authors are employees (with equity interests) of Symphogen, a biotech
company that is developing recombinant therapeutic polyclonal antibodies.
References
1. Neuberger, M. S. 2002. Novartis Medal Lecture, antibodies: a paradigm for the
evolution of molecular recognition. Biochem. Soc. Trans. 30: 341–350.
2. Foote, J., and C. Milstein. 1991. Kinetic maturation of an immune response.
Nature 352: 530–532.
3. Sagawa, T., M. Oda, M. Ishimura, K. Furukawa, and T. Azuma. 2003. Thermo-
dynamic and kinetic aspects of antibody evolution during the immune response
to hapten. Mol. Immunol. 39: 801–808.
4. Liu, J., L. Liu, and R. Jemmerson. 2000. Immunoglobulin gene joints compensate
for reduced on-rates imposed by somatic mutations in a VH gene. Mol. Immunol.
37: 95–105.
5. Roost, H. P., M. F. Bachmann, A. Haag, U. Kalinke, V. Pliska, H. Hengartner,
and R. M. Zinkernagel. 1995. Early high-affinity neutralizing anti-viral IgG re-
sponses without further overall improvements of affinity. Proc. Natl. Acad. Sci.
USA 92: 1257–1261.
6. Goldbaum, F. A., A. Cauerhff, C. A. Velikovsky, A. S. Llera, M. M. Riottot, and
R. J. Poljak. 1999. Lack of significant differences in association-rates and affin-
ities of antibodies from short-term and long-term responses to hen egg lysozyme.
J. Immunol. 162: 6040–6045.
7. Foote, J., and H. N. Eisen. 1995. Kinetic and affinity limits on antibodies pro-
duced during immune responses. Proc. Natl. Acad. Sci. USA 92: 1254–1256.
8. Kramer, R. A., W. E. Marissen, J. Goudsmit, T. J. Visser, M. Clijsters-Van der
Horst, A. Q. Bakker, M. de Jong, M. Jongeneelen, S. Thijsse, H. H. Backus,
et al. 2005. The human antibody repertoire specific for rabies virus glycoprotein
as selected from immune libraries. Eur. J. Immunol. 35: 2131–2145.
9. Ohlin, M., H. Owman, M. Mach, and C. A. Borrebaeck. 1996. Light chain shuf-
fling of a high affinity antibody results in a drift in epitope recognition. Mol.
Immunol. 33: 47–56.
10. Meijer, P. J., P. S. Andersen, H. M. Haahr, L. Steinaa, A. Jensen, J. Lantto,
M. B. Oleksiewicz, K. Tengbjerg, T. R. Poulsen, V. W. Coljee, et al. 2006.
Isolation of human antibody repertoires with preservation of the natural heavy
and light chain pairing. J. Mol. Biol. 358: 764–772.
3849The Journal of Immunology
11. Thompson, J. D., D. G. Higgins, and T. J. Gibson. 1994. CLUSTAL W: improv-
ing the sensitivity of progressive multiple sequence alignment through sequence
weighting, position-specific gap penalties and weight matrix choice. Nucleic Ac-
ids Res. 22: 4673–4680.
12. Behlke, M. A., D. G. Spinella, H. S. Chou, W. Sha, D. L. Hartl, and D. Y. Loh.
1985. T-cell receptor -chain expression: dependence on relatively few variable
region genes. Science 229: 566–570.
13. Brezinschek, H. P., S. J. Foster, R. I. Brezinschek, T. Dorner, R. Domiati-Saad,
and P. E. Lipsky. 1997. Analysis of the human VH gene repertoire: differential
effects of selection and somatic hypermutation on human peripheral CD5/IgM
and CD5 IgM B cells. J. Clin. Invest. 99: 2488–2501.
14. Foster, S. J., H. P. Brezinschek, R. I. Brezinschek, and P. E. Lipsky. 1997.
Molecular mechanisms and selective influences that shape the  gene repertoire
of IgM B cells. J. Clin. Invest. 99: 1614–1627.
15. Andersen, P. S., M. Haahr-Hansen, V. W. Coljee, F. R. Hinnerfeldt, K. Varming,
S. Bregenholt, and J. S. Haurum. 2007. Extensive restrictions in the VH sequence
usage of the human antibody response against the Rhesus D antigen. Mol. Im-
munol. 44: 412–422.
16. Adderson, E. E., P. G. Shackelford, A. Quinn, P. M. Wilson, M. W. Cunningham,
R. A. Insel, and W. L. Carroll. 1993. Restricted immunoglobulin VH usage and
VDJ combinations in the human response to Haemophilus influenzae type b cap-
sular polysaccharide: nucleotide sequences of monospecific anti-Haemophilus
antibodies and polyspecific antibodies cross-reacting with self antigens. J. Clin.
Invest. 91: 2734–2743.
17. Kaartinen, M., G. M. Griffiths, A. F. Markham, and C. Milstein. 1983. mRNA
sequences define an unusually restricted IgG response to 2-phenyloxazolone and
its early diversification. Nature 304: 320–324.
18. Wu, T. T., G. Johnson, and E. A. Kabat. 1993. Length distribution of CDRH3 in
antibodies. Proteins 16: 1–7.
19. Nemazee, D., and M. Weigert. 2000. Revising B cell receptors. J. Exp. Med. 191:
1813–1817.
20. de Wildt, R. M., R. M. Hoet, W. J. van Venrooij, I. M. Tomlinson, and G. Winter.
1999. Analysis of heavy and light chain pairings indicates that receptor editing
shapes the human antibody repertoire. J. Mol. Biol. 285: 895–901.
21. Ohlin, M., and C. A. Borrebaeck. 1996. Characteristics of human antibody rep-
ertoires following active immune responses in vivo. Mol. Immunol. 33: 583–592.
22. Newman, M. A., C. R. Mainhart, C. P. Mallett, T. B. Lavoie, and S. J. Smith-Gill.
1992. Patterns of antibody specificity during the BALB/c immune response to
hen eggwhite lysozyme. J. Immunol. 149: 3260–3272.
23. Vaughan, T. J., A. J. Williams, K. Pritchard, J. K. Osbourn, A. R. Pope,
J. C. Earnshaw, J. McCafferty, R. A. Hodits, J. Wilton, and K. S. Johnson. 1996.
Human antibodies with sub-nanomolar affinities isolated from a large nonimmu-
nized phage display library (see comments). Nat. Biotechnol. 14: 309–314.
24. Guermonprez, P., P. England, H. Bedouelle, and C. Leclerc. 1998. The rate of
dissociation between antibody and antigen determines the efficiency of antibody-
mediated antigen presentation to T cells. J. Immunol. 161: 4542–4548.
25. Batista, F. D., and M. S. Neuberger. 1998. Affinity dependence of the B cell
response to antigen: a threshold, a ceiling, and the importance of off-rate. Immu-
nity 8: 751–759.
26. Furukawa, K., A. Akasako-Furukawa, H. Shirai, H. Nakamura, and T. Azuma.
1999. Junctional amino acids determine the maturation pathway of an antibody.
Immunity 11: 329–338.
3850 LIMITS OF HUMAN POLYCLONAL ANTIBODY RESPONSES
Paper 2 
 
1 
Title: 
Limits for affinity maturation and repertoire diversification in 
human antibody responses towards antigen 
Authors: 
Tine Rugh Poulsen, Allan Jensen, John Haurum, and Peter Sejer Andersen*  
 
Symphogen A/S 
Elektrovej Building 375 
2800 Lyngby  
Denmark 
*Corresponding author: psa@symphogen.com 
 
 
The immune system is known to generate a diverse panel of high affinity 
antibodies by adaptively improving the recognition of pathogens during ongoing 
immune responses. We here report the biological limits for antigen-driven 
affinity maturation and repertoire diversification by analyzing antibody 
repertoires in two adult volunteers after each of three consecutive booster 
vaccinations with tetanus toxoid. Maturation of on- and off-rates occurred 
independently, indicating a kinetically controlled affinity maturation process. 
The third vaccination induced no significant changes in the distribution of 
somatic mutations and binding rate constants implying that the limits for 
affinity maturation and repertoire diversification had been reached. These fully 
matured antibody repertoires remained similar in size, genetically diverse and 
dynamic. Somatic mutations and kinetic rate constants showed normal and log-
normal distribution profiles, respectively. Mean values can therefore be 
considered as biological constants defining the observed boundaries. The mean 
level of somatic mutations was saturated at 13.7 and 7.4 amino acid transitions 
per VH and VK gene segment, respectively. At physiological temperature, affinity 
maturation peaked at kon=1.6x10
4M-1s-1 and koff=1.7x10
-4s-1 leading to a 
maximum mean affinity of KD=1.0x10
-9M. At ambient temperature, the average 
affinity increased to KD=3.4x10
-10M mainly due to slower off-rates. This 
experimentally determined set of constants can be used as a benchmark when 
analyzing the maturation level of human antibody responses. 
 
2 
When challenged with a foreign substance the immune system mounts a response of 
specific antibodies, which initially are of predominantly low to intermediate binding 
strength 1-3. Binding strength of subsequent generations of antibodies is improved by 
introducing mutations in the V regions and the resulting variants are selected on the 
basis of binding to the antigen 2-4. Kinetic boundaries for such maturation of antibody 
affinity have been proposed 5,6. By considering physiochemical limits for association rates 
(kon) and the rate of receptor internalization upon antigen binding as limiting dissociation 
rate (koff) maturation, Foote and Eisen predicted a maximum natural kon in the range of 
105-106M-1s-1 and minimal natural koff in the range of 10
-3-10-4s-1 leading to a natural 
affinity ceiling with equilibrium dissociation constants (KD) in the order of 10
-8-10-10M. 
These theoretical boundaries have been difficult to verify experimentally, due to the 
inability of existing antibody cloning techniques to generate a sufficient number of truly 
representative antibody clones from single repertoires of animal or human origin. Recent 
advances in the study of single B cells has eliminated this limitation and allowed for 
extremely detailed studies of the composition and functionality of antigen-driven 
antibody repertoires at any given time point 7-12. 
Herein, we determine experimentally the ceiling for natural affinity maturation and 
the limits for genetic diversification of human antibody repertoires developing over time 
in response to a single antigen. Antibody responses were followed in two human 
volunteers subjected to three consecutive boosts with the standard tetanus toxoid (TT) 
vaccine. Vaccinations were separated by at least 1.5 years and blood was drawn for 
analysis 6 days after each challenge, at which time point the circulating antibody 
secreting cells specific for TT are known to peak 13,14.  
Using the SymplexTM technology 15, antibody repertoires were prepared from 
circulating plasma blasts separately after each challenge. Between 2100-3600 single 
clones from each of the repertoires were expressed as Fab fragments and screened for 
TT binding and specific antibodies were picked for DNA sequencing and functional 
characterization (table 1). As previously described 11, V and J gene segment usage and 
somatic mutations were determined by aligning VH and VL gene sequences to the IMGT 
database 16.  
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The amino acid sequences of 594 unique TT-specific antibody clones were analyzed, 
and estimated to originate from at least 195 different naïve B cell progenitors (termed 
clonotypes). The entire antibody panel was highly diverse and contained germline gene 
segments from all the major families of VH, JH, VK and JK except the rarely found VK6 (see 
supplementary data).  
Despite repeated antigen challenge and consequently consecutive rounds of somatic 
mutations and affinity selection, the overall number of somatic mutations present in each 
repertoire remained constant for each donor (figure 1A). Thus, the maximum tolerated 
level of somatic mutations appeared to have been reached. Statistical analysis of the 
combined distribution of amino acid somatic mutations in all six repertoires indicate a 
normal distribution around clearly defined mean values of 13.7, 7.4, and 21.1 for VH, VL 
and the combined repertoire, respectively. Previous reports on somatic mutations 7,8,17-19 
fall within the presently observed limits, which can thus be regarded as representative 
for a fully matured response. 
The number of unique clonotypes identified in each repertoire was between 29 and 
67 (table 1) and maximum likelihood estimates of the overall repertoire sizes were 
determined as previously reported 11,20 (figure 1B). It appears that antigen-induced 
human IgH-VK repertoires do not to exceed in the order of 100 clonotypes. As the 
antigen is not imposing any restrictions to the observed responses, the observed 
limitation in repertoire sizes is likely to be intrinsic to the immune system when 
responding to large, structurally complex antigens 12,15,18,21. Approximately two thirds of 
the clonotypes in the TT2 repertoires were found associated with only a single 
vaccination event. And this fraction also increased for TT1 repertoires as vaccinations 
progressed (Figure 1B). Further, several clonotypes unique to the TT1 repertoires carried 
no somatic mutations, notably after the second booster vaccination. Together, this 
suggest a constant influx of new clonotypes from the naïve repertoire to an already 
existing repertoire. So despite repeated exposure, antibody responses against complex 
antigens remain diverse and dynamic rather than converge towards a few clonotypes 
with optimal binding properties, as it has been reported for hapten-driven responses 22-25.  
To determine the progression in affinity maturation, kon and koff were determined at 
25°C for a genetically diverse set of 19-35 antibodies from each repertoire (figure 2). 
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The differences between the six repertoires in distributions of kon values were not 
statistically significant, indicating that the ceiling for maturation of kon had already been 
reached prior to the first booster vaccinations of this study, in accordance with the fact 
that the Danish child vaccination program involves at least four tetanus immunizations. 
To quantify the limit for affinity maturation of kon, koff  and KD, selected data sets were 
combined and analyzed statistically (figure 3A-C; Table 2). The joint distribution of kon 
appeared log-normal with a geometric mean of 2.0x105M-1s-1. For both donors, 
repertoires from the first vaccination had significantly faster koff (TT1: p=0.001; TT2: 
p<0.001) indicating that the limit for maturation of koff was first reached after the second 
vaccination. Thus, to quantify the limit for affinity maturation of koff, the four data sets 
from the last two vaccinations were combined for statistical analysis. They showed a 
clear log-normal distribution with a geometric mean at 7.0x10-5s-1. As a consequence of 
the relatively dispersed and fully matured kon, differences between repertoires were 
insignificant for KD. The combined average KD from the second and third vaccinations was 
determined to be 3.4x10-10M. The log-normal distribution of binding constants is in 
accord with their logarithmic relationship with the Gibbs free binding energy. 
Multiplicative standard deviations ranged from 3.7 to 8.6 indicating strongly skewed 
distributions compared to log-normal distributions in other biological systems, where 
coefficients usually range from 1.1 to 3.226. The observed separate maturation of kinetic 
rate constants supports that maturation of antibody responses is kinetically rather than 
thermodynamically controlled1,2,27. 
To determine the limits for affinity maturation at physiologically relevant 
temperature, the rate constants were determined at 37°C for a representative set of 50 
antibodies from the last two vaccinations from both donors. As observed for 
measurements at ambient temperature, data was log-normally distributed around clearly 
defined mean values (Figure 4A-D). The geometric mean for kon was not affected by the 
change in temperature. In contrast, the koff geometric mean value increased 2.4-fold to 
1.7x10-4s-1 which corresponds to a drop in average interaction half life from 165 min. to 
70 min. when binding at physiological temperature. Combined this gave a 3.0-fold 
change in the mean KD at 1.0x10
-9M (Table 2). 
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In summary, to determine the natural boundaries for maturation of human antibody 
repertoires in response to antigen, Symplex™ repertoires were made from two human 
donors after each of three booster vaccinations with TT. Analysis of the genetic diversity, 
somatic maturations, and kinetic rate constants revealed that despite being saturated in 
terms of binding and somatic mutations, repertoires remained genetically dynamic and 
diverse. The most likely immunological significance of this dynamic behavior is that it 
provides an efficient countermeasure to the constant genetic evolution of pathogenic 
microorganisms. Finally, we provide the first experimental determination of the limits for 
antibody affinity maturation and repertoire diversification in single individuals in response 
repeated vaccinations. The identified kinetic mean constants are in accordance with the 
theoretical ranges proposed by Foote & Eisen 5 although the relatively long mean half-life 
at physiological temperature of 70 minutes suggests that apart from antigen 
internalization, with a half life of 8 minutes, additional factors such as competition for 
antigen in germinal centers 28,29 can influence the affinity maturation process. The 
reported biological constants can be used to evaluate the maturation level of antibody 
repertoires, polyclonal sera and monoclonal antibodies in particular and are hence of 
value in basic immunological science as well as in antibody drug discovery and vaccine 
development. 
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Table 1: Results of SymplexTM repertoire cloninga.  
 
Donor Boost 
no. 
Estimated 
no. of 
isolated 
antibody 
producing 
cellsa  
No. of 
bacterial 
clones 
screened 
No. of 
TT-
specific 
clones 
No. of  
clones 
sequenced 
No. of 
unique VH-
VK amino 
acid 
sequences 
Estimated 
number of 
clonotypes 
TT1 V1 400 3600 338 169 120 30b 
TT1 V2 1700 2100 427 155 108 50 
TT1 V3 2400 2600 372 176 154 67 
TT2 V1 400 3400 187 102 84 42b 
TT2 V2 1600 3500 95 82 69 36 
TT2 V3 1400 3600 104 83 59 29 
Total  7900 18800 1523 767 594 195 
aRepertoire sizes were estimated by gel electrophoresis of a representative set of single 
cell RT-PCR samples (from 10-20% of the total). Unique V genes were identified based 
on the deduced amino acid sequences from DNA sequencing. Antibodies were assigned 
as the same clonotype if they shared VH, JH, VK, and JK family segments, heavy chain 
CDR3 lengths and a consensus sequence in CDR3 for both heavy and light chains. bThe 
estimated number of clonotypes from Poulsen et al. 11 (TT1-V1 and TT2-V1) were 
adjusted from 29 and 40 to 30 and 42, respectively, due to a slightly stricter clonotype 
definition.   
 
 
 
 
 
Table 2. Biological constants for affinity maturation at different temperaturesa.  
 
  
kon, M
-1
·s-1 koff, s
-1
 KD, M 
b
 t½, min
-1, c
 
x*, geometric mean 2.0x105 7.0x10-5 3.4x10-10 165 
     
68% upper CI (x*·s*) 1.2x106 2.6x10-4 2.9x10-9 619 
68% lower CI (x*/s*) 3.1x104 1.9x10-5 3.9x10-11 44 2
5°
C 
s*, multiplicative standard deviation d 6.4 3.7 8.6 3.7 
 
     
x*, geometric mean 1.6x105 1.7x10-4 1.0x10-9 70 
     
68% upper CI (x*·s*) 7.6x105 5.5x10-4 7.6x10-9 232 
68% lower CI (x*/s*) 3.5x104 5.0x10-5 1.3x10-10 21 3
7°
C 
s*, multiplicative standard deviation d 4.6 3.3 7.6 3.3 
a Values were obtained by fitting the standard equation for a normal distribution to log10-
transformed experimentally determined data sets; b KD was calculated as koff/kon; 
c t½ 
was calculated as ln(2)/(koff/60); d Multiplicative standard deviations are unitless; 
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Materials and Methods 
Donors and vaccination 
Two healthy donors were boosted with the tetanus vaccine (State Serum Institute, 
Denmark) containing tetanus toxoid  three times each under informed consent. The first 
and the second repertoires were isolated with a 3.5 years interval and the third 
repertoires were isolated after another 1.5 years. The project was approved by the 
regional ethical committee in Copenhagen, Denmark. Blood was harvested with 
anticoagulant 6 days after vaccination.  
 
Isolation of plasma blasts and cell sorting 
Peripheral blood mononuclear cells (PBMC) were purified by density centrifugation using 
Lymphoprep (Axis-Shield PoC AS) and stained with anti-CD19-FITC (Becton Dickinson) in 
MACS buffer (phosphate buffered saline (PBS), pH 7.2, 0.5% (w/v) bovine serum 
albumin (BSA), 2mM EDTA), washed and labeled with anti-FITC conjugated magnetic 
beads in order to enrich for B cells on a MACS LS column (Miltenyi Biotec) according to 
the manufacturer’s recommendations. The first and the second repertoires were sorted 
as previously described 11,15. Shortly, the CD19-enriched fraction was resuspended in 
FACS buffer (PBS, pH 7.2, 2% fetal calf serum (FCS)) and incubated with anti-CD19-FITC 
(Becton Dickinson), anti-CD38-APC (Becton Dickinson), anti-lambda-PE (Becton 
Dickinson), and anti-CD45-PerCP (Becton Dickinson) for 20 minutes at 4°C in the dark, 
washed and resuspended in FACS buffer and stained for viability with propidium iodide 
(PI). Viable cells were sorted based on the following expression profile: 
CD38high/CD19int/CD45int/lambdaneg. For the first repertoires, single cells were distributed 
into 96 well microtiter plates by limiting dilution based on manual pipetting. For the 
second repertoires, single cell sorting was performed on a FACSAria cell-sorting system 
(Becton Dickinson) where single cells where sorted directly into 384 well PCR plates 
(Applied Biosystems).  
For the third repertoires, the sorting procedure had been optimized to the following: the 
CD19-enriched B cell fraction was resuspended in FACS buffer (PBS, pH 7.2, 2% FCS) 
and incubated with anti-CD19-FITC (Becton Dickinson), anti-CD38-PE-Cy7 (Becton 
Dickinson), anti-CD20-PerCP (Becton Dickinson), anti-CD27-APC (Becton Dickinson), 
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anti-IgD-PE (Becton Dickinson), and anti-lambda-APC-Cy7 (Becton Dickinson) for 20 
minutes at 4°C in the dark, washed and resuspended in FACS buffer. Single cell sorting 
was performed on a FACSAria cell-sorting system (Becton Dickinson) where plasma 
blasts were sorted into 384 well PCR plates (Applied Biosystems) based on the following 
expression profile: CD19int/CD38high/IgDneg/CD20neg/CD27high/lambdaneg. All FACS analysis 
was performed using FACSDiva software. 97-99% purity was detected on all single cell 
sorting. 
Plasma blasts were sorted directly into wells containing all reagents necessary for the 
Symplex PCR except for reverse transcriptase, DNA polymerase and dNTPs as described 
previously 11 and stored at -80°C for later processing. 
 
Single cell RT-PCR and PCR of antibody variable region genes 
VH and LCκ genes were amplified and linked through primer overlap extension as 
described previously 15. Briefly, VH and LCκ from each cell were amplified in a one-step 
RT-PCR reaction using a cocktail of sense primers specific for the leader regions and 
antisense primers to the Cγ constant regions for heavy chains and Cκ for the light chain. 
One microliter from each RT-PCR reaction was transferred to new plates containing 
reagents for a nested PCR and VH and LCκ genes were linked and amplified in separate 
PCR reactions using nested primers with overlap extensions and containing restriction 
sites at the ends of the heavy chain variable regions and the full κ light chains as 
previously described 15. 
 
Cloning and Screening 
Linked antibody gene fragments (VH-LCκ) were pooled and cloned into expression 
vectors using the PCR introduced restriction sites as described previously 11,15. For the 
first two repertoires from each donor, linked antibody genes were cloned into a bacterial 
Fab expression vector 15 and the gene linker was replaced by a bidirectional bacterial 
promoter fragment (lac-tac) by sub-cloning. To overcome low expression levels for many 
of the bacterial clones in the first and second repertoires, for the third repertoire from 
each donor, linked antibody genes were cloned into a mammal Fab expression vector 30 
and the gene linker was replaced by a bidirectional mammal promoter fragment (double 
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CMV promoter) by sub-cloning. The vectors were transformed into bacteria (E.coli, 
TOP10) by electroporation and transformants were selected on 2xYT or LB broth agar 
containing 100µg/ml of carbenicillin. Single E.coli colonies were picked into 96 or 384 
well plates. Fabs were expressed directly in E.coli by induction with isopropyl-β-D-
thiogalactopyranoside (IPTG) which was added to a final concentration of 0.1 mM for 
screening in the first and second repertoires. Plasmids from clones in the third repertoire 
were transfected into HEK293 cells in the following manner: 1µl suspension of E.coli 
picked into 384 plates as single clones (CFU) were lysed by incubation for 15 minutes in 
4M NaOH. Plasmid DNA was amplified using the TempliPhi Amplification kit (GE 
Amersham) by transferring 1µl lysed cell suspension to a mix of the kit enzyme and 
buffer and incubating at 30°C overnight and then inactivating the enzyme for 10 minutes 
at 65°C. TempliPhi plasmids were transfected into HEK293 cells using Optimem 
(Invitrogen) and 293Fectin (Invitrogen) in 384 well plates in FreeStyle HEK293 medium 
(Invitrogen). The plates were incubated shaking at 37°C overnight and Tryptone N1 
(Organotechnie) was added to all wells to a final concentration of 0.4%. Plates were 
incubated while shaking another 72 hours at 37°C.  
Both bacterial and mammal clone supernatants were screened for activity against TT; the 
first repertoires were screened by ELISA and the second and third repertoire from each 
donor was screened by bead based fluorescence-linked immunosorbent assay (FMAT 
8100 HTS; Applied Biosystems). At compatible number of positive clones were selected 
for DNA sequencing of V genes (Eurofins, MWG/Operon; see table 1).  The VH-Vκ 
sequences were aligned and grouped into clusters according to sequence homology. For 
each group, the V-D-J usage and location of somatic mutations were determined by 
alignment with germline sequences using the IMGT sequence directory 16. 
 
Fab production for kinetic measurements 
Fab fragments in E.coli were produced for SPR analysis (all clones selected for further 
analysis from the first repertoires and 6 and 4 clones from the second repertoire of donor 
TT1 and TT2, respectively) essentially as described previously 11. Due to low bacterial Fab 
expression levels, it was decided to express Fab in HEK293 during the expression of the 
second repertoires. The rest of the clones selected for analysis in the second repertoires 
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were cloned into the mammal HEK293 expression vector, antibody sequences were 
verified, and plasmids were transfected into HEK293 cells using Optimem (Invitrogen) 
and 293Fectin (Invitrogen) in FreeStyle HEK293 medium (Invitrogen) in volumes of 30-
100 ml. Cultures were incubated while shaking at 37°C for 6 days after which 
supernatants were harvested by centrifugation. Fab fragments were purified using Poly-
prep columns (Bio-Rad) with protein L immobilized on agarose (Pierce) according to the 
manufacturer's instructions. 
The concentration of purified Fab was determined by an indirect immuno assay. 
 
Surface plasmon resonance (SPR) 
Affinities (KD), on-rates (ka) and off-rates (kd) were determined by SPR analysis on 
Biacore 2000 (GE Healthcare/Biacore, Uppsala, Sweden) or Proteon XPR36 (Bio-Rad). 
Briefly, TT was immobilized at low ligand densities on CM5 chips (Biacore) or GLC chips 
(Bio-Rad), resulting in maximum response unit (RU) values of ~100 RU or less. Fab 
fragments were diluted to 96 or 48 nM, and rate constants were measured by injection of 
at least four serial 2-fold dilutions of the antibodies at 50µl/min. Purified Fab was diluted 
in running buffer (10 mM HEPES pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.005% surfactant 
P20 on Biacore 2000 and PBS pH 7.2, 0.005% Tween20 on Bio-Rad) and passed over the 
chip at 50 µl/min.  
All measurements were conducted at 25°C or 37°C. Association was measured for 5 min 
and dissociation for 20-30 min. However, for interactions with very slow off-rates (below 
1x10-4 s-1), dissociation was measured for longer periods of time, up to 16 h, depending 
on the off-rate. Sensorgrams were fitted globally to a single exponential 1:1 interaction 
model.using the BIAevalution or Proteon 2.0 software.  
 
Statistics 
All statistics were performed using SAS JMP 7.0 or 8.0. Log-transformed experimental 
data was fitted to the normal distribution: 
Normal distribution: 
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Estimates of the geometric mean and the multiplicative standard deviations describing 
the normal distribution were obtained using the following expressions:  
 
Geometric mean: ( )[ ]
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Legends  
  
Figure 1: statistical analysis of the frequency of somatic amino acid mutations in V gene 
segments and repertoire size. (A-C) The number of somatic mutations for each heavy 
chains (A), light chains (B) and heavy and light pair combined (C) are plotted for each 
repertoire (indicated below). Quantile box plots show distributions of the full data set 
combined containing all six repertoires. The box plots show the maximum, minimum and 
median values, the 25th and 75th interquartile values, and the 90% and 10% percentiles. 
The central diamond marks the mean with a 95% confidence interval. To the far right, 
distributions are shown as histograms including a superimposed fitted normal distribution 
profiled. “n” indicates the number of unique amino acid sequences in each data set. (D) 
Analysis of repertoire sizes. The darker shade (bottom column) represents the number of 
clonotypes observed in at least two of the repertoires from each donor. The lighter shade 
(top column) represents the clonotypes that are uniquely associated with a single 
repertoire. Diamonds illustrate statistical maximum likelihood estimates of repertoire 
sizes derived statistically from the total number of unique sequences and the number of 
clonotypes from each repertoire 11,20.   
 
 
Figure 2: limits for affinity maturation measured at 25°C. (a-c) Experimentally 
determined kon (a), koff (b), and calculated KD (c) values are plotted for each repertoire as 
indicated. Medians are shown as black bars. A two-way analysis of variance (ANOVA) was 
conducted for each data set (on-rates, off-rates, and affinities) to test for differences 
between repertoires. The arrow indicates that the off-rate of this particular antibody was 
too slow to measure accurately using SPR. Hence this data point only indicates an upper 
limit for the off-rate and affinity. (d-f) Statistical analysis of the distribution of binding 
constants. Distributions of log10 transformed kon (d), koff (e), and calculated KD (f) 
plotted as normal quantile plots (upper panels) and histograms (lower panels). Data on 
all six repertoires were combined in the analysis of on-rate and data on the last two 
vaccinations were combined for the analysis of the distribution of off-rates and affinities. 
The log10 transformed data was fitted by the normal distribution to identify the limit for 
16 
affinity maturation on kinetic constants. The horizontal line in the normal quantile plots 
represents the mean while the curved dotted lines are 95% confidence intervals. 
 
Figure 3: Limits for affinity maturation measured at 37°C. (a-c) Binding constants kon (a), 
koff (b), and calculated KD (c) were determined from a set of 50 antibodies evenly 
selected from the four repertoires of the last two booster vaccinations. (d-f) Statistical 
analysis of the distribution of binding constants measured at physiological temperature 
as presented in figure 2. 
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Figure 1 
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Figure 2  
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Figure 3 
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Supplementary information: 
Supplementary table 1a. Repertoire and affinities of antibody clonotypes from donor TT1 
Repertoire VH gene D gene JH gene H-CDR3
# of 
SHM, 
H VK gene JK gene K-CDR3
# of 
SHM, 
L
On-rate, 
25C
Off-rate, 
25C
Calc. KD, 
25C, M
On-rate, 
37C
Off-rate, 
37C
Calc. KD, 
37C, M
V1 IGHV1-18*01 IGHD1-26*01 IGHJ4*02 CARDFYSGSYRSFDYW 21 IGKV1-39*01 IGKJ1*01 CQQSYSTSWTF 6
V1 IGHV1-18*01 IGHD1-26*01 IGHJ4*02 CARDFYSGSYRSFDCW 20 IGKV1-39*01 IGKJ1*01 CQQSYSTSWTF 7
V1 IGHV1-18*01 IGHD1-26*01 IGHJ4*02 CARDFYSGSYRSFDYW 20 IGKV1-39*01 IGKJ1*01 CQQSYSTSWTF 6
V1 IGHV1-18*01 IGHD4-23*01 IGHJ4*02 CARDFYSGTYRSFDYW 30 IGKV1-39*01 IGKJ1*01 CQQSYGTSWTF 10
V1 IGHV1-18*01 IGHD4-23*01 IGHJ4*02 CARDFYSGTYRSFDHW 30 IGKV1-39*01 IGKJ1*01 CQQSYGTSWTF 10
V1 IGHV1-18*01 IGHD4-23*01 IGHJ4*02 CARDFYSGTYRSFDYW 29 IGKV1-39*01 IGKJ1*01 CQQSYGTSWTF 10 2,02E+05 1,97E-03 9,77E-09
V2 IGHV1-18*01 IGHD4-23*01 IGHJ4*02 CARDFYSGSYRSFDYW 27 IGKV1-39*01 IGKJ1*01 CQQSYGTSWTF 10
V3 IGHV1-18*01 IGHD4-23*01 IGHJ4*02 CARDFYSGSYRSFDYW 28 IGKV1-39*01 IGKJ1*01 CQQSYGTSWTF 10 1,16E+05 3,07E-05 2,64E-10
V1 IGHV1-18*01 IGHD4-4*01 IGHJ4*02 CARDYSSPYHFDYW 13 IGKV1-39*01 IGKJ2*03 CQQSKSPPYNF 10
V2 IGHV1-18*01 IGHD4-4*01 IGHJ4*02 CARDYSSPYHFDYW 14 IGKV1-39*01 IGKJ2*03 CQQSKSPPYNF 12
V2 IGHV1-18*01 IGHD4-4*01 IGHJ4*02 CARDYSSPYHFDYW 14 IGKV1-39*01 IGKJ2*03 CQQSKSPPYNF 13 1,63E+06 2,30E-05 1,41E-11 2,98E+05 7,23E-05 2,42E-10
V3 IGHV1-18*01 IGHD4-4*01 IGHJ4*02 CARDYSSPYHFDYW 15 IGKV1-39*01 IGKJ2*03 CQQSKSPPYNF 10
V3 IGHV1-18*01 IGHD4-4*01 IGHJ4*02 CTRDYSSPYYFEFW 17 IGKV1-39*01 IGKJ2*01 CQQSTGPPYTF 7 3,13E+05 2,10E-06 6,71E-12
V3 IGHV1-18*01 IGHD4-4*01 IGHJ4*02 CARDYSSPYYFEHW 11 IGKV1-39*01 IGKJ2*01 CQASNGPPYTF 9
V1 IGHV1-18*01 IGHD3-10*01 IGHJ4*02 CVRDYNGSGKYYFEYW 10 IGKV1-39*01 IGKJ2*01 CQQSYKTPYTF 7
V2 IGHV1-18*01 IGHD3-10*01 IGHJ4*02 CVRDYNGSGKYYFEYW 10 IGKV1-39*01 IGKJ2*01 ND 14
V2 IGHV1-18*01 IGHD3-10*01 IGHJ4*02 CARDYFGSGSVYYFDYW 22 IGKV1-39*01 IGKJ2*01 CQQSYRTPYTF 12 1,21E+05 4,70E-05 3,90E-10 2,56E+05 6,99E-05 2,73E-10
V2 IGHV1-18*01 IGHD3-10*01 IGHJ4*02 CARDYFGSGSVYYFDYW 22 IGKV1-39*01 IGKJ2*01 CQQSYKTPYTF 12 4,40E+04 3,30E-05 7,49E-10
V2 IGHV1-18*01 IGHD3-10*01 IGHJ4*02 CARDYFGSGSVYYFDYW 22 IGKV1-39*01 IGKJ2*01 CQQSYKTPYTF 13 5,60E+05 1,70E-06 3,03E-12
V2 IGHV1-18*01 IGHD3-10*01 IGHJ4*02 CARDYFGSGSVYYFDYW 22 IGKV1-39*01 IGKJ2*01 CQQSYKTPYTF 13
V2 IGHV1-18*01 IGHD3-10*01 IGHJ4*02 CARDYFGSGSVYYFDYW 23 IGKV1-39*01 IGKJ2*01 CQQSYKTPYTF 12
V3 IGHV1-18*01 IGHD3-10*01 IGHJ4*02 CARDYFGSGSIYYFDYW 17 IGKV1-39*01 IGKJ2*01 CQQSYSTPYTF 8 1,48E+05 7,50E-06 5,07E-11 8,46E+04 7,28E-05 8,60E-10
V3 IGHV1-18*01 IGHD6-19*01 IGHJ4*02 CARDPRTVAGMSYFLHW 5 IGKV1-39*01 IGKJ2*01 CQQTSSTMYTF 5
V3 IGHV1-18*01 IGHD6-19*01 IGHJ4*02 CARDPRTVAGMSYFLYW 5 IGKV1-39*01 IGKJ2*01 CQQTSSPMYTF 8
V1 IGHV1-18*01 IGHD3-3*01 IGHJ5*02 CARDRGRITLFGEVILRAGWFDSW 16 IGKV1D-33*01 IGKJ2*02 CQQCDSLPPVF 9 1,40E+06 5,01E-05 3,58E-11
V1 IGHV1-18*01 IGHD3-3*01 IGHJ5*02 CARDRGRITLFGEVILRAGWFDSW 16 IGKV1D-33*01 IGKJ2*02 CQQCDSLPPVF 9
V1 IGHV1-18*01 IGHD3-3*01 IGHJ5*02 CARDRGRITLFGEVILRAGWFDSW 16 IGKV1D-33*01 IGKJ2*02 CQQCDSLPPVF 6 9,62E+04 3,23E-05 3,36E-10
V1 IGHV1-18*01 IGHD3-3*01 IGHJ5*02 CARDRGRITLFGEVILRAGWFDSW 15 IGKV1D-33*01 IGKJ2*02 CQQCDSLPPVF 9
V3 IGHV1-18*01 IGHD3-3*01 IGHJ5*02 CARDRGRITLFGEVILRAGWFDSW 16 IGKV1D-33*01 IGKJ2*02 CQQCDSLPPVF 7 7,39E+05 3,01E-05 4,07E-11 7,18E+06 5,71E-05 7,95E-12
V3 IGHV1-18*01 IGHD3-3*01 IGHJ5*02 CARDRGRITLFGEVILRAGWFDSW 15 IGKV1D-33*01 IGKJ2*02 CQQCDSLPPVF 8
V2 IGHV1-8*01 ND IGHJ3*01 CARGGSSAFDVW 19 IGKV1D-33*01 IGKJ3*01 CQVYDNPGATF 13
V3 IGHV1-3*01 IGHD3-9*01 IGHJ6*02 CTRARNAFYTLPHYDMDVW 15 IGKV2-28*01 IGKJ5*01 CMQPLQAPPTF 3
V3 IGHV1-3*01 IGHD3-22*01 IGHJ6*02 CTRARNVHYTLPHYDMDVW 18 IGKV2-28*01 IGKJ5*01 CMQPLQAPPTF 6
V2 IGHV1-3*01 IGHD1-14*01 IGHJ4*02 CARDRWMGGYPRNFFDSW 23 IGKV1-5*03 IGKJ2*02 CQQYNANPATF 17
V3 IGHV1-69*06 IGHD3-16*01 IGHJ6*03 CARVGGGTRGYYYMAVW 13 IGKV1-27*01 IGKJ3*01 CQKYNDDLFTF 4
V1 IGHV1-69*06 IGHD4-23*01 IGHJ6*02 CARDYGGTRHYYALDAW 15 IGKV1-27*01 IGKJ1*01 CQKYNSDPRTF 4 5,84E+04 6,61E-04 1,13E-08
V1 IGHV1-69*06 IGHD7-27*01 IGHJ6*03 CARHRGGTLPYYYFDVW 16 IGKV1-27*01 IGKJ1*01 CQKYDSAPRTF 6
V2 IGHV1-69*06 IGHD4-23*01 IGHJ6*02 CARDYGGTRHYYALDAW 15 IGKV1-27*01 IGKJ1*01 CQKYNSEPRTF 6
V2 IGHV1-69*06 IGHD4-23*01 IGHJ6*02 CARDYGGTRHYYALDAW 16 IGKV1-27*01 IGKJ1*01 CQKYNSEPRTF 6 7,79E+06 1,90E-05 2,44E-12
V3 IGHV1-69*06 IGHD4-23*01 IGHJ6*02 CARDYGGTRHYYALDAW 14 IGKV1-27*01 IGKJ1*01 CQKYNSDPRTF 6
V3 IGHV1-69*06 IGHD4-23*01 IGHJ6*02 CARDYGGTRHYYALDAW 14 IGKV1-27*01 IGKJ1*01 CQKYNSDPRTF 5
V3 IGHV1-69*06 IGHD4-23*01 IGHJ6*02 CARDYGGTRHYYALDAW 14 IGKV1-27*01 IGKJ1*01 CQKYNSDPRTF 4
V3 IGHV1-69*06 IGHD4-23*01 IGHJ6*02 CARDYGGTRDYYALDAW 13 IGKV1-27*01 IGKJ1*01 CQKYNSDPRTF 6 3,55E+05 1,35E-04 3,80E-10 1,74E+05 1,84E-04 1,06E-09
V1 IGHV1-69*01 ND IGHJ6*02 CARVFGGTRLYYALNVW 16 IGKV1-27*01 IGKJ3*01 CQKYDSGLIFTF 6
V1 IGHV1-69*01 ND IGHJ6*02 CARVFGGTRLYYALNVW 15 IGKV1-27*01 IGKJ3*01 CQKYDSGLIFTF 8
V1 IGHV1-69*01 ND IGHJ6*02 CARVLGGTRLYYALNVW 14 IGKV1-27*01 IGKJ3*01 CQRYDSGLIFTF 8
V1 IGHV1-69*01 ND IGHJ6*02 CARVFGGTRLYYALNVW 14 IGKV1-27*01 IGKJ3*01 CQKYDSGLIFTF 6
V1 IGHV1-69*01 ND IGHJ6*02 CARVFGGTRLYYALNVW 14 IGKV1-27*01 IGKJ3*01 CQKYDSGLIFTF 6
V1 IGHV1-69*01 ND IGHJ6*02 CARVFGGTRLYYALNVW 13 IGKV1-27*01 IGKJ3*01 CQKYDSGLIFTF 6 6,38E+06 1,73E-05 2,71E-12
V1 IGHV1-69*01 IGHD2-2*03 IGHJ6*02 CARVLGGTRLYYALNVW 11 IGKV1-27*01 IGKJ3*01 CQKYDSGLRFTF 6
V1 IGHV1-69*01 IGHD2-2*03 IGHJ6*02 CARVLGGTRLYYALNVW 11 IGKV1-27*01 IGKJ3*01 CQKYDSGLRFTF 4
V1 IGHV1-69*01 IGHD2-2*03 IGHJ6*02 CARVLGGTRLYYALNVW 11 IGKV1-27*01 IGKJ3*01 CQKYDGGLRFTF 4
V1 IGHV1-69*01 IGHD2-2*03 IGHJ6*02 CARVLGGTRLYYALNVW 11 IGKV1-27*01 IGKJ3*01 CQKYDSGLRFTF 5
V1 IGHV1-69*01 IGHD2-2*03 IGHJ6*02 CARVLGGTRLYYALNVW 10 IGKV1-27*01 IGKJ3*01 CQKYDSGLRFTF 4
V1 IGHV1-69*01 IGHD2-2*03 IGHJ6*02 CARVLGGTRLYYALNVW 10 IGKV1-27*01 IGKJ3*01 CQKYDSGLRFTF 5
V1 IGHV1-69*01 IGHD2-2*03 IGHJ6*02 CARVLGGTRLYYALNVW 10 IGKV1-27*01 IGKJ3*01 CQKYDSGLRFTF 6 2,66E+06 5,60E-05 2,11E-11
V1 IGHV1-69*01 IGHD2-2*03 IGHJ6*02 CARVLGGTRLYYALNVW 10 IGKV1-27*01 IGKJ3*01 CQKYDSGLRFTF 4 4,64E+06 7,35E-05 1,58E-11
V1 IGHV1-69*01 IGHD2-2*03 IGHJ6*02 CARVLGGTRLYYALNVW 11 IGKV1-27*01 IGKJ3*01 CQKYDSGLRFTF 4
V2 IGHV1-69*01 ND IGHJ6*02 CARVLGGTRLYYALNVW 11 IGKV1-27*01 IGKJ3*01 CQKYDSGLRFTF 4
V2 IGHV1-69*01 ND IGHJ6*02 CARVLGGTRLYYALNVW 11 IGKV1-27*01 IGKJ3*01 CQKYDSGLRFTF 5
V2 IGHV1-69*01 IGHD1-26*01 IGHJ6*02 CARVLGGTRLYYALNVW 12 IGKV1-27*01 IGKJ3*01 CQKYDSGLRFTF 5
V2 IGHV1-69*01 ND IGHJ6*02 CGRVLGGTRLYYALNVW 12 IGKV1-27*01 IGKJ3*01 CQKYDSDLIFTF 6 2,14E+05 1,93E-05 9,02E-11
V2 IGHV1-69*01 ND IGHJ6*02 CGRVLGGTRLYYALNVW 12 IGKV1-27*01 IGKJ3*01 CQKYDSGLIFTF 7
V3 IGHV1-69*01 IGHD1-26*01 IGHJ6*02 CARVLGGTRLYYALNVW 9 IGKV1-27*01 IGKJ3*01 CQKYDSGLRFTF 4
V3 IGHV1-69*01 IGHD1-26*01 IGHJ6*02 CARVLGGTRLYYALNVW 10 IGKV1-27*01 IGKJ3*01 CQKYDSGLRFTF 4
V3 IGHV1-69*01 IGHD1-26*01 IGHJ6*02 CARVLGGTRLYYALNVW 10 IGKV1-27*01 IGKJ3*01 CQKYDSGLRFTF 5
V3 IGHV1-69*01 IGHD6-19*01 IGHJ6*02 CARVLGGTRVYYALNVW 13 IGKV1-27*01 IGKJ3*01 CQKYDSGLRFTF 5
V3 IGHV1-69*01 IGHD3-16*02 IGHJ6*02 CARVFGGTRLYYALNVW 13 IGKV1-27*01 IGKJ3*01 CQKYDSGLKFTF 7
V3 IGHV1-69*01 IGHD4-17*01 IGHJ6*02 CARVLGGTRLYYALNVW 15 IGKV1-27*01 IGKJ3*01 CQKYDSALIFTF 5
V3 IGHV1-69*01 IGHD2-2*03 IGHJ6*02 CARVLGGTRLYYALHIW 19 IGKV1-27*01 IGKJ3*01 CQKYDSGLRFTF 6
V3 IGHV1-69*01 IGHD1-26*01 IGHJ6*02 CARVLGGTRLYYAQNVW 10 IGKV1-27*01 IGKJ3*01 CQKYDSGLRFTF 4
V3 IGHV1-69*01 IGHD1-26*01 IGHJ6*02 CARVLGGTRLYYAQNVW 9 IGKV1-27*01 IGKJ3*01 CQKYDSGLRFTF 4
V3 IGHV1-69*01 IGHD1-26*01 IGHJ6*02 CARVLGGTRLYYAQNVW 9 IGKV1-27*01 IGKJ3*01 CQKYDSGLRFTL 4
V3 IGHV1-69*01 IGHD1-26*01 IGHJ6*02 CARVLGGTRLYYAMNVW 9 IGKV1-27*01 IGKJ3*01 CQKYDSGLKFTF 5 7,60E+05 5,10E-05 6,71E-11
V3 IGHV1-69*01 IGHD1-26*01 IGHJ6*02 CARVLGGTRLYYAMNVW 9 IGKV1-27*01 IGKJ3*01 CQKYDSGLKFTF 5
V3 IGHV1-69*01 IGHD1-26*01 IGHJ6*02 CARLLGGTRHYYALNVW 20 IGKV1-27*01 IGKJ3*01 CQKYDSALIFTF 6
V1 IGHV1-69*06 IGHD1-26*01 IGHJ6*02 CARVVGGTRSYYALGFW 11 IGKV1-27*01 IGKJ3*01 CQEYSNALIFTF 5
V2 IGHV1-69*06 IGHD1-26*01 IGHJ6*02 CARVVGGTRSYYALGFW 12 IGKV1-27*01 IGKJ3*01 CQEYSNALIFTF 6
V2 IGHV1-69*06 IGHD1-26*01 IGHJ6*02 CARVVGGTRSYYALGFW 13 IGKV1-27*01 IGKJ3*01 CQEYSNALIFTF 6 6,82E+04 5,95E-05 8,72E-10 4,11E+04 4,99E-05 1,22E-09
V3 IGHV1-69*06 IGHD1-26*01 IGHJ6*02 CARVVGGTRSYYALGVW 13 IGKV1-27*01 IGKJ3*01 CQEYSSALIFTF 7
V3 IGHV1-69*06 IGHD1-26*01 IGHJ6*02 CARVVGGTRSYYALGFW 10 IGKV1-27*01 IGKJ3*01 CQEYSNALIFTF 6 3,99E+06 7,72E-05 1,94E-11
V3 IGHV1-69*06 IGHD1-26*01 IGHJ6*02 CARVVGGTRPYYALGLW 10 IGKV1-27*01 IGKJ3*01 CQEYSNVLIFTF 6
V3 IGHV1-69*06 IGHD1-26*01 IGHJ6*02 CARVVGGTRSYYALGVW 16 IGKV1-27*01 IGKJ3*01 CQEYSSALIFTF 7
V1 IGHV1-69*06 ND IGHJ6*03 CARDRGGTRHHYYMDVW 24 IGKV3-20*01 IGKJ2*02 CQQYSGPLRTF 8 6,37E+06 4,55E-05 7,15E-12
V1 IGHV1-69*06 ND IGHJ6*03 CARDRGGTRHHYYMDVW 22 IGKV3-20*01 IGKJ2*02 CQQYSGPLRTF 8
V1 IGHV3-21*01 ND IGHJ6*03 CTRCRGGTRTYYYMDVW 14 IGKV3-20*01 IGKJ1*01 CQQYGDSVFTF 12
V1 IGHV3-21*01 ND IGHJ6*03 CTRCRGGTRTYYYMDVW 14 IGKV3-20*01 IGKJ1*01 CQQYGDSVFTF 12
V1 IGHV3-21*01 ND IGHJ6*03 CTRCRGGTRTYYYMDVW 14 IGKV3-20*01 IGKJ1*01 CQ.YGDSVFTF 11
V1 IGHV3-21*01 ND IGHJ6*03 CTRCRGGTRTYYYMDVW 14 IGKV3-20*01 IGKJ1*01 CQQYGDSVFTF 11
V1 IGHV3-21*01 ND IGHJ6*03 CTRCRGGTRTYYYMDIW 14 IGKV3-20*01 IGKJ1*01 CQRYGDSVFTF 11
V1 IGHV3-21*01 ND IGHJ6*03 CTRCRGGTRTYYYMDVW 15 IGKV3-20*01 IGKJ1*01 CQQYGDSVFTF 11 1,18E+05 6,33E-05 5,36E-10
V3 IGHV3-21*01 IGHD2-15*01 IGHJ6*03 CTRCRGGTRTYYYMDVW 15 IGKV3-20*01 IGKJ1*01 CQQYGDSVFTF 11
V3 IGHV3-21*01 IGHD2-15*01 IGHJ6*03 CARCRGGTRSYYYMDVW 10 IGKV3-20*01 IGKJ1*01 CQQYGDSVFTF 10
V3 IGHV3-21*01 IGHD2-15*01 IGHJ6*03 CARCRGGTRSYYYMDVW 19 IGKV3-20*01 IGKJ1*01 CQQYGDSLNTF 10
V3 IGHV3-21*01 IGHD2-15*01 IGHJ6*03 CARCRGGTRHYYYLDVW 9 IGKV3-20*01 IGKJ1*01 CQQYVSSFSTF 8
V3 IGHV3-21*01 IGHD2-15*01 IGHJ6*03 CARCRGGTRHYYYLDVW 9 IGKV3-20*01 IGKJ1*01 CQQYVSSFSTF 7
V3 IGHV3-21*01 IGHD2-15*01 IGHJ6*03 CARCRGGTRQYYYLDVW 9 IGKV3-20*01 IGKJ1*01 SQQYVSSFSTF 11
V3 IGHV3-21*01 IGHD2-15*01 IGHJ6*03 CARCRGGTRQYYYLDVW 9 IGKV3-20*01 IGKJ1*01 CQQYVSSFSTF 9  
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V2 IGHV1-69*06 IGHD2-2*02 IGHJ4*02 CASGYCSSTSCYDYW 0 IGKV3-20*01 IGKJ5*01 CQQYGSSPYSF 6
V2 IGHV1-69*01 IGHD3-22*01 IGHJ5*02 CARRHGYSDQRNWFDSW 17 IGKV1-39*01 IGKJ2*01 CQQCYETPYTF 8
V2 IGHV1-69*06 IGHD5-24*01 IGHJ4*02 CALRDGSNFVYFDYW 16 IGKV1-5*03 IGKJ2*02 CQQYNSLQGTF 6 5,35E+06 1,57E-04 2,93E-11
V2 IGHV1-69*06 IGHD5-24*01 IGHJ4*02 CALRDGSNFVYFDYW 16 IGKV1-5*03 IGKJ2*02 CQQYNSLQGTF 7
V2 IGHV1-69*06 IGHD5-24*01 IGHJ4*02 CALRDGSNFVYFDYW 17 IGKV1-5*03 IGKJ2*02 CQQYNSLQGTF 6 1,57E+06 1,11E-04 7,07E-11
V2 IGHV1-69*06 IGHD5-24*01 IGHJ4*02 CALRDGSNFVYFDFW 17 IGKV1-5*03 IGKJ2*02 CQHYNSLRGTF 11 7,91E+04 2,64E-05 3,34E-10
V3 IGHV1-69*06 IGHD5-24*01 IGHJ4*02 CALRDGSNFVYFDFW 17 IGKV1-5*03 IGKJ2*02 CQHYNSLRGTF 12
V3 IGHV1-69*06 IGHD5-24*01 IGHJ4*02 CALRDGSNFVYFDFW 16 IGKV1-5*03 IGKJ2*02 CQHYNSLRGTF 10
V3 IGHV1-69*06 IGHD5-24*01 IGHJ4*02 CALRDGNNFVYFDYW 16 IGKV1-5*03 IGKJ2*02 CQQYNSLQGTF 10 1,12E+05 1,05E-04 9,38E-10
V3 IGHV1-69*06 IGHD5-24*01 IGHJ4*02 CALRDGNNLVYFDYW 15 IGKV1-5*03 IGKJ2*02 CQHYNSLQGTF 10
V2 IGHV1-69*01 IGHD1-26*01 IGHJ4*01 CARLYSGSYYPVEYW 18 IGKV3-20*01 IGKJ1*01 CHQYGSSPRTF 19
V2 IGHV1-69*01 IGHD1-26*01 IGHJ4*01 CARLYSGSYYPVEYW 17 IGKV3-20*01 IGKJ1*01 CHQYGSSPRTF 19
V2 IGHV1-69*01 IGHD1-26*01 IGHJ4*01 CARLYSGSYYPVEYW 17 IGKV3-20*01 IGKJ1*01 CHQYGSSPRTF 20
V2 IGHV1-69*11 IGHD6-13*01 IGHJ4*02 CARVREGQQVLVFDSW 23 IGKV1-5*03 IGKJ1*01 CQHYNSLRGTF 10
V2 IGHV1-69*06 IGHD6-13*01 IGHJ4*02 CARVREGQQVLVFDSW 23 IGKV1-5*03 IGKJ1*01 CQHYNSLRGTF 10 4,18E+05 3,69E-04 8,83E-10
V2 IGHV1-69*06 IGHD6-13*01 IGHJ4*02 CARVREGQQVLVFDSW 23 IGKV1-5*03 IGKJ1*01 CQHYNSLRGTF 10
V2 IGHV1-69*06 IGHD6-13*01 IGHJ4*02 CARVREGQQVLVFDSW 21 IGKV1-5*03 IGKJ1*01 CQHYNSLRGTF 7
V2 IGHV1-69*11 IGHD6-13*01 IGHJ4*02 CARVREGQQVLVFDSW 19 IGKV1-5*03 IGKJ1*01 CQHYNSLRGTF 8 2,45E+06 4,64E-04 1,90E-10
V2 IGHV1-69*06 IGHD6-13*01 IGHJ4*02 CARVREGQQVLVFDSW 19 IGKV1-5*03 IGKJ1*01 CQHYNSLRGTF 9
V2 IGHV1-24*01 ND IGHJ4*02 CATGRGLEFDYW 16 IGKV1-5*03 IGKJ1*01 CQQFHTYRTF 6
V1 IGHV5-51*01 IGHD3-9*01 IGHJ6*03 CARHLDSYDVFNGYNLGGYMDVW 15 IGKV3-20*01 IGKJ1*01 CQQYGSSPQTF 7
V1 IGHV5-51*01 IGHD3-9*01 IGHJ6*03 CARHLDSYDVFNGYNLGGYMDVW 14 IGKV3-20*01 IGKJ1*01 CQQYGSSPQTF 6
V1 IGHV5-51*01 IGHD3-9*01 IGHJ6*03 CARHLDSYDVFNGYNLGGYMDVW 13 IGKV3-20*01 IGKJ1*01 CQQYGSSPQTF 6 2,66E+04 1,20E-03 4,50E-08
V1 IGHV5-51*01 IGHD3-9*01 IGHJ6*03 CARHLDSYDVFTGYNLGGYMDVW 11 IGKV3-20*01 IGKJ1*01 CQQYGSSPQTF 5
V1 IGHV5-51*01 IGHD3-9*01 IGHJ6*03 CARHLDSYDVFTGYNLGGYMDVW 10 IGKV3-20*01 IGKJ1*01 CQQYGSSPQTF 5 2,09E+04 1,52E-04 7,28E-09
V1 IGHV5-51*01 IGHD3-9*01 IGHJ6*03 CARHLDSYDVFTGYNLGGYMDVW 10 IGKV3-20*01 IGKJ1*01 CQQYGSSPQTF 6
V1 IGHV5-51*01 IGHD3-9*01 IGHJ6*03 CARHLDSYDVFTGYNLGGYMDVW 10 IGKV3-20*01 IGKJ1*01 CQQYGSSPQTF 5
V1 IGHV5-51*01 IGHD3-9*01 IGHJ6*03 CARHLDSYDVFTGYNLGGYMDVW 10 IGKV3-20*01 IGKJ1*01 CQQYGSSPRTF 5
V2 IGHV5-51*01 IGHD3-9*01 IGHJ6*03 CARHLDSYDVFTGYNLGGYMDLW 8 IGKV3-20*01 IGKJ1*01 CQQYGSSPQTF 4
V2 IGHV5-51*01 IGHD3-9*01 IGHJ6*03 CARHLDSYDVFTGYNLGGYMDLW 9 IGKV3-20*01 IGKJ1*01 CQQYGSSPQTF 4 7,06E+05 1,29E-03 1,83E-09
V2 IGHV5-51*01 IGHD3-9*01 IGHJ6*03 CARHLDSHDVFTGYNLGGYMDLW 9 IGKV3-20*01 IGKJ1*01 CQQYGSSPQTF 6 3,95E+05 1,09E-03 2,77E-09
V3 IGHV5-51*01 IGHD3-9*01 IGHJ6*03 CARHLDSYDVFDGYNLGGYMDVW 14 IGKV3-20*01 IGKJ1*01 CQQYGSSPQTF 8
V2 IGHV5-51*01 IGHD2-15*01 IGHJ4*02 CARHRGGWAKRGPFDYW 18 IGKV1-5*03 IGKJ2*01 CQQYHDYSPEYTF 7
V2 IGHV5-51*01 IGHD2-15*01 IGHJ4*02 CARHRGGWAKRGPFDYW 17 IGKV1-5*03 IGKJ2*01 CQQYHDYSPEYTF 7
V2 IGHV5-51*01 IGHD2-15*01 IGHJ4*02 CARHRGGWAKRGPFDYW 17 IGKV1-5*03 IGKJ2*01 CQQYHDYSPEYTF 7
V3 IGHV5-51*01 IGHD2-15*01 IGHJ4*02 CARHRGGWAKRGPFDYW 15 IGKV1-5*03 IGKJ2*01 CQQYHSYSPEYTF 7
V3 IGHV5-51*01 ND IGHJ4*02 CARHRGGWAKRGPFDYW 13 IGKV1-5*03 IGKJ2*01 CQQYHSYSPEYTF 7
V1 IGHV5-51*01 IGHD3-10*02 IGHJ4*02 CARQDSNTLYFFDLW 11 IGKV3-11*01 IGKJ2*01 CQHRSKYTF 7
V1 IGHV3-21*01 IGHD2-15*01 IGHJ3*02 CARRPGWAATRAAGAFDIW 0 IGKV1-27*01 IGKJ2*01 CQKYNSAPYTF 0 9,10E+03 1,29E-04 1,42E-08
V1 IGHV3-21*01 ND IGHJ4*02 CASGNTHDYW 14 IGKV1-39*01 IGKJ1*01 CQQIYSQVRTF 10
V1 IGHV3-21*01 ND IGHJ4*02 CASGNTHDYW 14 IGKV1-39*01 IGKJ1*01 CQQIYSQVRTF 9
V1 IGHV3-21*01 ND IGHJ4*02 CASGNTHDYW 13 IGKV1-39*01 IGKJ1*01 CQQIYSHVRTF 9
V2 IGHV3-21*01 ND IGHJ4*02 CASGNTHDYW 13 IGKV1-39*01 IGKJ1*01 CQQIYSNVRTF 5 2,02E+05 9,61E-05 4,75E-10
V2 IGHV3-21*01 ND IGHJ4*02 CASGNTHDYW 12 IGKV1-39*01 IGKJ1*01 CQQIYSNVRTF 5
V2 IGHV3-21*01 ND IGHJ4*02 CASGNTHDYW 11 IGKV1-39*01 IGKJ1*01 CQQIYSNVRTF 5
V2 IGHV3-21*01 ND IGHJ4*02 CASGNTHDYW 11 IGKV1-39*01 IGKJ1*01 CQQIYSNVRTF 6
V2 IGHV3-21*01 ND IGHJ4*02 CASGNTHDYW 10 IGKV1-39*01 IGKJ1*01 CQQIYSHVRTF 12 4,89E+05 3,42E-03 6,98E-09 2,36E+04 3,25E-05 1,38E-09
V2 IGHV3-21*01 ND IGHJ4*02 CASGNTHDYW 10 IGKV1-39*01 IGKJ1*01 CQQIYSHVRTF 11
V2 IGHV3-21*01 ND IGHJ4*02 CASGNTHDYW 10 IGKV1-39*01 IGKJ1*01 CPQIYSNVRKF 5 9,58E+05 1,05E-04 1,10E-10
V2 IGHV3-21*01 ND IGHJ4*02 CASGNTHDYW 10 IGKV1-39*01 IGKJ1*01 CQQIYSNVRTF 4
V3 IGHV3-21*01 ND IGHJ4*02 CASGNTHDYW 10 IGKV1-39*01 IGKJ1*01 CQQIYSHVRTF 9 1,01E+05 1,66E-04 1,64E-09 7,22E+05 2,63E-04 3,64E-10
V3 IGHV3-21*01 ND IGHJ4*02 CASGNTHDYW 12 IGKV1-39*01 IGKJ1*01 CQQIYSNVRTF 5
V3 IGHV3-21*01 ND IGHJ4*02 CASGNTHDYW 10 IGKV1-39*01 IGKJ1*01 CQQIYSHVRTF 11 4,00E+05 9,82E-05 2,46E-10 1,93E+05 3,01E-05 1,56E-10
V3 IGHV3-21*01 ND IGHJ4*02 CASGNTHDYW 10 IGKV1-39*01 IGKJ1*01 CLQTYSNVRTF 7
V3 IGHV3-21*01 ND IGHJ4*02 CLTGSSLDYW 7 IGKV1-39*01 IGKJ1*01 CLQTYSVIRTF 10
V3 IGHV3-21*01 ND IGHJ4*02 CASGVTHDYW 19 IGKV1-9*01 IGKJ1*01 CLQRYTYRRTF 10
V3 IGHV3-21*01 ND IGHJ4*02 CASGRSLDYW 10 IGKV1-39*01 IGKJ1*01 CHQTYCTTRTF 6 3,94E+04 1,80E-04 4,57E-09
V2 IGHV3-21*01 ND IGHJ4*02 CASGNTLDYW 17 IGKV3-20*01 IGKJ2*02 CHQYCYSRTF 8
V3 IGHV3-21*01 ND IGHJ4*02 CATGRTLDYW 10 IGKV3-20*01 IGKJ1*01 CHQYPTSRAF 11
V1 IGHV3-21*01 ND IGHJ4*02 CVSGSSFDYW 16 IGKV1-39*01 IGKJ1*01 CLQTYSSHRTF 10
V1 IGHV3-21*01 ND IGHJ4*03 CVTGSSLDYW 15 IGKV1-39*01 IGKJ1*01 CLQTYSVIRTF 14
V1 IGHV3-21*01 ND IGHJ4*02 CVTGSSLDYW 14 IGKV1-39*01 IGKJ1*01 CLQTYSVIRTF 13 1,04E+05 4,19E-04 4,04E-09
V3 IGHV3-21*01 ND IGHJ4*02 CVTGSSLDYW 12 IGKV1-39*01 IGKJ1*01 CLQTYSVIRTF 11
V3 IGHV3-21*01 ND IGHJ4*02 CVTGSSLDYW 11 IGKV1-39*01 IGKJ1*01 CLQTYSVIRTL 12
V3 IGHV3-21*01 ND IGHJ4*02 CVTGSSLDYW 7 IGKV1-39*01 IGKJ1*01 CLQTYSVIRTF 10 5,06E+04 1,33E-04 2,63E-09 2,11E+04 1,51E-04 7,18E-09
V3 IGHV3-21*01 ND IGHJ4*02 CVTGSSLDYW 7 IGKV1-39*01 IGKJ1*01 CLQTYCVIRTF 11
V1 IGHV3-23*01 IGHD4-17*01 IGHJ4*02 CAKDLYGDYDLDYW 6 IGKV2-30*01 IGKJ4*01 CMQGTHWPPITF 1
V1 IGHV3-23*01 IGHD6-19*01 IGHJ4*02 CAKAHKQWLAHYNFDYW 8 IGKV3-20*01 IGKJ4*01 CQQHDTSPLTF 5
V2 IGHV3-20*01 IGHD1-26*01 IGHJ3*02 CAGAKVGVGGENAFDIW 10 IGKV4-1*01 IGKJ2*01 CQQYYSTQYTF 9
V1 IGHV3-64*05 IGHD6-19*01 IGHJ4*02 CVKRRRQWLVNSSFDFW 17 IGKV3-15*01 IGKJ5*01 CQQYHVWPPITF 18
V1 IGHV3-64*05 IGHD6-19*01 IGHJ4*02 CVKRRRQWLVNSSFDFW 20 IGKV1-5*03 IGKJ1*01 CQQYNPYSWTF 6 5,77E+04 3,22E-04 5,57E-09
V3 IGHV3-64*05 IGHD6-19*01 IGHJ4*02 CVKRRRQWLVNSSFDFW 17 IGKV1-5*03 IGKJ1*01 CQQYNPYSWTF 4
V3 IGHV3-64*05 IGHD6-19*01 IGHJ4*02 CVKRRRQWLVNSSFDFW 18 IGKV1-5*03 IGKJ1*01 CQQYNPYSWTF 4
V1 IGHV3-30*04 IGHD3-3*01 IGHJ4*02 CARDRGAQITLFGAPLIRPSSFDSW 19 IGKV1D-33*01 IGKJ4*01 CQQYDGPVLTF 5
V1 IGHV3-30*04 IGHD3-3*01 IGHJ4*02 CARDRGAQITLFGAPLIRPSSFDSW 19 IGKV1D-33*01 IGKJ4*01 CQQYDGPVLTF 6
V1 IGHV3-30*04 IGHD3-3*01 IGHJ4*02 CARDRGAQITLFGAPLIRPSSFDSW 19 IGKV1D-33*01 IGKJ4*01 CQQYDGPVLTF 6
V1 IGHV3-30*04 IGHD3-3*01 IGHJ4*02 CARDRGAQITLFGAPLIRPSSFDSW 19 IGKV1D-33*01 IGKJ4*01 CQQYDGPVLTF 5
V1 IGHV3-30*04 IGHD3-3*01 IGHJ4*02 CARDRGAQITLFGAPLIRPSSFDSW 20 IGKV1D-33*01 IGKJ4*01 CQQYDGPVLTF 6
V1 IGHV3-30*04 IGHD3-3*01 IGHJ4*02 CARDRGAQITLFGAPLIRPSSFDSW 20 IGKV1D-33*01 IGKJ4*01 CQQYDGPVLTF 5
V1 IGHV3-30-3*01 IGHD3-3*01 IGHJ4*02 CARDRGAQITLFGAPLIRPSSFDSW 20 IGKV1D-33*01 IGKJ4*01 CQQYDGPVLTF 5
V1 IGHV3-30*04 IGHD3-3*01 IGHJ4*02 CARDRGAQITLFGAPLIRPSSFDSW 20 IGKV1D-33*01 IGKJ4*01 CQQYDGPVLTF 5
V2 IGHV3-30*04 IGHD3-3*01 IGHJ4*02 CARDRGAQITLFGAPLIRPSSFDSW 20 IGKV1D-33*01 IGKJ4*01 CQQYDGPVLTF 5 2,74E+05 4,10E-05 1,03E-10 5,27E+05 9,34E-05 1,77E-10
V2 IGHV3-30*04 IGHD3-3*01 IGHJ4*02 CARDRGAQITLFGAPLIRPSSFDSW 21 IGKV1D-33*01 IGKJ4*01 CQQYDGPVLTF 5
V2 IGHV3-30*14 IGHD3-3*01 IGHJ4*02 CARDRGAHLTLFGEPLIRPSSFDFW 25 IGKV1D-33*01 IGKJ4*01 CQQYDGPVLTF 6
V2 IGHV3-30*14 IGHD3-3*01 IGHJ4*02 CARDRGAHLTLFGEPLIRPSSFDFW 25 IGKV1D-33*01 IGKJ4*01 CQQYDGPVLTF 6
V2 IGHV3-30*14 IGHD3-3*01 IGHJ4*02 CARDRGAHLTLFGEPLIRPSSFDFW 25 IGKV1D-33*01 IGKJ4*01 CQQYDGPVLTF 8 8,04E+05 2,47E-05 3,07E-11 3,78E+05 1,93E-04 5,12E-10
V3 IGHV3-30*03 IGHD3-3*01 IGHJ4*02 CARDRGAQITLFGAPLIRPSSFDSR 19 IGKV1D-33*01 IGKJ4*01 CQQYDGPVLTF 6 1,76E+05 3,68E-05 2,10E-10 2,19E+05 8,40E-05 3,84E-10
V3 IGHV3-30*04 IGHD3-3*01 IGHJ4*02 CARDRGAQITLFGAPLIRPSSFDSW 19 IGKV1D-33*01 IGKJ4*01 CQQYDGPVLTF 5 2,32E+05 1,74E-05 8,62E-11 4,15E+04 8,44E-05 2,04E-09
V3 IGHV3-30*04 IGHD3-3*01 IGHJ4*02 CARDRGAQITLFGAPLIRPSSFDSW 20 IGKV1D-33*01 IGKJ4*01 CQQYDGPVLTF 6
V1 IGHV3-30*04 IGHD2-15*01 IGHJ4*02 CARARLLFCSGGRCDMDSW 16 IGKV1-9*01 IGKJ1*01 CQQIIRYPRTF 7 1,78E+06 1,53E-07 8,60E-14
V1 IGHV3-30*04 IGHD2-15*01 IGHJ4*02 CARARLLFCSGGRCDMDSW 16 IGKV1-9*01 IGKJ1*01 CQQIIRYPRTF 7
V2 IGHV3-30*03 IGHD2-15*01 IGHJ4*02 CARARLLYCSGGRCDMDYW 14 IGKV1-9*01 IGKJ1*01 CQQLIRYPRTF 7 1,67E+05 6,32E-06 3,79E-11 5,84E+05 2,70E-05 4,62E-11
V2 IGHV3-30*03 IGHD2-15*01 IGHJ4*02 CARARLLYCSGGRCDMDYW 15 IGKV1-9*01 IGKJ1*01 CQQLIRYPRTF 7
V2 IGHV3-30*03 IGHD2-15*01 IGHJ4*02 CARARLLYCSGGRCDMDYW 17 IGKV1-9*01 IGKJ1*01 CQQLIRYPRTF 7
V3 IGHV3-30*03 IGHD2-15*01 IGHJ4*02 CARARLLYCSGGRCDMDYW 12 IGKV1-9*01 IGKJ1*01 CQQLIRYPRTF 5
V3 IGHV3-30*03 IGHD2-15*01 IGHJ4*02 CARARLLYCSGGRCDMDYW 13 IGKV1-9*01 IGKJ1*01 CQQLIRYPRTF 5 2,84E+05 3,03E-05 1,07E-10
V3 IGHV3-30*03 IGHD2-15*01 IGHJ4*02 CARARLLYCSGGRCDMDYW 13 IGKV1-9*01 IGKJ1*01 CQHLIRYPRTF 5
V3 IGHV3-30*03 IGHD2-15*01 IGHJ4*02 CARARLLYCSGGRCDMDYW 13 IGKV1-9*01 IGKJ1*01 CQQPIRYPRTF 6 3,34E+05 1,13E-05 3,39E-11 3,14E+06 1,19E-05 3,78E-12
V3 IGHV3-30*03 IGHD2-15*01 IGHJ4*02 CARARLLYCSGGRCDMDYW 14 IGKV1-9*01 IGKJ1*01 CQQLIRYPRTF 8  
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V2 IGHV3-30*18 IGHD3-22*01 IGHJ4*02 CAKEPAPFNYYDSSAYYGGGYYFDYW 9 IGKV1-5*03 IGKJ2*01 CHQYGSSFPYSF 9
V2 IGHV3-30*18 IGHD3-22*01 IGHJ4*02 CAKEPAPFNYYDSSAYYGGGYYFDYW 9 IGKV1-5*03 IGKJ2*01 CHQYGSSFPYSF 9
V2 IGHV3-30*18 IGHD3-16*02 IGHJ3*02 CAKDRQLKDAFDIW 0 IGKV1D-33*01 IGKJ3*01 CQQYDNLPPL 1 1,01E+06 2,63E-05 2,6E-11
V2 IGHV3-30*18 IGHD3-22*01 IGHJ5*02 CAKGLSQALNYYGSGSPFL 11 IGKV3-20*01 IGKJ1*01 CQQYGTSPWTF 14
V2 IGHV3-33*03 IGHD2-15*01 IGHJ5*02 CARDICSAGNCYPGNGLDPW 11 IGKV3-20*01 IGKJ1*01 CQHYGSSSWTF 10
V2 IGHV3-30*18 IGHD2-8*02 IGHJ4*02 CAKDLESFYCTDGGCPFDYW 18 IGKV1-5*03 IGKJ1*01 CQHYASHSQTF 9
V2 IGHV3-30*18 IGHD2-8*02 IGHJ4*02 CAKDLESFYCTDGGRPFDYW 18 IGKV1-5*03 IGKJ1*01 CQHYASHSQTF 9
V2 IGHV3-30*18 IGHD2-8*02 IGHJ4*02 CAKDLESFYCTDGGCPFDYW 17 IGKV1-5*03 IGKJ1*01 CQHCASHSQTF 8
V2 IGHV3-30*18 IGHD3-9*01 IGHJ4*02 CTKDRYRGHVLTGNSFEHW 13 IGKV1-39*01 IGKJ1*01 CQQSYHARWTF 8
V2 IGHV3-30-3*01 IGHD3-10*01 IGHJ4*02 CARGGPGNVRVNLGRGVFDFW 17 IGKV1D-16*01 IGKJ4*01 CQQYYSFPLSF 7
V2 IGHV3-30-3*01 IGHD3-10*01 IGHJ4*02 CARGGPGNVRVNLGRGVFDFW 17 IGKV1D-16*01 IGKJ4*01 CQQYYSFPLSF 7
V2 IGHV3-30-3*01 IGHD3-10*01 IGHJ4*02 CARGGPGNVRVNLGRGVFDFW 18 IGKV1D-16*01 IGKJ4*01 CQQYYSFPLSF 7
V2 IGHV3-30-3*01 IGHD3-10*01 IGHJ4*02 CARGGPGNVRVNLGRGVFDFW 18 IGKV1D-16*01 IGKJ4*01 CQQYYSFPLSF 6
V2 IGHV3-30-3*01 IGHD3-10*01 IGHJ4*02 CARGGPGNVRVNLGRGVFDFW 17 IGKV1D-16*01 IGKJ4*01 CQQYYSSPLSF 6
V2 IGHV3-30-3*01 IGHD3-10*01 IGHJ4*02 CARGGPGNLRVNLGRGVFDFW 13 IGKV1D-16*01 IGKJ4*01 CQQYYSFPLSF 8 7,66E+06 1,30E-04 1,70E-11
V2 IGHV3-30-3*01 IGHD3-10*01 IGHJ4*02 CARGGPGNLRVNLGRGVFDFW 13 IGKV1D-16*01 IGKJ4*01 CQQYYSFPLSF 9
V2 IGHV3-30-3*01 IGHD3-10*01 IGHJ4*02 CARGGPGNLRVNLGRGVFDFW 13 IGKV1D-16*01 IGKJ4*01 CQQYYSFPLSF 9
V2 IGHV3-64*05 IGHD3-22*01 IGHJ3*02 CVKDPRRRTWFFHRSGFDIW 24 IGKV1-9*01 IGKJ5*01 CQQFNSYPITF 14 1,31E+05 8,20E-05 6,26E-10
V2 IGHV3-64*05 IGHD3-22*01 IGHJ3*02 CVKDPRRRTWFFHRSGFDIW 23 IGKV1-9*01 IGKJ5*01 CQQFNSYPITF 14
V2 IGHV3-64*05 IGHD3-22*01 IGHJ3*02 CVKDPRRRTWFFHRSGFDIW 23 IGKV1-9*01 IGKJ5*01 CQQFNSYPITF 13 4,36E+05 4,86E-05 1,11E-10 7,52E+05 1,86E-04 2,47E-10
V1 IGHV3-15*01 IGHD4-23*01 IGHJ4*02 CTTHDYW 5 IGKV1-9*01 IGKJ4*01 CQQLDTYPLTL 5
V2 IGHV3-15*01 IGHD3-10*01 IGHJ4*02 CTTGTVVVPNDYW 0 IGKV3-20*01 IGKJ4*01 CQQYGSSPKLTF 7
V2 IGHV3-15*01 IGHD3-3*01 IGHJ6*02 CTTDFSILRAYLLRFLEWPSYGMDVW 2 IGKV1-16*01 IGKJ5*01 CQQYNSYCHL 0
V2 IGHV3-15*01 ND IGHJ4*02 CATDGAGYSSNLW 11 IGKV1-39*01 IGKJ2*02 CQQSYGTPLTF 0
V2 IGHV3-15*01 ND IGHJ4*03 CATDGAGYSSNLW 12 IGKV1-39*01 IGKJ2*02 CQQSYSTPLTF 0
V2 IGHV3-15*07 IGHD1-26*01 IGHJ1*01 CATGGDIGSYHSGGYFHHW 7 IGKV2-28*01 IGKJ4*01 CMQALQIPLTF 7
V2 IGHV3-49*03 IGHD2-2*02 IGHJ6*02 CSPRGDCSSTNCYENFFHDLDVW 18 IGKV1D-33*01 IGKJ3*01 CQQYDTLFSF 17
V2 IGHV3-49*03 IGHD2-2*02 IGHJ6*02 CSPRGDCSSTNCYENFFHDLDVW 20 IGKV1D-33*01 IGKJ3*01 CQQYDTLFSF 17
V1 IGHV4-39*01 IGHD1-1*01 IGHJ4*02 CARIVGYNWKGEGNFDYW 26 IGKV1-39*01 IGKJ4*01 CQQSFSTPQTF 7 4,03E+05 1,95E-04 4,84E-10
V3 IGHV4-39*01 IGHD6-19*01 IGHJ4*02 CARQEPKQWLVDYYFDSW 18 IGKV3-20*01 IGKJ1*01 CLQYGSSPWTF 18
V3 IGHV4-39*01 IGHD6-6*01 IGHJ4*02 CARLQSFYTSQNSVRRPFDSW 17 IGKV1-5*03 IGKJ2*01 CQQYTTYLYTF 5
V3 IGHV4-39*01 IGHD3-16*01 IGHJ4*02 CARLQSFYTSQNSVRRPFDSW 17 IGKV1-5*03 IGKJ2*01 CQQYTTYLYTF 5
V1 IGHV4-59*02 IGHD6-25*01 IGHJ4*02 CARVSGWGPRGGIYFDYW 12 IGKV1-39*01 IGKJ1*01 CQQSYDMPRTF 8
V1 IGHV4-59*02 IGHD6-25*01 IGHJ4*02 CARVSGWGPRGGIYFDYW 12 IGKV1-39*01 IGKJ1*01 CQQSYDMPRTF 8 1,69E+05 4,70E-05 2,78E-10
V1 IGHV4-59*01 IGHD6-25*01 IGHJ4*02 CARVSGWGPRGGIYFDYW 12 IGKV1-39*01 IGKJ1*01 CQQSYSMPRTF 8
V1 IGHV4-59*02 IGHD6-25*01 IGHJ4*02 CARVSGWGPRGGIYFDYW 12 IGKV1-39*01 IGKJ1*01 CXQSXDMPRTF 16
V1 IGHV4-59*02 IGHD6-25*01 IGHJ4*02 CARVSGWGPRGGIYFDYW 12 IGKV1-39*01 IGKJ1*01 CQQSYDMPRTF 9
V1 IGHV4-59*01 IGHD6-25*01 IGHJ4*02 CARVSGWGPRGGIYFDYW 11 IGKV1-39*01 IGKJ1*01 CQQSYSMPRTF 8 3,14E+04 5,47E-05 1,74E-09
V1 IGHV4-59*01 IGHD6-25*01 IGHJ4*02 CARVSGWGPRGGIYFDFW 11 IGKV1-39*01 IGKJ1*01 CQQSYSMPRTF 10
V1 IGHV4-59*01 IGHD6-25*01 IGHJ4*02 CARVSGWGPRGGIYFDFW 10 IGKV1-39*01 IGKJ1*01 CQQSYSMPRTF 13
V3 IGHV4-59*01 IGHD5-5*01 IGHJ4*02 CARGGRYSYGYASFFDYW 14 IGKV1-39*01 IGKJ4*01 CQQSYSLPFTF 11
V3 IGHV4-59*01 IGHD5-5*01 IGHJ4*02 CARGGRYSYGYASFFDYW 14 IGKV1-39*01 IGKJ4*01 CQQSYSLPFTF 13
V2 IGHV4-59*01 IGHD3-16*02 IGHJ4*02 CVRPPSWRYHYFDSW 20 IGKV3-15*01 IGKJ4*02 CQQYDKWPPEITF 11
V3 IGHV4-59*01 IGHD6-13*01 IGHJ4*02 CARPPSWRYHYFGSW 19 IGKV3-15*01 IGKJ4*01 CQQYDKWPPEPTF 11
V3 IGHV4-59*01 IGHD6-13*01 IGHJ4*02 CARPPSWRYHYFGSW 19 IGKV3-15*01 IGKJ4*01 CQQYDKWPPEPTF 11
V3 IGHV4-59*01 IGHD6-13*01 IGHJ4*02 CARPPSWRYHYFDSW 17 IGKV3-15*01 IGKJ4*01 CQQYDKWPPELTF 16
V3 IGHV4-59*01 IGHD3-16*02 IGHJ4*02 CARPPSWRYHYFDSW 17 IGKV3-15*01 IGKJ4*01 CQQYDKWPPEPTF 10
V3 IGHV4-59*01 IGHD6-13*01 IGHJ4*02 CARPPSWRYHYFDSW 16 IGKV3-15*01 IGKJ4*01 CQQYDKWPPEITF 8
V3 IGHV4-59*01 IGHD6-13*01 IGHJ4*02 CARPPSWRYHYFDSW 16 IGKV3-15*01 IGKJ4*01 CQQYDKWPPELTF 8
V3 IGHV4-59*01 IGHD6-13*01 IGHJ4*02 CARPPSWRYHYFDSW 16 IGKV3-15*01 IGKJ4*02 CQQYDRWPPELTF 8
V3 IGHV4-59*01 IGHD6-13*01 IGHJ4*02 CARPPSWRYHYFDSW 15 IGKV3-15*01 IGKJ4*01 CQQYDKWPPELTF 8
V3 IGHV4-59*01 IGHD6-13*01 IGHJ4*02 CARPPSWRYHYFDSW 14 IGKV3-15*01 IGKJ4*01 CQQYDKWPPELTF 8
V2 IGHV4-34*01 IGHD5-12*01 IGHJ6*02 CARLPIIGSGYDAVSLGNYGMDVW 0 IGKV5-2*01 IGKJ4*01 CLQHDNF 0
V2 IGHV4-34*01 IGHD1-7*01 IGHJ3*02 CARVPLFFSNWNLRAFDIW 2 IGKV1D-33*01 IGKJ4*01 CQQYDNLPLTF 0
V3 IGHV4-34*01 IGHD4-17*01 IGHJ5*02 CSRVGPFDPW 11 IGKV1-39*01 IGKJ1*01 CQQIYNTPYTF 9 2,81E+05 1,27E-04 4,52E-10 2,03E+05 2,46E-04 1,21E-09
V3 IGHV4-34*01 IGHD4-17*01 IGHJ5*02 CSRVGPFDPW 11 IGKV1-39*01 IGKJ2*01 CQQIYNTPYTF 10
V3 IGHV4-34*01 IGHD4-17*01 IGHJ5*02 CSRVGPFDPW 11 IGKV1-39*01 IGKJ2*01 CQQIYNTPYTF 12
V1 IGHV1-69*06 IGHD6-6*01 IGHJ4*02 CVTAPDDTGTILARHNRYYFDSW 17 IGKV3-20*01 IGKJ2*01 CHQYGSSPNTF 8
V1 IGHV1-69*06 IGHD6-6*01 IGHJ4*02 CVTAPDDTGTILARHNRYYFDSW 18 IGKV3-20*01 IGKJ2*01 CHQYGSSPNTF 8
V1 IGHV1-69*06 IGHD6-6*01 IGHJ4*02 CARAPRGTSTIAARFNRYFFDSW 22 IGKV3-11*01 IGKJ2*01 CQQRRLWYTF 3
V1 IGHV1-69*10 IGHD6-6*01 IGHJ4*02 CARAPRGTSTIAARFNRYFFDSW 23 IGKV3-11*01 IGKJ2*01 CQQRRLWYTF 3
V1 IGHV1-69*10 IGHD6-6*01 IGHJ4*02 CARAPRGTSTIAARFNRYFFDSW 23 IGKV3-11*01 IGKJ2*01 CQQRRLWYTF 4
V1 IGHV1-69*06 IGHD6-6*01 IGHJ4*02 CARAPRGTSTIAARFNRYFFDSW 18 IGKV3-20*01 IGKJ2*01 CHQYGSSDNTF 8
V1 IGHV1-69*06 IGHD6-6*01 IGHJ4*02 CARAPRGTSTIAARFNRYFFDSW 18 IGKV3-20*01 IGKJ2*01 CHQYGSSDNTF 7
V1 IGHV1-69*06 IGHD6-6*01 IGHJ4*02 CARAPRGTSTIAARFNRYFFDSW 19 IGKV3-20*01 IGKJ2*01 CHQYGSSDNTF 7
V1 IGHV1-69*06 IGHD6-6*01 IGHJ4*02 CVSAPRDTSTIAARFNRYFFDTW 18 IGKV3-20*01 IGKJ2*01 CHQYGASDNTF 7
V1 IGHV1-69*06 IGHD6-6*01 IGHJ4*02 CVSAPRDTSTIAARFNRYFFDTW 18 IGKV3-20*01 IGKJ2*01 CHQYGASDNTF 7
V1 IGHV1-69*06 IGHD6-6*01 IGHJ4*02 CVSAPRDTSTIAARFNRYFFDTW 19 IGKV3-20*01 IGKJ2*01 CHQYGASDNTF 7 1,85E+05 1,70E-04 9,18E-10
V1 IGHV1-69*06 IGHD6-6*01 IGHJ4*02 CVSAPRDTSTIAARFNRYFFDTW 19 IGKV3-20*01 IGKJ2*01 CHQYGASDNTF 7 6,49E+05 1,98E-04 3,05E-10
V1 IGHV1-69*06 IGHD6-6*01 IGHJ4*02 CAKAPRGTSTIAARFNRYFFDSW 23 IGKV3-20*01 IGKJ2*01 CHQYGSSDNTF 10
V1 IGHV1-69*06 IGHD6-6*01 IGHJ4*02 CAKAPRGTSTIAARFNRYFFDSW 23 IGKV1-5*03 IGKJ2*02 CHQYHSYSGTF 9
V1 IGHV1-69*06 IGHD6-6*01 IGHJ4*02 CAKAPRGTSTIAARFNRYFFDSW 24 IGKV1-5*03 IGKJ2*02 CHQYHSYSGTF 13
V1 IGHV1-69*06 IGHD6-6*01 IGHJ4*02 CAKAPRGTSTIAARFNRYFFDSW 26 IGKV3-20*01 IGKJ2*01 CHQYGSTDNTF 8
V1 IGHV1-69*06 IGHD6-6*01 IGHJ4*02 CAKAPRGTSTIAARFNRYFFDSW 26 IGKV1-39*01 IGKJ2*02 CQQSYRTPCTF 7
V1 IGHV1-69*06 IGHD6-6*01 IGHJ4*02 CAKAPRGTSTIAARFNRYFFDSW 27 IGKV1-39*01 IGKJ2*01 CQQSYRTPYTF 8
V1 IGHV1-69*06 IGHD6-6*01 IGHJ4*02 CASAPRDTSTIAARFNRYFFDFW 23 IGKV3-20*01 IGKJ2*01 CHQYGSSENTF 11
V1 IGHV1-69*06 IGHD6-6*01 IGHJ4*02 CASAPRDTSTIAARFNRYFFDFW 23 IGKV3-20*01 IGKJ2*01 CHQYGSSENTF 8 3,68E+05 3,76E-04 1,02E-09
V2 IGHV1-69*06 IGHD6-6*01 IGHJ4*02 CASAPRDTSTIAARLNRYFFDFW 23 IGKV3-20*01 IGKJ2*01 CHQYGSSENTF 8 6,40E+05 1,02E-03 1,59E-09 5,06E+04 1,40E-04 2,77E-09
V2 IGHV1-69*06 IGHD6-6*01 IGHJ4*02 CASAPRDASTIAARFNRYFFDFW 23 IGKV3-20*01 IGKJ2*01 CHQYGSSENTF 8
V2 IGHV1-69*06 IGHD6-6*01 IGHJ4*02 CASAPRDTSTIAARFNRYFFDFW 24 IGKV3-20*01 IGKJ2*01 CHQYGSSENTF 8
V2 IGHV1-69*06 IGHD6-6*01 IGHJ4*02 CASAPRDTSTIAARFNRYFFDFW 24 IGKV3-20*01 IGKJ2*01 CHQYGSSENTF 9 8,00E+05 4,32E-04 5,4E-10
V2 IGHV1-69*06 IGHD6-6*01 IGHJ4*02 CARAPRDTSTIAARFNRYFFDSW 24 IGKV3-20*01 IGKJ2*01 CHQYGSSENTF 8
V2 IGHV1-69*06 IGHD6-6*01 IGHJ4*02 CVRAPRGTSTIAARFNRYFFDSW 23 IGKV3-20*01 IGKJ2*01 CHQYGSSDNTF 8
V3 IGHV1-69*06 IGHD6-6*01 IGHJ4*02 CARAPRGTSTISARFNRYFFESW 18 IGKV3-20*01 IGKJ2*01 CHQYGSSDNTF 7 1,50E+05 8,67E-05 5,78E-10 6,54E+04 2,44E-04 3,74E-09
V3 IGHV1-69*06 IGHD6-6*01 IGHJ4*02 CATAPRGTSTIAARFNRYFFDSW 18 IGKV3-20*01 IGKJ2*01 CHQYGSSDNTF 7 6,72E+05 4,58E-04 6,82E-10 1,46E+05 2,39E-03 1,64E-08
V3 IGHV1-69*06 IGHD6-6*01 IGHJ4*02 CVSAPRDTSTIAARFNRYFFDTW 18 IGKV3-20*01 IGKJ2*01 CHQYGASDNTF 7
V3 IGHV1-69*06 IGHD6-6*01 IGHJ4*02 CVSAPRDTSTIAARFNRYFFDTW 18 IGKV3-20*01 IGKJ2*01 CHQYGASDNTF 6
V3 IGHV1-69*06 IGHD6-6*01 IGHJ4*02 CVSAPRDTSTIAARFNRYFFDTW 19 IGKV3-20*01 IGKJ2*01 CHQYGASDNTF 8
V3 IGHV1-69*06 IGHD6-6*01 IGHJ4*02 CASAPRGTSTIAARHNRYFFDYW 19 IGKV3-20*01 IGKJ2*01 CHQYGSSENTF 8
V3 IGHV1-69*06 IGHD6-6*01 IGHJ6*01 CASAPRGTSTIAARFNRYFFDFW 19 IGKV3-20*01 IGKJ2*01 CHQYGSSDNTF 9
V3 IGHV1-69*06 IGHD6-6*01 IGHJ4*02 CASAPRGTSTIAARFNRYFFDFW 21 IGKV3-20*01 IGKJ2*01 CHQYGSSDNTF 10
V3 IGHV1-69*06 IGHD6-6*01 IGHJ4*02 CARAPRDTSTIAARHNRYQFDSW 21 IGKV3-20*01 IGKJ2*01 CHQYGSSDNTF 10 4,07E+05 1,53E-04 3,76E-10 4,87E+04 6,73E-04 1,38E-08
V3 IGHV1-69*06 IGHD6-6*01 IGHJ4*02 CARAPPGTSTIAARFNRYFFDSW 22 IGKV3-20*01 IGKJ2*01 CHQYGSSDNTF 9
V3 IGHV1-69*10 IGHD6-6*01 IGHJ4*02 CERAPPGTSTIAARFNRYFFDSW 21 IGKV3-20*01 IGKJ2*01 CHQYGSSENTF 9
V3 IGHV1-69*06 IGHD6-6*01 IGHJ4*02 CARAPPGTSTIAARFNRYFFDSW 21 IGKV3-20*01 IGKJ2*01 CHQYGSSDNTF 10
V3 IGHV1-69*06 IGHD6-6*01 IGHJ4*02 CAKAPRGTSTIAARFNRYFFDSW 21 IGKV3-20*01 IGKJ2*01 CHQYGSSDNTF 11
V3 IGHV1-69*06 IGHD6-6*01 IGHJ4*02 CARAPRGTSTIAARFNRYFFDSW 21 IGKV3-20*01 IGKJ2*01 CHQYGSSDNTF 9
V3 IGHV1-69*06 IGHD6-6*01 IGHJ4*02 CAKAPRATSTIAARFNRYFFDAW 22 IGKV3-20*01 IGKJ2*01 CHQYGSSDNTF 8
V3 IGHV1-69*06 IGHD6-6*01 IGHJ4*02 CARAPGGTSTIAARFNRYFFDSW 22 IGKV3-20*01 IGKJ2*01 CHQYGSSDNTF 7
V3 IGHV1-69*06 IGHD6-6*01 IGHJ4*02 CARAPPGTSTIAARFNRYFFDSW 24 IGKV3-20*01 IGKJ2*01 CHQYGSSDNTF 8
V3 IGHV1-69*06 IGHD6-6*01 IGHJ4*02 CVTAPDDTETIPARHNRYYFDSW 16 IGKV3-20*01 IGKJ2*01 CHQYGSSPNTF 8
V3 IGHV1-69*06 IGHD6-6*01 IGHJ4*02 CVTAPDDTETIPARHNRYYFDSW 16 IGKV3-20*01 IGKJ2*01 CHQYGSSPNTF 8  
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Repertoire VH gene D gene JH gene H-CDR3
# of 
SHM, 
H VK gene JK gene K-CDR3
# of 
SHM, 
L
On-rate, 
25C
Off-rate, 
25C
Calc. KD, 
25C, M
On-rate, 
37C
Off-rate, 
37C
Calc. KD, 
37C, M
V1 IGHV2-5*10 IGHD3-3*02 IGHJ4*02 CARTMGVVLPFDYW 9 IGKV1-5*03 IGKJ1*01 CQQFNSFSPWTF 6
V1 IGHV2-5*10 IGHD3-3*02 IGHJ4*02 CARTMGVVLPFDYW 9 IGKV1-5*03 IGKJ1*01 CQQFNSFSPWTF 6
V1 IGHV2-5*10 IGHD3-3*02 IGHJ4*02 CARTMGVVLPFDYW 9 IGKV1-5*03 IGKJ1*01 CQQFNSFSPWTF 6
V1 IGHV2-5*10 IGHD3-3*02 IGHJ4*02 CARTMGVVLPFDYW 8 IGKV1-5*03 IGKJ1*01 CQQFNSFSPWTF 7
V1 IGHV2-5*10 IGHD3-3*02 IGHJ4*02 CARTMGVVLPFDYW 8 IGKV1-5*03 IGKJ1*01 CQQFNSFSPWTF 6 2,05E+03 6,01E-04 2,94E-07
V3 IGHV2-5*10 IGHD3-3*02 IGHJ4*02 CARTVGVVLPFDYW 9 IGKV1-5*03 IGKJ1*01 CQQFNRNSPWTF 7 6,66E+05 5,36E-05 8,05E-11
V2 IGHV2-5*10 IGHD3-10*01 IGHJ4*02 CARTVRGVVPFDYW 12 IGKV1-5*03 IGKJ1*01 CQEYNSDSRTF 8 1,46E+04 1,37E-05 9,34E-10
V3 IGHV2-5*10 IGHD3-10*01 IGHJ4*02 CARTVRGVVPFDYW 11 IGKV1-5*03 IGKJ1*01 CQQYNSDSRTF 8
V3 IGHV2-5*10 IGHD3-10*01 IGHJ4*02 CARTVGAFGRFPFDFW 7 IGKV1-5*03 IGKJ4*01 CQQYNSDSLTF 10
V3 IGHV2-5*01 IGHD3-10*02 IGHJ4*02 CARHIRGVTPFDYR 8 IGKV1-5*03 IGKJ1*01 CQQYDSYFWTF 6
V1 IGHV2-5*01 IGHD6-13*01 IGHJ4*02 CARTVASLGTAFDYW 13 IGKV1-9*01 IGKJ1*01 CQQLNSYPTF 7 2,77E+05 1,09E-04 3,94E-10
V1 IGHV2-5*04 IGHD2-2*02 IGHJ4*02 CARSVVPATRAFDFW 20 IGKV1-5*03 IGKJ1*01 CQHYDGNSLTF 12 1,70E+05 1,60E-04 9,39E-10
V2 IGHV2-5*01 IGHD2-2*02 IGHJ4*02 CARSVVPATRAFDFW 22 IGKV1-5*03 IGKJ1*01 CQQYDGNSLTF 10 4,19E+05 5,19E-06 1,24E-11
V3 IGHV2-5*10 IGHD2-2*02 IGHJ4*02 CARSVVPATRAFDFW 17 IGKV1-5*03 IGKJ1*01 CQHYDGNSLTF 10 5,79E+04 9,21E-05 1,59E-09
V3 IGHV2-5*01 IGHD2-2*02 IGHJ4*02 CARSVVPATRAFDFW 16 IGKV1-5*03 IGKJ1*01 CQHYDGNSLTF 10
V3 IGHV2-5*01 IGHD2-2*02 IGHJ4*02 CARSVVPATRAFDFW 20 IGKV1-5*03 IGKJ1*01 CQQYDGNSLTF 10
V3 IGHV2-5*04 IGHD2-15*01 IGHJ4*02 CARAGVPATRSFDFW 16 IGKV1-5*03 IGKJ1*01 CQQYDGHSLTF 12
V3 IGHV2-5*10 IGHD2-2*02 IGHJ4*02 CARSVVPATRSFDYW 12 IGKV1-5*03 IGKJ1*01 CQQYDGNSLTF 9
V2 IGHV1-69*01 IGHD2-21*02 IGHJ6*02 CARDSRTRARGSGGFYRGNVYYYAMDVW 20 IGKV3-20*01 IGKJ4*01 CQQNGRSPLSF 13
V3 IGHV1-69*01 IGHD6-19*01 IGHJ6*02 CARDSRTRARGSGGWYRGNVYYYAMDVW 21 IGKV3-20*01 IGKJ4*01 CQQNGRSPLTF 7
V2 IGHV2-26*01 ND IGHJ6*03 CARMRRIFINHYSSYMDVW 13 IGKV3-20*01 IGKJ4*01 CQQHGRPPLTF 7
V3 IGHV2-26*01 ND IGHJ6*03 CARMRRIFINHYSSYMDVW 15 IGKV3-20*01 IGKJ4*01 CQQHGRPPLTF 10 1,66E+04 4,68E-04 2,82E-08 4,18E+04 2,95E-04 7,06E-09
V3 IGHV2-26*01 ND IGHJ6*03 CARMRRIFINHYSSYMDVW 15 IGKV3-20*01 IGKJ4*01 CQQHGRPPLTF 8
V1 IGHV2-5*10 IGHD1-26*01 IGHJ4*02 CARIVGTHGFDYW 18 IGKV1-9*01 IGKJ2*01 CQQLNRYPPYTF 7
V1 IGHV2-5*10 IGHD1-26*01 IGHJ4*02 CARIVGTHGFDYW 17 IGKV1-9*01 IGKJ2*01 CQQLNRYPPYTF 7
V1 IGHV2-5*10 IGHD1-26*01 IGHJ4*02 CARIVGTHGFDYW 16 IGKV1-9*01 IGKJ2*01 CQQLNRYPPYTF 7
V1 IGHV2-5*10 IGHD1-26*01 IGHJ4*02 CARIVGTHGFDYW 16 IGKV1-9*01 IGKJ2*01 CQQLNRYPPYTF 7
V1 IGHV2-5*10 IGHD1-26*01 IGHJ4*02 CARIVGTHGFDYW 15 IGKV1-9*01 IGKJ2*01 CQQLNRYPPYTF 7 4,08E+04 2,09E-04 5,14E-09
V1 IGHV2-5*10 IGHD1-26*01 IGHJ4*02 CARIVGTHGFDYW 15 IGKV1-9*01 IGKJ2*01 CQQLNRYPPYTF 8
V1 IGHV2-5*10 IGHD1-26*01 IGHJ4*02 CARIVGTHGFDYW 15 IGKV1-9*01 IGKJ2*01 CQQLNRYPPYTF 8
V1 IGHV2-5*10 IGHD1-26*01 IGHJ4*02 CARIVGTHGFDYC 17 IGKV1-9*01 IGKJ2*01 CQQLNRYPPYTF 8 1,83E+05 1,39E-03 7,61E-09
V1 IGHV4-61*08 IGHD5-12*01 IGHJ4*02 CARARRTYSGYDSAFDYW 13 IGKV1-39*01 IGKJ2*01 CQQSFGTPYTF 9 1,08E+06 1,63E-04 1,51E-10
V1 IGHV4-61*08 IGHD5-12*01 IGHJ4*02 CARARRTYSGYDSAFDYW 13 IGKV1-39*01 IGKJ2*01 CQQSFGTPYTF 10
V1 IGHV4-61*08 IGHD5-12*01 IGHJ4*02 CARARRTYSGYDSAFDYW 14 IGKV1-39*01 IGKJ2*01 CQQSFGTPYTF 9
V3 IGHV4-61*01 IGHD5-12*01 IGHJ4*02 CARARRTFSGYDSAFDYW 14 IGKV1-39*01 IGKJ2*01 CQQSYSTPYTF 7 5,09E+04 2,11E-04 4,14E-09
V3 IGHV4-61*01 IGHD3-9*01 IGHJ4*02 CARARRTFSGYYSAFDYW 13 IGKV1-39*01 IGKJ2*01 CQQSYSTPYTF 7
V1 IGHV4-61*01 IGHD2-2*02 IGHJ6*02 CARIKDVGHCSGGSCYSGAGWFDPW 3 IGKV3-20*01 IGKJ1*01 CQQSGSSPLTF 1
V3 IGHV4-30-4*01 IGHD1-7*01 IGHJ4*02 CARGDKWAFWFGEIDYW 4 IGKV4-1*01 IGKJ4*01 CQQYYSTPLTF 6 6,14E+04 1,47E-05 2,39E-10 3,67E+04 3,16E-05 8,61E-10
V3 IGHV4-39*01 ND IGHJ5*02 CARQTDNWFDPW 16 IGKV3-15*01 IGKJ2*01 CQQYKNWPPYTF 3
V3 IGHV4-39*01 ND IGHJ5*02 CARQTDNWFDPW 17 IGKV3-15*01 IGKJ2*01 CQQYKNWPPYTF 3 1,63E+03 1,18E-04 7,24E-08
V1 IGHV4-61*01 IGHD3-10*01 IGHJ3*02 CARDVRRRFGEFLRPFDLW 16 IGKV1-16*01 IGKJ4*01 CHQYNTYPPTF 6 7,32E+04 3,77E-04 5,15E-09
V1 IGHV4-61*08 IGHD3-10*01 IGHJ3*02 CARDVRRRFGEFFRPFDLW 17 IGKV1-16*01 IGKJ4*01 CHQYNTYPPTF 7
V1 IGHV4-61*08 IGHD3-10*01 IGHJ3*02 CARDVRRRFGEFFRPFDLW 17 IGKV1-16*01 IGKJ4*01 CHQYNTYPPTF 6
V1 IGHV4-61*08 IGHD3-10*01 IGHJ3*02 CARDVRRRFGEFFRPFDLW 18 IGKV1-16*01 IGKJ4*01 CHQYNTYPPTF 6
V2 IGHV4-61*08 IGHD3-10*01 IGHJ3*02 CARDIRRRFGEFFRPFDFW 20 IGKV1-16*01 IGKJ4*01 CHQYNTYPRTF 10 4,60E+05 4,01E-05 8,71E-11
V3 IGHV4-61*08 IGHD3-10*01 IGHJ3*02 CARDIRRRFGEFFRPFDFW 20 IGKV1-16*01 IGKJ4*01 CHQYNTYPRTF 9 7,16E+04 1,14E-04 1,59E-09
V2 IGHV4-61*01 IGHD5-5*01 IGHJ4*02 CARSGPEYSYGYTFDYW 0 IGKV1-5*03 IGKJ1*01 CQQYNSYSGTF 0
V2 IGHV4-34*01 IGHD2-2*03 IGHJ4*02 CARGHFKEEPTLPTMSRPTTPPYFDYW 0 IGKV3-11*01 IGKJ4*01 CQQRSNWPLTF 7
V2 IGHV3-48*01 IGHD1-26*01 IGHJ3*02 CTRDLYTGSPVEAFDIW 19 IGKV1-6*01 IGKJ1*01 CLHDNGYPQTF 7
V2 IGHV3-49*03 IGHD3-10*01 IGHJ4*02 CTRDREGSGSSKPPGPPHFDYW 0 IGKV1D-33*01 IGKJ3*01 CQQYDNLPPVTF 0
V2 IGHV3-30*04 IGHD2-15*01 IGHJ3*02 CARDEDGVAGAFDIW 0 IGKV1-5*03 IGKJ2*01 CQQYNSYPYTF 0 1,77E+02 3,03E-05 1,71E-07 6,53E+04 8,77E-04 1,34E-08
V2 IGHV1-69*06 IGHD3-22*01 IGHJ6*02 CARADHYDSSGSNFFFYGMDVW 8 IGKV3-11*01 IGKJ3*01 CQQRSNWPPLFSF 4
V2 IGHV4-34*01 IGHD2-2*02 IGHJ6*02 CARGPCRSTSCPSYYYGMDVW 0 IGKV1-39*01 IGKJ1*01 CQQSYSTLRAF 0
V3 IGHV7-4-1*02 IGHD3-22*01 IGHJ4*02 CARASYHYDSSGSSPQYYFDSW 13 IGKV1-39*01 IGKJ4*01 CQQSYGTLLTF 4 1,48E+04 1,93E-04 1,30E-08
V3 IGHV1-46*01 IGHD5-5*01 IGHJ6*02 CARDVDLWLTADKGDYYGMDFW 10 IGKV1-16*01 IGKJ5*01 CQRSKTYPPVWRLTN 11
V3 IGHV5-51*01 IGHD3-9*01 IGHJ4*02 CARVYYDW 16 IGKV3-15*01 IGKJ1*01 CQQYNNWPPATF 5 3,31E+03 5,38E-04 1,63E-07 7,55E+03 6,08E-04 8,05E-08
V3 IGHV3-49*03 ND IGHJ5*02 CTRLQYCSYVS 5 IGKV2-28*01 IGKJ3*01 CMQALQSPPFTF 3 1,93E+05 1,12E-05 5,79E-11 1,77E+05 5,70E-05 3,23E-10
V3 IGHV4-59*01 ND IGHJ6*03 CARVMKVGDYYFYYMDVW 13 IGKV3-11*01 IGKJ1*01 CQQRRFWPWTF 5
V3 IGHV3-21*01 IGHD2-21*02 IGHJ4*03 CARDPRARGLLFGNFDYW 12 IGKV3-15*01 IGKJ2*01 CQQYNAWPPYTF 8
V3 IGHV3-15*02 IGHD7-27*01 IGHJ5*02 CTTSAGALAGPGILW 13 IGKV3-20*01 IGKJ4*02 CQQYSISHPLTF 11
V3 IGHV4-59*01 IGHD2-2*02 IGHJ4*02 CARGGPSWTVIDHW 12 IGKV1-39*01 IGKJ3*01 CQQSYSAPLF 7
V3 IGHV4-30-2*01 IGHD3-16*01 IGHJ3*02 CARSSAYVYAFDIW 12 IGKV1-39*01 IGKJ2*01 CQHSSSTPYTF 4
V3 IGHV3-74*01 IGHD2-15*01 IGHJ3*02 CASGDCNSGSCYFRDAFDIW 5 IGKV4-1*01 IGKJ2*01 CQQYKSIPYTF 2 2,16E+03 4,11E-05 1,91E-08 7,10E+03 2,11E-04 2,97E-08
V3 IGHV1-69*01 ND IGHJ6*03 CARGVGTAGTGMDVW 10 IGKV3-15*01 IGKJ3*01 CQNYNDWPRIFTF 5
V3 IGHV4-34*12 IGHD4-17*01 IGHJ5*02 CAQGVVGSW 18 IGKV4-1*01 IGKJ2*01 CQQYYTTPYTF 8 2,36E+05 4,58E-05 1,94E-10
V3 IGHV2-5*04 IGHD2-2*02 IGHJ4*02 CARAVVPARVPFDFW 13 IGKV1-5*03 IGKJ5*01 CQHSNTYVF 11
V3 IGHV4-39*01 IGHD5-12*01 IGHJ5*02 CGRQDATIRLNGPIDLW 12 IGKV1-5*03 IGKJ2*02 CQQYNTYYSTF 9
V3 IGHV3-23*01 IGHD6-19*01 IGHJ3*02 CAKYRRQWLSNECFDIW 12 IGKV3-20*01 IGKJ3*01 CQQYVSSPLTF 7
V3 IGHV2-5*10 IGHD3-10*01 IGHJ4*02 CARSMRMVRGRIEQFDYW 10 IGKV1-9*01 IGKJ5*01 CQHLNNNLITF 4
V3 IGHV1-2*02 IGHD1-26*01 IGHJ4*02 CARGVFSRANYGFLYSFDSW 24 IGKV1-39*01 IGKJ4*01 CQQTFPTSVSF 6
V3 IGHV1-46*01 IGHD2-2*03 IGHJ4*02 CARDPKVWSASSGFDYW 17 IGKV3-20*01 IGKJ1*01 CQQYGSSPRTF 5
V3 IGHV3-15*01 IGHD2-2*02 IGHJ4*02 CTARYCTRTSCYGTPDYW 9 IGKV1-5*03 IGKJ1*01 CQQYNSYSLWTF 7
V3 IGHV3-30*18 IGHD6-19*01 IGHJ4*02 CAKGITRPGVAVRERFDHW 14 IGKV1-39*01 IGKJ4*01 CQQSYNTPFTF 14
V3 IGHV2-5*01 IGHD7-27*01 IGHJ5*02 CARKAPGWGPAFDWFGPW 13 IGKV1-39*01 IGKJ1*01 CQQSHTFPWTF 18
V3 IGHV3-74*01 IGHD7-27*01 IGHJ3*02 CARLGLIW 11 IGKV1-39*01 IGKJ2*01 CQQNYNTPYTF 13
V3 IGHV3-23*01 IGHD6-19*01 IGHJ3*02 CAKHAMGGWYGFGAFDIW 14 IGKV1-5*03 IGKJ1*01 CQHYDTYSPTF 8
V3 IGHV3-21*01 ND IGHJ4*02 CVSGGSLDYW 7 IGKV1-39*01 IGKJ1*01 CLQTFTQSRTF 13
V3 IGHV2-26*01 IGHD3-3*01 IGHJ4*02 CARVRGRRIPLFGGTIIRGARFDYW 16 IGKV1D-33*01 IGKJ3*01 CQQYDYLPDSAF 5 2,08E+05 2,38E-05 1,14E-10
V3 IGHV3-74*01 IGHD3-16*02 IGHJ3*01 CARKLRVWGPFRLDAFDVW 10 IGKV1-39*01 IGKJ4*02 CHQSYITPLTF 10
V3 IGHV3-48*01 IGHD2-21*02 IGHJ3*02 CVRVLRWNNDAFHIW 16 IGKV3-20*01 IGKJ2*01 CQQYGSSPYTF 11
V3 IGHV4-59*01 IGHD5-24*01 IGHJ3*01 CARSREPYDMKAFDVW 14 IGKV4-1*01 IGKJ2*03 CQQYLNTPYIF 10
V3 IGHV3-23*01 IGHD5-12*01 IGHJ4*02 CAKAGIQWLRDYFYDSW 12 IGKV1-5*03 IGKJ1*01 CQPYNGDSPTF 6
V3 IGHV3-64*05 IGHJ5*02 CVKDSGVTPSVW 5 IGKV4-1*01 IGKJ1*01 CQQYYSSLPWTF 1 1,89E+04 3,07E-05 1,63E-09
V3 IGHV4-59*02 IGHD6-19*01 IGHJ4*02 CAREKESAGWNAHYFDYW 30 IGKV1-5*03 IGKJ1*01 CQQYYSYPWA 5 3,84E+05 1,74E-05 4,53E-11 5,76E+04 1,97E-04 3,43E-09  
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Supplementary table 1b. Repertoire and affinities of antibody clonotypes from donor TT2 
Repertoire VH gene D gene JH gene H-CDR3
# of 
SHM, 
H VK gene JK gene K-CDR3
# of 
SHM, 
L
On-rate, 
25C
Off-rate, 
25C
Calc. KD, 
25C, M
On-rate, 
37C
Off-rate, 
37C
Calc. KD, 
37C, M
V2 IGHV1-18*01 IGHD4-4*01 IGHJ4*02 CARDYSSPYYFDYW 10 IGKV1-39*01 IGKJ2*01 CQESYKIPYTF 6
V2 IGHV1-18*01 IGHD4-4*01 IGHJ4*02 CARDYSSPYYFDYW 10 IGKV1-39*01 IGKJ2*01 CQESYKIPYTF 6 1,31E+06 1,21E-04 9,25E-11
V2 IGHV1-18*01 IGHD4-4*01 IGHJ4*02 CARDYSSPYYFDYW 9 IGKV1-39*01 IGKJ2*01 CQESYKIPYTF 6 2,72E+05 1,44E-04 5,27E-10 9,45E+04 7,00E-04 7,41E-09
V2 IGHV1-18*01 IGHD3-16*01 IGHJ4*02 CARDHSSPYYFDYW 9 IGKV1-39*01 IGKJ2*01 CQESYKIPYTF 6
V2 IGHV1-18*01 IGHD4-4*01 IGHJ4*02 CARDYSSPYYFDYW 9 IGKV1-39*01 IGKJ2*01 CQESYKIPYTF 7
V1 IGHV1-18*01 IGHD3-10*01 IGHJ4*02 CARDYFGSGPIYYFDHW 17 IGKV1-39*01 IGKJ2*01 CQQSYKTPYTF 7
V1 IGHV1-18*01 IGHD3-10*01 IGHJ4*02 CARDYFGSGPIYYFDHW 17 IGKV1-39*01 IGKJ2*01 CQQSYKTPYTF 7
V1 IGHV1-18*01 IGHD3-10*01 IGHJ4*02 CARDYFGSGPIYYFDHW 16 IGKV1-39*01 IGKJ2*01 CQQSYKTPYTF 7
V1 IGHV1-18*01 IGHD3-10*01 IGHJ4*02 CARDYYGSGSHYYFDYW 9 IGKV1-39*01 IGKJ2*02 CQQIYSTPRTF 10 3,31E+07 8,94E-05 2,70E-12
V3 IGHV1-18*01 IGHD3-10*01 IGHJ4*02 CARDWNQGSGIYYISDW 8 IGKV1-39*01 IGKJ2*01 CQQTYRTPYTF 7 1,82E+05 2,54E-05 1,40E-10 2,03E+06 1,95E-04 9,61E-11
V3 IGHV1-18*01 IGHD3-10*01 IGHJ4*02 CARDWNQGSGIYYISDW 8 IGKV1-39*01 IGKJ2*01 CQQTYRTPYTF 7
V3 IGHV1-18*01 IGHD3-10*01 IGHJ4*02 CARDWNQGSGIYYISDW 8 IGKV1-39*01 IGKJ2*01 CQQTYRTPYTF 8
V3 IGHV1-18*01 IGHD3-10*01 IGHJ4*02 CARDWNQGSGIYYISDW 8 IGKV1-39*01 IGKJ2*01 CQQTYRTPYTF 8 1,21E+05 4,26E-05 3,53E-10 1,35E+05 2,22E-04 1,64E-09
V3 IGHV1-18*01 IGHD3-10*01 IGHJ4*02 CARDWNQGSGIYYISDW 8 IGKV1-39*01 IGKJ2*01 CQQTYRTPYTF 8
V2 IGHV1-8*01 ND IGHJ5*02 CARGAGAQGYDWFDPW 6 IGKV1-17*01 IGKJ1*01 CLQCDNTGRSAKGPRW 5
V1 IGHV1-2*02 IGHD2-2*02 IGHJ4*02 CATWVSRESSFDYW 12 IGKV3-11*01 IGKJ2*01 CQQRSYWYTF 4
V2 IGHV1-3*01 IGHD4-17*01 IGHJ1*01 CARVSRYGDYGPEYFQHW 10 IGKV2-28*01 IGKJ1*01 CVQGLQSRTF 1
V1 IGHV1-46*01 IGHD2-2*03 IGHJ6*03 CARQYCSSASCYASLRHSGQFYYFMDVW 18 IGKV3-20*01 IGKJ5*01 CQERITF 6
V1 IGHV1-46*01 IGHD2-2*03 IGHJ6*03 CARQYCSSASCYVSLRHSGQFYYFMDVW 18 IGKV3-20*01 IGKJ5*01 CQERITF 6
V1 IGHV1-46*01 IGHD2-2*03 IGHJ6*03 CARQYCSSASCYVSLRHSGQFYYFMDVW 18 IGKV3-20*01 IGKJ5*01 CQERITF 7
V3 IGHV1-46*01 IGHD3-10*01 IGHJ5*02 CARATLTDWSGRFWFDPW 7 IGKV3-20*01 IGKJ3*01 CQQYDDSGHFTF 8
V1 IGHV3-21*01 ND IGHJ6*03 CARYLGSTRGYYYMDVW 18 IGKV3-20*01 IGKJ3*01 CQQYGSSPPITF 6 7,49E+04 2,09E-04 2,79E-09
V1 IGHV3-21*01 ND IGHJ6*03 CARYLGSTRGYYYMDVW 19 IGKV3-20*01 IGKJ3*01 CQQYGSSPPITF 6
V2 IGHV3-21*01 ND IGHJ6*03 CARYRGGTRGYYYMDVW 13 IGKV3-20*01 IGKJ3*01 CQQYASSPPITF 8 3,63E+06 8,72E-06 2,40E-12
V2 IGHV3-21*01 ND IGHJ6*03 CARYRGGTRGYYYMDVW 14 IGKV3-20*01 IGKJ3*01 CQQYASSPPITF 8
V2 IGHV1-69*01 IGHD1-14*01 IGHJ6*02 CARARYSYYDSSGYYRLDFW 6 IGKV1-9*01 IGKJ3*01 CQQLNSPPLTF 4
V1 IGHV1-69*08 IGHD2-2*02 IGHJ5*02 CARGKDCRANNCYLSERNNWFDPW 18 IGKV1-5*03 IGKJ4*01 CQQYNSYFLTF 1 3,84E+05 3,97E-05 1,03E-10
V2 IGHV1-69*01 IGHD2-2*02 IGHJ5*02 CARGKDCRSNNCYLSERNNWFDPW 17 IGKV1-5*03 IGKJ4*01 CQQYNSYFLTF 2 3,49E+05 4,53E-05 1,30E-10 7,46E+05 1,50E-04 2,01E-10
V2 IGHV1-69*01 IGHD2-2*02 IGHJ5*02 CARGKDCRSNNCYLSERSNWFDPW 17 IGKV1-5*03 IGKJ4*01 CQQYNSYFLTF 2
V2 IGHV1-69*11 IGHD2-2*02 IGHJ5*02 CARGKDCRSNNCYLSERNNWFDPW 17 IGKV1-5*03 IGKJ4*01 CQQYNSYFLTF 3
V3 IGHV1-69*01 IGHD2-2*02 IGHJ5*02 CARGKDCRSNGCFLSERNNWFDPW 18 IGKV1-5*03 IGKJ4*01 CQQYNSYFLTF 2 5,60E+05 2,48E-05 3,91E-11 1,13E+05 7,27E-05 6,45E-10
V3 IGHV1-69*01 IGHD2-2*02 IGHJ5*02 CARGKDCRSNGCFLSERNNWFDPW 18 IGKV1-5*03 IGKJ4*01 CQQYNSYFLTF 8
V3 IGHV1-69*01 IGHD2-2*02 IGHJ5*02 CARGKDCRSNGCFLSERNNWFDPW 18 IGKV1-5*03 IGKJ4*01 CQQYNSYFLTF 3 2,76E+04 6,67E-05 2,42E-09 5,70E+04 5,18E-05 9,08E-10
V3 IGHV1-69*01 IGHD2-2*02 IGHJ5*02 CARGKDCRSNGCFLSERNNWFDPW 18 IGKV1-5*03 IGKJ4*01 CQQYNSYFLTF 3
V1 IGHV1-69*01 IGHD6-6*01 IGHJ3*02 CARGVAGIASRRHAYDIW 12 IGKV1-39*01 IGKJ2*02 CQQSYSIPSTF 4
V1 IGHV1-69*01 IGHD1-26*01 IGHJ4*02 CAKLPSGSYYDYFDSW 16 IGKV3-20*01 IGKJ4*01 CQHYGNSLAPPF 6
V1 IGHV1-46*01 IGHD2-21*02 IGHJ6*02 CARLGIAARHYFYGVDVW 17 IGKV1-27*01 IGKJ1*01 CQKYNSAPLTF 4 8,01E+04 3,18E-03 3,97E-08
V1 IGHV1-46*01 IGHD2-21*02 IGHJ6*02 CARLGIAARHYFYGVDVW 18 IGKV1-27*01 IGKJ1*01 CQKYNSAPLTF 4
V1 IGHV1-24*01 IGHD3-3*01 IGHJ4*02 CTTVGEALITLFGTVIRRARDFDSW 6 IGKV1-16*01 IGKJ4*01 CQQYDGYPLTF 6
V2 IGHV1-24*01 IGHD3-3*01 IGHJ4*02 CATVGETRFTLFGTLMRRPRELRDW 18 IGKV1-16*01 IGKJ4*01 CQQYDSYPLTF 8 4,53E+05 8,68E-05 1,92E-10
V3 IGHV5-51*01 IGHD3-3*01 IGHJ6*03 CARTQYDAWSGSVLEDIYYYYYMDVW 6 IGKV3-20*01 IGKJ1*01 CQYQGPF 5
V3 IGHV5-51*01 IGHD3-3*01 IGHJ6*03 CARTQYDAWSGSVLEDIYYYYYMDVW 6 IGKV3-20*01 IGKJ1*01 CQYQGPF 6
V3 IGHV5-51*01 IGHD3-3*01 IGHJ6*03 CARTQYDAWSGSVLEDIYYYYYMDVW 7 IGKV3-20*01 IGKJ1*01 CQYQGPF 6
V3 IGHV5-51*01 IGHD3-3*01 IGHJ6*03 CARTQYDAWSGSVLEDIYYYYYMDVW 7 IGKV3-20*01 IGKJ1*01 CQYQGPF 5
V3 IGHV5-51*01 IGHD3-3*01 IGHJ6*03 CARTQYDAWSGSVLEDIYYYYYMDVW 7 IGKV3-20*01 IGKJ1*01 CQYQGPF 5 1,93E+05 3,17E-05 1,64E-10
V3 IGHV5-51*01 IGHD3-3*01 IGHJ6*03 CARTQYDAWSGSVLEDIYYYYYMDVW 7 IGKV3-20*01 IGKJ1*01 CQYQGPF 5
V1 IGHV5-51*01 IGHD6-6*01 IGHJ5*02 CARLMRYSSPSGRLEGLVGRFDPW 14 IGKV1-39*01 IGKJ2*01 CQQSYSTPYTF 11
V1 IGHV3-21*01 ND IGHJ4*02 CASGSTLDYW 8 IGKV1-39*01 IGKJ1*01 CLQNYIPRRTF 9
V1 IGHV3-21*01 ND IGHJ4*02 CASGSTLDYW 7 IGKV1-39*01 IGKJ1*01 CLQNYIPRRTF 9
V1 IGHV3-21*01 ND IGHJ4*02 CVSGSSLDYW 11 IGKV1-39*01 IGKJ1*01 CLQTYSPRRTF 8
V1 IGHV3-21*01 ND IGHJ4*02 CVSGSSLDYW 11 IGKV1-39*01 IGKJ1*01 CLQTYSPRRTF 8
V1 IGHV3-21*02 ND IGHJ4*02 CVSGSSLDYW 12 IGKV1-39*01 IGKJ1*01 CLQTYSPRRTF 8
V1 IGHV3-21*01 ND IGHJ4*02 CVSGSSLDYW 12 IGKV1-39*01 IGKJ1*01 CLQTYSPRRTF 8
V1 IGHV3-21*01 ND IGHJ4*02 CATGVTMDYW 13 IGKV3-20*01 IGKJ1*01 CQQYGSLPRTF 4 1,41E+03 6,72E-04 4,78E-07
V2 IGHV3-21*01 IGHD4-23*01 IGHJ4*02 CATGNTLDYW 10 IGKV3-20*01 IGKJ1*01 CHQYFSSPRTF 8
V2 IGHV3-21*01 ND IGHJ4*02 CATGNTLDYW 10 IGKV3-20*01 IGKJ1*01 CHQYFSSPRTF 8
V2 IGHV3-21*01 ND IGHJ4*02 CATGNTLDYW 11 IGKV3-20*01 IGKJ1*01 CHQYFSSPRTF 8
V2 IGHV3-21*01 ND IGHJ4*02 CTSGVTFDYW 16 IGKV3-20*01 IGKJ2*02 CRQYGSSPTTF 10 3,75E+05 1,01E-04 2,68E-10
V2 IGHV3-21*01 ND IGHJ4*02 CTSGVTFDYW 17 IGKV3-20*01 IGKJ2*02 CRQYGSSPTTF 10
V2 IGHV3-21*01 ND IGHJ4*02 CTSGVTFDYW 17 IGKV3-20*01 IGKJ2*02 CRQYGSSPTTF 11
V2 IGHV3-21*01 IGHD1-26*01 IGHJ1*01 CVNGDYVV 10 IGKV2-30*01 IGKJ1*01 CMQGTHWPRTF 2
V3 IGHV3-21*01 IGHD4-17*01 IGHJ4*02 CVNGDYVV 7 IGKV2-30*01 IGKJ1*01 CMQGTHWPRTF 5 3,68E+05 9,29E-06 2,52E-11 7,02E+05 1,48E-05 2,11E-11
V3 IGHV3-21*01 IGHD2-21*02 IGHJ4*02 CVNGDYVV 14 IGKV2-30*01 IGKJ1*01 CMQGTHWPRTF 3
V1 IGHV3-21*01 ND IGHJ4*02 CVTGSSHDFW 15 IGKV1-39*01 IGKJ1*01 CQQTYSDIRTF 7
V1 IGHV3-21*01 IGHD6-25*01 IGHJ3*01 CARDRAQIWGYRRGGDALDVW 13 IGKV3-20*01 IGKJ1*01 CHQYGSSPPWTF 3
V2 IGHV3-11*01 IGHD7-27*01 IGHJ2*01 CARRPNLWGSALWYFDLW 12 IGKV1-9*01 IGKJ5*01 CQQLNSFPTF 4
V3 IGHV3-11*01 IGHD7-27*01 IGHJ2*01 CARRPNLWGSALWYFDLW 16 IGKV1-9*01 IGKJ5*01 CQQLNSFPTF 7 1,08E+05 4,75E-04 4,39E-09 5,90E+04 7,79E-04 1,32E-08
V1 IGHV3-23*01 IGHD3-3*02 IGHJ3*01 CVKYLWGGYAIDVW 10 IGKV1-39*01 IGKJ1*01 CQQSYITPWTF 14
V1 IGHV3-23*01 IGHD3-3*02 IGHJ6*02 CVKYLWGGYAIDVW 10 IGKV1-39*01 IGKJ1*01 CQQSYITPWTF 13 8,14E+05 1,57E-04 1,93E-10
V1 IGHV3-23*01 IGHD4-17*01 IGHJ6*02 CAKYLSGGYAIDVW 13 IGKV1-39*01 IGKJ1*01 CQQSYITPWTF 11 4,29E+06 2,51E-04 5,84E-11
V2 IGHV3-23*01 IGHD2-8*02 IGHJ6*02 CAKYLSGGYAIDVW 20 IGKV1-39*01 IGKJ1*01 CQQSYITPWTF 11  
25 
Repertoire VH gene D gene JH gene H-CDR3
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37C
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37C
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V1 IGHV3-23*01 IGHD3-3*01 IGHJ4*02 CAEGLIFGVAAYYFDHW 5 IGKV3-11*01 IGKJ4*01 CQHRGNWPRTF 4
V1 IGHV3-23*01 IGHD3-3*01 IGHJ4*02 CAKGLIFGVAAYYFDHW 5 IGKV3-11*01 IGKJ4*01 CQHRGNWPRTF 4
V1 IGHV3-23*01 IGHD3-3*01 IGHJ4*02 CAKGLIFGVAAYYFDHW 5 IGKV3-11*01 IGKJ4*01 CQHRGNWPRTF 4
V1 IGHV3-23*01 IGHD3-3*01 IGHJ4*02 CAKGLIFGVAAYYFDYW 6 IGKV3-11*01 IGKJ4*01 CQHRGNWPRTF 6
V1 IGHV3-23*01 IGHD3-3*01 IGHJ4*02 CAKGLIFGVAAYYFDYW 7 IGKV3-11*01 IGKJ4*01 CQHRGNWPRTF 4 5,19E+05 1,38E-04 2,66E-10
V1 IGHV3-23*01 IGHD3-3*01 IGHJ4*02 CAKGLIFGVPAYYFDSW 9 IGKV3-11*01 IGKJ4*01 CQHRGNWPRTF 2
V1 IGHV3-23*01 IGHD3-3*01 IGHJ4*02 CAKDLILGVPHYYFDSW 9 IGKV3-11*01 IGKJ1*01 CQHRANWPRTF 7
V1 IGHV3-23*01 IGHD3-3*01 IGHJ4*02 CAKDLILGVPHYYFDSW 10 IGKV3-11*01 IGKJ1*01 CQHRANWPRTF 7
V1 IGHV3-23*01 IGHD3-3*01 IGHJ4*02 CAKDLILGVPHYYFDSW 10 IGKV3-11*01 IGKJ1*01 CQHRANWPRTF 6 4,45E+05 2,65E-04 5,95E-10
V1 IGHV3-23*01 IGHD3-3*01 IGHJ4*02 CAKGLIFGVPAYYFDSW 11 IGKV3-11*01 IGKJ4*01 CQHRGNWPRTF 3 2,79E+05 1,01E-03 3,62E-09
V2 IGHV3-23*01 IGHD3-3*02 IGHJ4*02 CAKGLIFGVAAYYFDSW 16 IGKV3-11*01 IGKJ4*01 CQHRGNWPRTF 6 3,53E-10
V3 IGHV3-23*01 IGHD3-3*01 IGHJ4*02 CAKSLIFGVAAYYFDSW 15 IGKV3-11*01 IGKJ4*01 CQHRGNWPRTF 4
V3 IGHV3-23*01 IGHD3-3*01 IGHJ4*02 CAKSLIFGVAAYYFDSW 15 IGKV3-11*01 IGKJ4*01 CQHRGNWLLTF 9
V3 IGHV3-23*01 IGHD2-2*02 IGHJ4*02 CAKADNIVLVPAALTRPVDYW 13 IGKV4-1*01 IGKJ1*01 CQQYYTTPWTF 4 1,17E+05 3,13E-05 2,68E-10
V3 IGHV3-23*01 IGHD2-2*02 IGHJ4*02 CAKADNIVLVPAALTRPVDYW 13 IGKV4-1*01 IGKJ1*01 CQQYYTTPWTF 5
V1 IGHV3-48*02 IGHD5-24*01 IGHJ6*03 CARGVLGGYNNGLYYYYYLDVW 13 IGKV3-20*01 IGKJ5*01 CQQCGSSPYAF 3
V1 IGHV3-48*02 IGHD3-3*02 IGHJ4*02 CARDLFFGPLKGLFDSW 6 IGKV3-20*01 IGKJ1*01 CQQYHNSPWTF 7
V1 IGHV3-48*02 IGHD3-3*02 IGHJ4*02 CARDLFFGPLKGLFDSW 5 IGKV3-20*01 IGKJ1*01 CQQYHNSPWTF 6
V1 IGHV3-23*01 IGHD6-19*01 IGHJ4*02 CAKGRKQWLVPDFDSW 13 IGKV1-12*01 IGKJ5*01 CQQTKTFPLTF 10 1,10E+05 4,65E-04 4,22E-09
V1 IGHV3-74*01 IGHD2-8*02 IGHJ6*03 CVRPRGYCADGLCYPALYFYYMDVW 4 IGKV1-27*01 IGKJ3*01 CQKYNSVPLTF 4
V2 IGHV3-30*18 IGHD2-2*03 IGHJ6*01 CAKGLSQALNYYGSGSPFL 11 IGKV1-9*01 IGKJ2*01 CQQLNSYPYTF 10
V2 IGHV3-30*18 ND IGHJ4*02 CAKDRITAADYW 13 IGKV1-39*01 IGKJ1*01 CQQSYTIWWTF 13
V2 IGHV3-33*01 IGHD2-8*01 IGHJ4*02 CARERGHDTNGQPDNW 8 IGKV1-39*01 IGKJ2*02 CQQSYSPPFTF 10 3,23E+05 9,40E-05 2,90E-10
V2 IGHV3-33*01 IGHD2-8*01 IGHJ4*02 CARERGHDTNGQPDNW 8 IGKV1-39*01 IGKJ2*02 CQQSYSPPFTF 10
V2 IGHV3-33*01 IGHD3-10*02 IGHJ5*02 CARARGPYSGTYYATGWW 11 IGKV1D-33*01 IGKJ3*01 CQQYHNLPLTF 10
V2 IGHV3-33*01 IGHD3-10*02 IGHJ5*02 CARARGPYSGTYYATGWW 11 IGKV1-39*01 IGKJ2*01 CQQSFSTLYTF 6
V1 IGHV3-33*01 IGHD3-10*02 IGHJ4*02 CARGSGTYSFLDNW 7 IGKV1-17*01 IGKJ1*01 CLQHNSYPPTF 7 3,96E+04 3,58E-04 9,03E-09
V1 IGHV3-33*01 IGHD6-25*01 IGHJ3*02 CARDSAPLSRRGALGIW 15 IGKV1-6*01 IGKJ2*01 CLQDYNYPYSF 3 3,20E+03 7,96E-04 2,49E-07
V1 IGHV3-33*01 IGHD6-25*01 IGHJ3*02 CARDSAPLSRRGALGIW 16 IGKV1-6*01 IGKJ2*01 CLQDYNYPYSF 4
V1 IGHV3-30*18 IGHD3-3*01 IGHJ6*03 CGKDHIGYNSQSGYRPESYYYMDLW 11 IGKV3-11*01 IGKJ4*01 CQQRNNWPPLTF 6
V1 IGHV3-30*18 IGHD3-3*01 IGHJ6*03 CGKDHIGYNSRSGYRPESYYYMDLW 11 IGKV3-11*01 IGKJ4*01 CQQRNNWPPLTF 5
V1 IGHV3-30*18 IGHD3-3*01 IGHJ6*03 CGKDHVGYNSRSGYRPESYYYMDLW 11 IGKV3-11*01 IGKJ4*01 CQQRNNWPPLTF 5
V1 IGHV3-7*01 IGHD6-13*01 IGHJ4*03 CARAGSSWSLRPTTFDYW 14 IGKV1-6*01 IGKJ1*01 CQQFYHYPRTF 7
V1 IGHV3-7*01 IGHD6-13*01 IGHJ4*02 CARASSSWSLRPTTFDYW 14 IGKV1-6*01 IGKJ1*01 CQQFYHYPRTF 7
V2 IGHV3-7*01 IGHD6-13*01 IGHJ4*02 CARAGSSWSLRPTTFDYW 14 IGKV1-6*01 IGKJ1*01 CQQFYHYPRTF 7
V2 IGHV3-7*01 IGHD6-13*01 IGHJ4*02 CARAGSSWSLRPTTFDYW 14 IGKV1-6*01 IGKJ1*01 CQQFYHYPRTF 7 1,21E+06 1,47E-04 1,22E-10 6,57E+05 7,35E-04 1,12E-09
V1 IGHV3-7*01 IGHD6-13*01 IGHJ4*02 CARAGSSWSLRPTTFDYW 13 IGKV1-6*01 IGKJ1*01 CQQFYHYPRTF 7 9,07E+05 1,45E-04 1,60E-10
V2 IGHV3-7*01 IGHD6-13*01 IGHJ4*02 CARAGSSWSLRPTTFDYW 13 IGKV1-6*01 IGKJ1*01 CQQFYHYPRTF 7 2,89E+05 1,27E-04 4,38E-10 1,30E+06 7,01E-04 5,40E-10
V2 IGHV3-7*01 IGHD6-13*01 IGHJ4*02 CARAGTSWSLRPTTFDYW 13 IGKV1-6*01 IGKJ1*01 CQQFYHYPRTF 7
V3 IGHV3-7*01 IGHD6-13*01 IGHJ4*02 CARAGSSWSLRPTTFDYW 13 IGKV1-6*01 IGKJ1*01 FQQFYHYPRTF 8 8,93E+05 2,29E-04 2,56E-10
V3 IGHV3-7*01 IGHD6-13*01 IGHJ4*02 CARAGSSWSLRPTTFDYW 13 IGKV1-6*01 IGKJ1*01 CQQFYHYPRTF 8
V3 IGHV3-7*01 IGHD6-13*01 IGHJ4*02 CARAGSSWSLRPTTFDYW 13 IGKV1-6*01 IGKJ1*01 CQQFYHYPRTF 7
V1 IGHV3-7*01 IGHD3-16*02 IGHJ5*02 CARDGVITLGGVIELRWYDPW 16 IGKV1-9*01 IGKJ4*01 CQQLHSYPFTF 8 1,70E+03 5,58E-04 3,28E-07
V2 IGHV3-7*01 IGHD5-24*01 IGHJ4*02 CARSTHSSADYW 9 IGKV3-11*01 IGKJ1*01 CQQRSHWPPTWTF 10
V2 IGHV3-15*01 IGHD3-3*01 IGHJ4*02 CTATYYDFWSGLSRGGYW 7 IGKV1-5*01 IGKJ4*01 CQQYNAYSALTF 5
V2 IGHV3-15*01 IGHD3-3*01 IGHJ4*02 CTATYYDFWSGLSRGGYW 7 IGKV1-5*03 IGKJ1*01 CQQYNSFPWTF 9
V2 IGHV3-49*03 IGHD2-21*02 IGHJ6*02 CARGCPEIAVRAIYYYGMDVW 10 IGKV1-39*01 IGKJ1*01 CQHSYTTPWSF 5
V1 IGHV4-59*01 IGHD2-2*02 IGHJ3*02 CARRHYCSSTSCYDAFDIW 10 IGKV1-39*01 IGKJ2*01 CQQTFSTLYTF 4 2,66E+05 1,12E-04 4,21E-10
V2 IGHV4-59*01 IGHD2-2*02 IGHJ3*02 CARRHYCRSTSCYDAFDIW 13 IGKV1-39*01 IGKJ2*01 CQQSFSTLYTF 6
V2 IGHV4-59*01 IGHD2-2*02 IGHJ3*02 CARRHYCRSTSCYDAFDIW 13 IGKV1-39*01 IGKJ2*01 CQQSFSTLYTF 7
V2 IGHV4-59*01 IGHD2-2*02 IGHJ3*02 CARRHYCRSTSCYDAFDTW 13 IGKV1D-33*01 IGKJ3*01 CQQYHNLPLTF 10 4,39E+04 1,00E-04 2,28E-09
V1 IGHV4-59*01 IGHD6-6*01 IGHJ5*02 CAREEFTSSSRWFDPW 14 IGKV1-39*01 IGKJ2*01 CQQSYSTPYTF 6
V1 IGHV4-59*01 IGHD6-6*01 IGHJ5*02 CAREEFTSSSRWFDPW 13 IGKV1-39*01 IGKJ2*01 CQQSYSTPYTF 5
V2 IGHV4-59*01 IGHD6-6*01 IGHJ5*02 CAREEFTSSSRWFDPW 13 IGKV1-39*01 IGKJ2*01 CQQSYSTPYTF 5 5,83E+05 2,36E-05 4,04E-11
V1 IGHV4-59*01 IGHD3-3*02 IGHJ5*02 CARVRINLYGALLLSWFDSW 20 IGKV1-39*01 IGKJ1*01 CQQSDIIPWTF 6
V1 IGHV4-59*01 IGHD3-3*01 IGHJ2*01 CARVRVSLIGVVVHRYFDLW 17 IGKV3-20*01 IGKJ4*01 CQQYYSSLTF 12
V1 IGHV4-59*01 IGHD3-3*02 IGHJ2*01 CVRERVRVYGEIVHKYFDLW 14 IGKV1-39*01 IGKJ4*02 CQHRYDTATVTF 12
V1 IGHV4-59*01 IGHD3-3*02 IGHJ2*01 CVRERVRVYGEIVHKYFDLW 13 IGKV3-15*01 IGKJ2*01 CQQYNNWPTLYTF 0
V1 IGHV4-59*01 IGHD3-3*02 IGHJ2*01 CARERVRVYGEIIHKYFDLW 11 IGKV1-39*01 IGKJ4*01 XQQRYSTATVTF 9  
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V2 IGHV3-13*01 IGHD4-17*01 IGHJ6*02 CARAKQGHTGLDVW 8 IGKV2-28*01 IGKJ2*02 CMQALQTPRTF 4
V1 IGHV1-8*01 ND IGHJ5*02 CAVVAENWFDPW 20 IGKV3-15*01 IGKJ2*01 CQQYRNWPPYTF 6
V1 IGHV1-8*01 ND IGHJ5*02 CAVVAENWFDPW 20 IGKV3-15*01 IGKJ2*01 CQQYRNWPPYTF 6
V1 IGHV4-4*02 IGHD2-21*02 IGHJ5*02 CARLPKHYIAEAVTW 12 IGKV1-5*03 IGKJ5*01 CQQYNSYPITF 10
V1 IGHV4-4*02 IGHD2-21*02 IGHJ1*01 CARLPKHYIAEAVTW 12 IGKV1-5*03 IGKJ5*01 CQQYNSYPITF 8
V1 IGHV4-4*02 IGHD2-21*02 IGHJ1*01 CARLPKHYIAEAVTW 10 IGKV1-5*03 IGKJ5*01 CQQYNSYPTTF 10 5,10E+04 7,54E-04 1,48E-08
V3 IGHV4-4*02 IGHD2-21*02 IGHJ5*02 CARLPKHYIAEAVTW 11 IGKV1-5*03 IGKJ5*01 CQQYNSYPITF 9 5,13E+04 2,03E-04 3,96E-09 8,91E+04 2,91E-04 3,26E-09
V3 IGHV4-4*02 IGHD2-21*02 IGHJ5*02 CARLPKHYIAEAVTW 11 IGKV1-5*03 IGKJ5*01 CQQYNSYPITF 9
V3 IGHV4-4*02 IGHD2-21*02 IGHJ1*01 CARLPKHYIAEAVTW 11 IGKV1-5*03 IGKJ5*01 CQQYNSYPITF 9
V2 IGHV3-30*03 IGHD3-10*01 IGHJ5*02 CARDLYSGSGSNWATNRFDPW 17 IGKV3-15*01 IGKJ3*01 CQQYNSWPLTF 6
V2 IGHV3-30*18 IGHD3-10*01 IGHJ5*02 CAKDLFSGSGSTWATNRLDPW 12 IGKV3-15*01 IGKJ3*01 CQQYNSWPLTF 6
V3 IGHV2-5*10 IGHD1-1*01 IGHJ4*02 CARSVFPVLPFDFW 10 IGKV1-5*03 IGKJ1*01 CQEYSNYSGTF 8
V3 IGHV2-5*10 IGHD1-1*01 IGHJ4*02 CARSVFPVLPFDFW 11 IGKV1-5*03 IGKJ1*01 CQEYSNYSGTF 8 5,58E+04 6,01E-05 1,08E-09 7,88E+04 1,09E-04 1,38E-09
V3 IGHV2-5*10 IGHD1-1*01 IGHJ4*02 CARSVFPVLPFDFW 11 IGKV1-5*03 IGKJ1*01 CQEYSNYSGTF 9 7,46E+04 4,29E-05 5,75E-10
V2 IGHV2-5*01 IGHD2-2*02 IGHJ4*02 CARTVVPAGVGFDYW 8 IGKV1-5*03 IGKJ2*03 CQQYNSYSSYDF 7
V3 IGHV2-5*01 IGHD2-2*02 IGHJ4*02 CARTVVPAGVGFDYW 7 IGKV1-5*03 IGKJ2*03 CQQYNSYSSYDF 8 5,12E+05 5,60E-04 1,09E-09
V3 IGHV2-5*01 IGHD2-2*02 IGHJ4*02 CARTVVPAGVGFDYW 7 IGKV1-5*03 IGKJ2*03 CQQYNSYSSYDF 7
V3 IGHV2-5*01 IGHD2-2*02 IGHJ4*02 CARTVLPATFAFDFW 17 IGKV1-5*03 IGKJ1*01 CQHYDTYSWTF 7 4,36E+04 9,58E-05 2,20E-09 6,98E+04 1,68E-04 2,41E-09
V3 IGHV2-5*01 IGHD2-2*02 IGHJ4*03 CARTVLPATFAFDFW 16 IGKV1-5*03 IGKJ1*01 CQHYDTYSWTF 7
V3 IGHV2-5*01 IGHD2-2*02 IGHJ4*02 CARTVLPATFAFDFW 16 IGKV1-5*03 IGKJ1*01 CQHYDTYSWTF 7
V3 IGHV2-5*01 IGHD2-2*02 IGHJ4*02 CARTVLPATFAFDFW 16 IGKV1-5*03 IGKJ1*01 CQHYDTYSWTF 8
V1 IGHV2-5*04 IGHD3-3*01 IGHJ4*02 CVHLPPYRISLFGEDLYRPTYFDFW 16 IGKV1D-33*01 IGKJ3*01 CQQYDDLPLTF 7
V1 IGHV2-26*01 IGHD3-3*01 IGHJ5*02 CARINGNVTIFGMVLPRGWFDPW 12 IGKV1D-33*01 IGKJ4*01 CQQYDTLPLSF 9
V1 IGHV2-26*01 IGHD3-3*01 IGHJ5*02 CARINGYVTVFGMILPRGWFDPW 11 IGKV1D-33*01 IGKJ4*01 CQQYDTLPLSF 7
V1 IGHV2-26*01 IGHD3-3*01 IGHJ5*02 CARINGNVKIFGMVLPRGWFDPW 10 IGKV1D-33*01 IGKJ4*01 CQQYDTLPLSF 10
V1 IGHV2-26*01 IGHD3-3*01 IGHJ5*02 CARINGYVTVFGMILPRGWFDPW 9 IGKV1D-33*01 IGKJ4*01 CQQYDTLPLSF 8 1,41E+06 8,84E-05 6,26E-11
V1 IGHV2-26*01 IGHD3-3*01 IGHJ5*02 CARVNGYVTVFGMILPRGWFDPW 9 IGKV1D-33*01 IGKJ4*01 CQQYDTLPLSF 7
V1 IGHV2-26*01 IGHD3-3*01 IGHJ5*02 CARINGNVTIFGMVLPRGWFDPW 9 IGKV1D-33*01 IGKJ4*01 CQQYDTLPLSF 7
V1 IGHV2-26*01 IGHD3-3*01 IGHJ5*02 CARINGNVMVFGMVLPRGWFDPW 8 IGKV1D-33*01 IGKJ4*01 CQQYDTLPLSF 8
V1 IGHV2-26*01 IGHD3-3*01 IGHJ5*02 CARINGNVTIFGMILPRGWFDPW 8 IGKV1D-33*01 IGKJ4*01 CQQYDTLPLSF 8 6,21E+04 6,87E-05 1,11E-09
V1 IGHV2-26*01 IGHD3-3*01 IGHJ5*02 CARINGNVTIFGMVLPRGWFDPW 8 IGKV1D-33*01 IGKJ4*01 CQQYDTLPLSF 8 5,22E+04 2,10E-04 4,02E-09
V2 IGHV2-26*01 IGHD3-3*01 IGHJ5*02 CARINGNVTIFGMVLPRGWFDPW 8 IGKV1D-33*01 IGKJ4*01 CQQYDTLPLSF 10 5,19E+05 5,63E-05 1,08E-10 8,62E+05 1,40E-04 1,63E-10
V2 IGHV2-26*01 IGHD3-3*01 IGHJ5*02 CARINGNVTIFGMVLPRGWFDPW 9 IGKV1D-33*01 IGKJ4*01 CQQYDTLPLSF 10
V2 IGHV2-26*01 IGHD3-3*01 IGHJ5*02 CARINGNVKIFGMVLPRGWFDPW 10 IGKV1D-33*01 IGKJ4*01 CQQYDTLPLSF 9 2,18E+05 2,25E-04 1,03E-09 5,63E+05 2,27E-04 4,03E-10
V3 IGHV2-26*01 IGHD3-3*01 IGHJ5*02 CARINGNVTIFGMVPPRGWFDPW 8 IGKV1D-33*01 IGKJ4*01 CQQYDTLPLSF 7 2,13E+05 5,51E-05 2,58E-10 1,34E+05 2,47E-04 1,84E-09
V3 IGHV2-26*01 IGHD3-3*01 IGHJ5*02 CARTNGNVTIFGMVLPRGWFDPW 8 IGKV1D-33*01 IGKJ4*01 CQQYDTLPLSF 8
V3 IGHV2-26*01 IGHD3-3*01 IGHJ5*02 CARINGNVTIFGMVLPRGWFDPW 9 IGKV1D-33*01 IGKJ4*01 CQQYDTLPLSF 8 2,23E+05 3,66E-05 1,64E-10 2,73E+05 1,77E-04 6,47E-10
V3 IGHV2-26*01 IGHD3-3*01 IGHJ5*02 CARINGNVTIFGMVLPRGWFDPW 9 IGKV1D-33*01 IGKJ4*01 CQQYDTLPLSF 8
V1 IGHV2-26*01 IGHD6-13*01 IGHJ6*02 CARIQVVSAADKEGLYYYNAMDVW 14 IGKV1-5*03 IGKJ3*01 CQQYNSFSFTF 9
V1 IGHV4-61*01 IGHD7-27*01 IGHJ4*02 CARVEWGSRRAFDSW 6 IGKV3-20*01 IGKJ3*01 CQQYGSSPLFTF 3 6,47E+05 1,72E-04 2,65E-10
V2 IGHV4-61*01 IGHD7-27*01 IGHJ4*02 CARVEWGSRRAFDSW 6 IGKV3-20*01 IGKJ3*01 CQQYGSSPLFTF 3 6,47E+05 1,72E-04 2,65E-10 1,60E+06 5,60E-04 3,49E-10
V2 IGHV4-61*01 IGHD7-27*01 IGHJ4*02 CARVEWGSRRAFDSW 6 IGKV3-20*01 IGKJ3*01 CQQYGSSPLFTF 5
V1 IGHV4-31*03 IGHD3-3*01 IGHJ5*02 CARRIAIFSVVLRSGWFDPW 13 IGKV1D-12*01 IGKJ5*01 CQQAYSFPITF 10 2,12E+04 1,13E-03 6,14E-08
V3 IGHV4-31*03 IGHD2-15*01 IGHJ4*02 CARDMGSRVAAPLDYW 13 IGKV1-12*01 IGKJ4*01 CQQALSFPVTF 14 5,18E+04 1,23E-04 2,38E-09
V3 IGHV4-31*03 IGHD2-15*01 IGHJ4*02 CARDMGSRVAAPLDYW 13 IGKV1-12*01 IGKJ4*01 CQQALSFPVTF 13
V1 IGHV4-39*01 IGHD1-14*01 IGHJ3*02 CARPHVTWTSRTAFDIW 10 IGKV3-20*01 IGKJ5*01 CQQYGSSRSITF 0
V1 IGHV4-39*01 ND IGHJ5*02 CTNQMDNWFDPW 17 IGKV3-15*01 IGKJ2*01 CQQYDNWPPYTF 5
V1 IGHV4-61*08 IGHD3-3*01 IGHJ4*02 CARRYDFWSGFLDYW 9 IGKV3-11*01 IGKJ5*01 CQTRNNWPLAF 4 1,41E+05 6,28E-04 4,46E-09
V1 IGHV4-61*08 IGHD3-3*01 IGHJ4*02 CARRYDFWSGFLDYW 10 IGKV3-11*01 IGKJ5*01 CQTRNNWPLAF 6
V2 IGHV6-1*01 IGHD1-26*01 IGHJ6*02 CARTSGGVEWLSSIYYGMDVW 5 IGKV1-12*02 IGKJ3*01 CQQANTFPFTF 10
V2 IGHV6-1*01 IGHD1-26*01 IGHJ6*02 CARTSGGVEWLSSIYYGMDVW 5 IGKV1-12*02 IGKJ3*01 CQQANTFPFTF 10
V2 IGHV6-1*01 IGHD1-26*01 IGHJ6*02 CARTSGGVEWLSSIYYGMDVW 4 IGKV1-12*02 IGKJ3*01 CQQANTFPFTF 10 7,78E+04 3,67E-05 4,72E-10
V2 IGHV6-1*01 IGHD1-26*01 IGHJ6*02 CARTSGGVEWLSSIYYGMDVW 4 IGKV1-12*02 IGKJ3*01 CQQANTFPFTF 11
V2 IGHV3-33*01 IGHD7-27*01 IGHJ4*02 CAAQSPFKGDHDYW 4 IGKV1-39*01 IGKJ2*02 CQQSYSSPPGF 4 1,09E+06 1,12E-04 1,03E-10
V2 IGHV3-15*01 IGHD3-3*02 IGHJ6*02 CTTVENFWSEFYGMDVW 7 IGKV1-39*01 IGKJ4*01 CQQSYSTLTF 1
V2 IGHV3-23*01 IGHD2-2*02 IGHJ4*02 CAKDLVIGQCTTTKCPRFFDSW 16 IGKV3-20*01 IGKJ4*01 CQLYGDPPPVTF 6
V2 IGHV4-34*01 IGHD3-10*01 IGHJ3*02 CALDHYYGSGSYYNLPAFDIW 0 IGKV3-20*01 IGKJ1*01 CQQYGSSPLWTF 8 2,53E+06 1,06E-04 4,17E-11
V2 IGHV3-15*01 ND IGHJ3*02 CTTGGSLSMPMW 12 IGKV1-5*03 IGKJ2*03 CQHYSSYPYNF 3
V2 IGHV4-59*01 IGHD3-10*01 IGHJ6*03 CARGEPDLYYYGSGSYSPRRVGDYYMDVW 3 IGKV1-39*01 IGKJ1*01 CQQSYSTPRTF 2 2,44E+05 7,07E-05 2,9E-10
V2 IGHV4-39*01 IGHD2-2*02 IGHJ4*02 CARHGGYCSSASCYSGAFLTGYYFDYW 6 IGKV3D-20*01 IGKJ2*02 CQQYGSSPGTF 5
V3 IGHV1-69*06 IGHD7-27*01 IGHJ6*02 CARDRLGTREYDWIFYGMEVW 18 IGKV1D-33*01 IGKJ4*01 CQQYDILPLTF 6 1,23E+05 1,12E-03 9,12E-09 8,19E+05 4,92E-03 6,01E-09
V3 IGHV1-69*06 IGHD7-27*01 IGHJ6*02 CARDRLGTREYDWIFYGMEVW 19 IGKV1-33*01 IGKJ4*01 CQQYDILPLTF 6
V3 IGHV4-31*03 IGHD2-8*01 IGHJ4*02 CAREMVGHSAPADYW 12 IGKV1-39*01 IGKJ1*01 CQQTYKTPPTF 10
V3 IGHV4-31*03 IGHD2-2*02 IGHJ4*03 CAREGYCSSIYCSFDYW 9 IGKV2-30*01 IGKJ1*01 CMQGTHWLPNV 7
V3 IGHV3-23*01 IGHD6-6*01 IGHJ4*03 CAKSPEPIPARLAPGHFDYW 12 IGKV1-5*03 IGKJ1*01 CQQYNSYSPETF 8 6,12E+04 1,35E-04 2,21E-09 9,20E+04 2,59E-04 2,82E-09
V3 IGHV1-18*01 IGHD3-10*01 IGHJ4*02 CARTNNFGSGNYDAWNYFFDYW 19 IGKV1-12*01 IGKJ4*01 CQQGKSFPLSF 10
V3 IGHV3-7*01 IGHD5-24*01 IGHJ4*02 CARWRWHQSEFDYW 7 IGKV1-39*01 IGKJ5*01 CQQNYSPPPITF 7
V3 IGHV3-30*03 IGHD6-19*01 IGHJ4*02 CARGGVGVASKLSHW 21 IGKV1-5*03 IGKJ2*01 CQHYNRNPYTF 17
V3 IGHV1-69*01 IGHD6-19*01 IGHJ4*02 CAMGDSSSKIEYW 8 IGKV2-30*01 IGKJ5*01 CMQGTHWPPITF 4
V3 IGHV4-4*02 IGHD2-15*01 IGHJ3*02 CARVKGYCGGGRCHWGVSDIW 17 IGKV1D-33*01 IGKJ2*01 CQQYRNLPYAF 13 1,39E+04 8,08E-05 5,83E-09 9,42E+03 1,93E-04 2,05E-08
V3 IGHV3-74*01 ND IGHJ4*02 CARDLGGIGSNW 10 IGKV2-28*01 IGKJ2*01 CMQALQTPYTF 7
V3 IGHV3-48*03 IGHD3-9*01 IGHJ4*02 CVRERQDGTMLTGLFNYFDHW 8 IGKV1-39*01 IGKJ4*01 CQQSYSMPPLTF 4
V3 IGHV1-18*01 ND IGHJ4*02 CAREYGDYKFDYW 7 IGKV1-12*01 IGKJ4*01 CQQADSFPLTF 4 6,80E+04 3,65E-05 5,37E-10
V3 IGHV3-21*01 ND IGHJ5*02 CSRDEVNRPHYIW 14 IGKV1-5*03 IGKJ1*01 CQQYNSYSWTF 3
V3 IGHV3-53*01 IGHD1-7*01 IGHJ4*02 CGNYDWNYGGVEFW 15 IGKV1-39*01 IGKJ2*01 CQQSYSSPPYTF 14  
 
Supplementary Table 1. IgH and Igκ chain gene sequence information and antibody 
binding affinity. ND indicates not determined. One member of each clonotype is indicated 
with the number of clonal relatives with various degrees of somatic mutations. a-b, 
Antibodies from tetanus specific IgG or IgA B cells from donor TT1 and TT2. Clonotypes 
are separated by alternating grey coloring.  
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Supplementary Figure 1a. VH gene segment usage in the six antibody repertoires. 
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Supplementary Figure 1b. JH gene segment usage in the six antibody repertoires. 
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Supplementary Figure 1c. Vκ gene segment usage in the six antibody repertoires. 
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Supplementary Figure 1d. Jκ gene segment usage in the six antibody repertoires. 
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Supplementary Figure 1. V and J gene segment usage in the six antibody repertoires. 
Gene segment usage for donor TT1 and TT2 are indicated in purple and green colors, 
respectively. The total gene distribution for both donors is indicated in black. 
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The role of genetic diversification mechanisms in antigen-induced 
antibody repertoires 
 
Authors: Tine Rugh Poulsen and Peter Sejer Andersen 
 
Abstract 
The humoral immunes system relies on a vast diversity of antibodies to combat foreign invaders. We 
have previously employed the Symplex technology for isolating antibody repertoires from two 
hyperimmune donors upon three consecutive immunizations with tetanus toxoid. A total of 594 unique 
antibodies with cognate heavy and light chain pairing were isolated from these donors. The isolated 
repertoires were diverse in terms of number of hypermutations and there was no change in either 
repertoire size or the number of somatic mutations although the repertoires appeared dynamic with an 
influx/efflux of clonotypes. Further, we reported affinities for a total of 156 antibodies from these 
repertoires which reached an affinity ceiling after the second immunization. Here we set out to 
characterize the genetic development and diversification of these large late repertoires and compare 
these to a repertoire from one tetanus naïve donor after receiving the first vaccination. We isolated 11 
tetanus specific antibodies from this primary repertoire. The consecutive repertoires from the two 
hyperimmune donors were diverse in terms of gene segment usage which did not change after several 
immunizations. Further, the usages were similar to that of the primary repertoire. We did not identify 
any insertions or cases of receptor editing indicating that these processes are not major contributors to 
diversification. Deletions were observed in 6% of the isolated clonotypes. Surprisingly, the primary 
repertoire isolated on day 6 after immunization consisted of antibodies with relatively high numbers of 
somatic hypermutations averaging 15 per antibody suggesting that somatic hypermutation occurs very 
fast after the first encounter with antigen. The affinity of one antibody from the primary repertoire was 
determined to be 0.26nM indicating that the primary tetanus repertoire includes high affinity binders. 
All the affinities were correlated to the number of hypermutations of each antibody. There was no 
correlation between on-rates, off-rates or affinities and the number of hypermutations even for 
antibodies of common clonal origin. However, off-rates were improved by the introduction of 
hypermutations to germline antibodies. Our results demonstrate that tetanus specific repertoires are 
highly diverse even after a single vaccination and they keep the level of diversification even after many 
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antigenic challenges. Further our results indicate that the quality of the primary antibody repertoire 
against a physiologically relevant antigen is better than predicted from hapten studies.  
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Introduction 
The immune system is known to generate a diverse repertoire of high affinity antibodies when exposed 
to foreign substances. The massive diversity of naïve antibody repertoires is generated by 
recombination of immunoglobulin V, (D) and J gene segments during the early stages of B cell 
development (39). Later upon encounter with antigen, B cell receptors undergo somatic hypermutation 
(SHM) in germinal centers (15) creating further antibody diversity. During the course of an antigen-
specific immune response, the affinity of serum antibodies has been observed to increase with time 
(7;35). Such a maturation results from specific alterations of the structure of the antibody molecules. 
Studies on specific hapten responses have led to the conclusion that the introduction of somatic 
hypermutations to germline antibodies increases the affinity of the antibody (36). In addition to the 
structural diversity introduced by the recombination of different gene segments and the generation of 
further diversity by somatic hypermutations, entire codons can be inserted or deleted in rearranged 
antibody genes. These often result in the generation of new combinations of canonical loop structures 
or entirely new loops creating an expanded antibody structure space (10). About 1-10% of normal B 
cells have been reported to carry insertions or deletions in their hypermutated antibody-encoding genes 
(10;12;23;30;44).   
Selection during affinity maturation ensures that the immune system creates a diverse repertoire of high 
quality specific antibodies in response to virtually any antigen. In recent years, newly developed 
antibody isolation techniques (16;20;21;27;38;40;43;45;46) have helped reveal the genetic makeup of 
specific antibody repertoires and characterize the diversity of these. However, the knowledge is still 
limited on genetic diversification and development of specific antibody repertoires.  
We have recently used the Symplex™ technology (22) for determining the biological limits for 
antigen-driven affinity maturation by isolating comprehensive antibody repertoires from two adult 
volunteers after receiving three consecutive booster vaccinations with tetanus toxoid separated by 4.5 
and 1.5 years (26). Here we set out to characterize the development and diversification of these large 
repertoires consisting of 594 antibodies combined with a repertoire isolated from an adult tetanus-naïve 
donor 6 days after the very first tetanus vaccination. The repertoires from the two previously described 
hyperimmune donors comprised 382 unique antibodies from donor TT1 (120, 108 and 154 antibodies 
from the first, second and third repertoires, respectively) and 212 antibodies (84, 69 and 59 antibodies 
from the first, second and third repertoires, respectively) from donor TT2. A primary repertoire of 11 
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tetanus specific antibodies was isolated from the naïve donor, TT3. Hence, a total of 605 unique 
antibodies with cognate heavy and light chain pairing were isolated from these three donors. Table 1 
shows all repertoire numbers. 
The repertoires were analyzed genetically by cluster analysis and assignment of gene segment usage 
and number of hypermutations. Representative subsets of these repertoires were expressed and purified 
for kinetic measurements in order to determine the role of hypermutation on binding in developing 
antibody repertories. 
Tetanus toxoid was chosen as antigen for these studies because it is one of the most potent vaccines in 
clinical use and it is safe. Further, it is a structurally complex antigen ensuring that the studied antibody 
repertoires are not restricted by the antigen. We anticipate that our tetanus specific results on 
developing antibody repertoires and diversification mechanisms can be transferred to a more general 
understanding of specific antibody repertoires.  
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Results 
Previously, 382 unique antibodies were isolated from donor TT1 (120, 108 and 154 antibodies from the 
first, second and third repertoires, respectively) while 212 antibodies (84, 69 and 59 antibodies from the 
first, second and third repertoires, respectively) were isolated from donor TT2. We have now further 
isolated 11 antibodies from the naïve donor, TT3. Table 1 summarizes all repertoire numbers.  
 
Cluster analysis of specific antibody repertoires from hyperimmune donors 
In order to determine the diversity and development of the three consecutive repertoires from each 
hyperimmune donor, we have previously conducted a cluster analysis and assigned sequences to 
clonotypes by the clustering. Unique V genes were identified based on the deduced amino acid 
sequences from DNA sequencing. Antibodies were assigned the same clonotype if they shared VH, JH, 
VK, and JK family segments, heavy chain CDR3 lengths and a consensus sequence in CDR3 for both 
heavy and light chains. 33 and 43 clusters of high sequence homology (clonotypes) were identified 
from donor TT1 and TT2, respectively. From donor TT1, 26, 59 and 54 singletons were isolated from 
the first, second and third repertoires, respectively, while the numbers for donor TT2 were 46, 45 and 
41.  
Figure 1 demonstrates the distribution of antibodies previously analyzed to be in different clusters for 
the 3 repertoires from each donor. Most of the clusters from donor TT1 were represented by antibodies 
from either two or all three repertoires. No new clusters were formed in the third repertoire although 
new singletons arrived. For donor TT2, the picture was a bit different. Here only the four larger clusters 
were represented by antibodies from all three repertoires and most clusters were only found in one 
repertoire. Additionally, new clusters were isolated in all three repertoires. In total, 260 and 81 
antibodies were represented in at least two repertoires from donor TT1 and TT2, respectively. This 
corresponds to 24 and 14 clonotypes for donor TT1 and TT2, respectively. The distributions 
demonstrate that there was a higher likelihood of finding new members of the larger older clusters 
when isolating consecutive repertoires.   
These findings supplement our earlier findings (26) that mature tetanus specific antibody responses are 
similar in size but dynamic regarding the clonotypes represented in each repertoire after consecutive 
immunizations. 
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The early specific repertoire 
The diversification of early antibody responses in humans is not well described. In order to compare 
the diversification and development of the hyperimmune repertoires to an early repertoire, the Symplex 
technology was employed for the isolation of a primary antibody repertoire from an adult tetanus-naïve 
donor (TT3) 6 days after receiving the tetanus vaccine for the very first time.   
A rather small number of 15 positive hits were obtained of which 11 were unique sequences of 
functional antibodies. A cluster analysis revealed that there were two clusters of similar antibodies with 
seemingly common clonal origin consisting of two antibodies each and 7 singleton antibodies yielding 
a total of 9 clonotypes, see table 2. These numbers were used to predict a maximum likelihood estimate 
on the actual repertoire size (4;27). The repertoire was most likely composed of 24 clonotypes 
(maximum likelihood estimate) at the time of isolation. The confidence interval (CI) was large with a 
95% CI at 71 clonotypes and hypermutated variants thereof. This size is, however, within the same 
range of under 100 clonotypes as repertoire sizes we have previously estimated for hyperimmune 
tetanus repertoires (26). 
 
Distribution of variable gene segments in human anti-TT antibody repertoires 
Major structural restrictions of antibody repertoires can be identified by a genetic analysis of the 
variable region gene segment usage. Previously, we have therefore analyzed the distributions of V gene 
segments and J gene segments for the VH and VK genes in the first repertoires from donor TT1 and TT2 
(27). Here, we included the second and third repertoires from these donors and the primary repertoire 
from donor TT3 which were all analyzed and compared to previously described naive peripheral IgM+ 
B cell repertoires of between 206-350 antibody clones (8;11) (figure 2). In accordance with earlier 
observations, the TT repertoires of all three donors showed extensive diversity in their V gene segment 
usage. The five most prevalent H chain V gene segment families were found with only minor 
differences relative to the naive repertoire (figure 2A). The H chain J gene segment usage also followed 
the naive repertoire except for the JH5 gene segments, which were less frequently used (figure 2B). The 
distribution of kappa-chain V gene families followed the naïve repertoire dominated by the VK1 and 
VK3 families, although the VK2 gene family was less prevalent in the TT repertoires (figure 2C). 
Similarly, kappa-chain J gene segment usage showed a similar distribution between the repertoires 
(figure 2D). Thus, all the TT repertoires – even the primary – showed extensive diversity without any 
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major biases in V and J gene segment usage. Further, the usage of VH, JH, VK, and JK segments did not 
seem to change in the three consecutive repertoires from each donor. Rather the usage of each segment 
was relatively constant and similar for both hyperimmune donors. The level of diversification in the 
primary repertoire seemed similar to the repertoires from the two hyperimmune donors. The fact that 
the primary repertoire consisted of at least 9 clonotypes using several different gene segments indicates 
that the primary tetanus specific repertoire is not restricted to few clonotypes. 
 
Somatic hypermutations 
In early hapten studies on development of antibody repertoires, Berek et al. reported that antibodies of 
primary repertoires displayed few or no somatic hypermutations on day 7 after immunization (7). In the 
later primary responses the numbers increased to up to 5 or 6 amino acid replacements per antibody 
and they were further increased upon several antigenic challenges. Therefore we analyzed the numbers 
of somatic hypermutations (SHM) for characterization of the maturity level and development of 
antibody repertoires. As reported previously (26), the number of amino acid (aa) SHM per antibody 
varied between 0 and 40 for hyperimmune responses with 50% of the antibodies having between 16 
and 25 SHM. As we then demonstrated, the numbers of hypermutations in these mature and saturated 
antibody repertoires were rather constant after several immunizations but differed slightly between 
individuals; SHM averaged 23 and 18 for donor TT1 and TT2, respectively. We also showed that the 
hypermutation data generally followed normal distributions for VH, VK, and VH+VK, although there 
was a slight bias for zero hypermutations (data not shown).  
SHM did not seem to continue excessively in matured antigen-specific cells; on two occasions, we 
found antibodies with identical amino acid sequence as found in earlier repertoires from the same 
donor indicating that some memory B cells escape new somatic hypermutation rounds upon the next 
encounter with antigen. Additionally, the mature antibody repertoires from donor TT1 included 6 
tetanus specific non-hypermutated antibodies (antibodies in germline configuration). In repertoires 
from both hyperimmune donors, new members of old clusters generally did not have more 
hypermutations, many even had less than older members (data not shown). 
Figure 3 shows the number somatic hypermutations in the heavy and light chain for each of the 11 
antibodies from the early antibody repertoire. The numbers of SHM spanned 6-22 amino acid 
replacements with an average of 15 which was surprisingly high at this early stage after the first 
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immunization. Also, it was higher than expected compared to the slightly higher numbers reported 
earlier in the hyperimmune repertoires. The relatively large numbers of hypermutations found in all 
primary antibodies indicates that somatic hypermutations occur fast after the first tetanus challenge. 
 
Insertions and deletions  
Insertions and deletions of entire codons have been suggested to contribute to diversification of 
antibody repertoires (23). We therefore analyzed whether our repertoires displayed insertions and 
deletions. 
Amino acid deletions had occurred in 6.4% of the clonotypes isolated based on analysis of V segments 
only, see figure 4. All deletions involved 1-5 aa with a small majority found in heavy chains with a 
frequency of 3:2 compared to light chains. No insertions were identified. Almost all deletions were 
found close to CDR1s or CDR2s in both heavy and light chains. Only a single antibody had a three aa 
deletion in framework 3 at positions 88-90 of its light chain. Insertions and deletions in the CDR3 
regions were not included in the analysis. 
The low number of observed deletions and the complete absence of identified insertions suggest that 
these mechanisms are not important in shaping tetanus specific antibody repertoires.   
 
The influence of hypermutation on binding 
The increase in the number of somatic hypermutations during antibody repertoire development has 
been connected with an increase in affinities (7). As previously reported, we have determined affinities 
and on- and off-rates for 156 antibodies from the TT1 and TT2 repertoires (26). Here we also 
determined the binding kinetics and affinity of an antibody from the primary repertoire from TT3. 
Remarkably, this very early antibody displayed a high affinity of 0.26nM.  
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Previously, we have plotted the number of hypermutations against the number of SHM in the first 
repertoires from the hyperimmune donors to test whether there was a correlation of number of SHM of 
each antibody and its binding kinetics (27). Here we included the affinities from the other two 
repertoires from the hyperimmune donors as well as the affinity from the primary repertoire, figure 5. 
Based on the 157 unique tetanus specific antibodies, we did not observe a correlation between the 
number of hypermutations for each antibody and its affinity to tetanus toxoid (see figure 5A). Neither 
did we observe a correlation between the number of SHM and on-rates (figure 5B) or off-rates (figure 
5C). Thus high numbers of hypermutations did not seem to correlate with either high or low affinity 
confirming our previous findings (27). In that study we also tested whether this was valid for a limited 
number of clonally related antibodies by plotting the on- and off-rates. Here we included 37 antibodies 
from the 6 larger clusters from TT1 and TT2 to test whether this also applied to related antibodies from 
different repertoires (figure 6). The number of hypermutations was displayed for each antibody. Just as 
in our previous study (27), there was an absence of a relationship between the number of 
hypermutation and binding kinetics or affinity for these clonally related antibodies. Further, there did 
not seem to be a one-directional development in either on-, off-rates or affinities for clonally related 
antibodies found in later repertoires than their cluster sisters from earlier repertoires. Hence this plot 
confirmed the lack of correlation observed in figure 5.     
In order to examine whether the lack of correlation between the number of SHM and binding kinetics 
was applicable to hypermutated antibodies only, we plotted the binding kinetics of two antibodies in 
germline configuration (non-hypermutated) isolated from donor TT1 (from repertoires 1 and 2), see 
figure 7. Also, we plotted the kinetics of two antibodies in deduced germline configuration described 
earlier (27) and hypermutated variants of these isolated from donor TT1 in all three consecutive 
repertoires. The kinetics for all of the plotted antibodies are summarized in table 3. We did not isolate 
any hypermutated variants of the two germline antibodies isolated directly from one of the donors. The 
number of amino acid hypermutations for heavy and light chains was displayed for each of the 
antibodies. Both of the germline antibodies isolated from one of the donors were of intermediate to low 
affinity comparable to one of the antibodies in deduced germline configuration. However, both 
displayed much slower on-rates and slower off-rates. We did not observe a strict relationship between 
the number of SHM and on-rates or affinity. However, all of the hypermutated variants of the two 
antibodies in deduced germline configuration displayed improved off-rates. The on-rates changed in 
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both positive and negative directions or were neutral resulting in hypermutated antibodies with both 
better, worse and equal affinity to their supposed ancestor.  
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Discussion 
Combining the present and earlier studies (26;27), we have isolated a total of 605 unique 
tetanus specific antibody sequences with cognate pairing of heavy and light chains using the Symplex 
technology. The majority of the sequences were derived from three consecutive repertoires isolated 
from each of two hyperimmune donors (26) whereas the last 11 sequences were from a tetanus-naïve 
donor who received the tetanus vaccine for the first time. We have analyzed these primary and late 
antibody repertoires to examine the development of specific antibody repertoires at early and late 
stages.  
The number of hypermutations found in the naïve donor was higher than expected only 
six days after the very first tetanus vaccination especially compared to what has been observed in 
primary responses against hapten (7). The total numbers for heavy and light chains combined are 
within the same magnitude as observed for the hyperimmune donors but at the lower end. These 
numbers also correlate well to numbers reported by others (21;33;37;45;46). One could suspect that the 
donor had encountered tetanus previously by natural exposure because of these relatively high numbers 
of SHM without developing disease which of course would have been recognized. However, the fact 
that so few tetanus specific antibodies were isolated compared to the repertoires of the hyperimmune 
donors is a strong indication that the donor was truly naïve at the time of vaccination. Kodo et al. (19) 
have observed a low number of specific antibody producing cells after a primary immunization with 
tetanus in humans compared to secondary or later vaccinations. Additionally, Andreas Radbruch has 
reported that the day when antigen-specific cells peak in the blood after vaccination varies between day 
5 and 9 depending on the donor (28). 
 The size of the early specific antibody repertoire is small but the fact that we find two 
clusters of clonally related antibodies among only 11 antibodies suggests that we have a good sampling 
of the repertoire suggesting that the actual repertoire was small at this stage. Again, this is indicative of 
a truly primary response which was also confirmed by a very low frequency of positive hits compared 
to the hyperimmune repertoires. The relatively large numbers of hypermutations found in all antibodies 
indicates that somatic hypermutations occur very early after the first encounter with antigen. The fact 
that the primary repertoire consisted of at least 9 clonotypes using several different gene segments 
indicates that the primary tetanus specific repertoire is not restricted to few clonotypes or gene 
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segments but it is diverse. This diversity at this early stage is reflected in the diversity observed in later 
responses.    
From the second to the third vaccination of the two hyperimmune donors there was no 
increase in repertoire size, somatic mutations, or change in the distribution of association rate, half life 
or affinity (26). Further, the gene segment usage did not change after several immunizations and did 
not seem to deviate from previously described naive peripheral IgM+ B cell repertoires (8;11) or the 
early repertoire investigated. These distributions seemed relatively constant after several 
immunizations indicating that the anti-tetanus repertoires were not skewed in a certain direction with 
more antigenic challenges. The early repertoire reflected the gene segment usages of both the naïve B 
cells and the hyperimmune repertoires. This indicated that the repertoires did not develop further 
genetically but instead kept reflecting the natural diversity of naïve repertoires. The relatively constant 
number of clusters and singletons observed in each repertoire for each donor was indicative of a rather 
constant sized repertoire consisting of a “base” and an influx/efflux of antibody clones. The fact that so 
few of the clusters from TT2 were represented in more than 1 repertoire compared to the TT1 
repertoires could be due to a significantly smaller sample size.  
When analyzing the sequences for insertions and deletions, it was apparent that most 
deletions were found close to CDR1s or CDR2s in both heavy and light chains while we did not 
identify any insertions. The proximity to CDRs supports findings by de Wildt et al. (10) that the 
processes often result in the generation of new combinations of canonical loop structures or entirely 
new loops which are then likely to contact the antigen directly. The fact that they are mostly found in 
conjunction with CDRs is probably because this is the only positions where larger molecular alterations 
can be tolerated without disrupting the immunoglobulin structure. Our results demonstrate that 
deletions are indeed found in mature specific antibody repertoires against tetanus. However, the 
relatively small fraction of the repertoires in which deletions were observed (6%) and the lack of 
identified insertions suggest that they are not a dominant means of diversification.  
We did not observe any instances of receptor editing in our repertoires. Yet we cannot 
rule out that the process had occurred. Receptor editing does, however, not seem to be a dominating 
diversification mechanism of developing antibody repertoires as has been proposed (24;25;29) 
although we may underestimate the extent of the process. 
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 Early immunologic studies on hapten responses have concluded that the introduction of 
hypermutations and clonal selection leads to a gradual increase in affinity of specific serum antibodies 
after repeated exposures (7;36). Further, Sagawa et al. have observed a positive correlation between on-
rates and SHM in a hapten response (32). We were not been able to establish a relationship between 
on-rates or affinities against the total number of hypermutations. However, we did observe an 
improvement in off-rates of all hypermutated variants of the two antibodies in deduced germline 
configuration. Further, we observed an overall improvement in affinity (and on- and off-rates) upon 
consecutive immunizations of the same donors within relatively short time intervals (1.5-4.5 years) 
(26). When only looking at the first repertoires from the two hyperimmune donors, we suggested that 
overall a higher average number of hypermutations in one of the donors correlated with this donor 
having overall higher affinities than the other donor (27). However, when looking at all three 
repertoires from each donor, it is apparent that the average number of SHM did not change for any of 
the donors (although it differed between the donors) but both donors improved the overall affinities 
after the first repertoire and kept the level after the second. This indicates that each hypermutation has 
truly stochastic effects but combined with others and selection they aid in improving the binding 
kinetics of a specific antibody repertoire.  This is consistent with the fact that the one antibody from the 
primary repertoire with a determined affinity is in the high end of the affinity span observed for the 
other repertoires although it has only 13 hypermutations. Further, we have previously found that non-
hypermutated can be of high affinity as well (27).  
Berek and Milstein (6) have argued that antigenic stimulation of memory B cells leads to 
further processes of hypermutation and selection, probably in germinal centers. The fact that we found 
antibodies with identical aa sequence as some found in earlier repertoires indicates that some B cells 
escape the SHM machinery upon secondary encounters with antigen. Further, many of the antibodies 
found in our later repertoires were equally or less hypermutated than their “cluster sisters”.  Hence, our 
data indicates that not all memory cells are hypermutated upon second or later encounters with antigen.   
We have found that both the hyperimmune repertoires and the small primary repertoire 
are relatively diverse with up to the order of 100 clonotypes which indicates that tetanus specific 
repertoires are generally diverse compared to some specific repertoires e.g. against influenza (vaccine) 
(45), Rhesus D (2), rotavirus (18) and Haemophilus influenzae type B (Hib) (1;3;14;34). However, 
other specific repertoires have been demonstrated to be as diverse as our tetanus repertoires. These 
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include HIV (33), Vaccinia (5) and vesicular stomatitis virus (VSV) (17;31). The diversity we observe 
is supported by early findings by Volk et al. who have observed specific antibodies against up to ~24 
different epitopes against tetanus toxin (41).  
Germinal center reactions have been shown to be pauciclonal, founded, on average, by 
three or fewer B lymphocytes (15). Hence, memory cells from former tetanus responses may not be 
represented in all new germinal centers that are formed following a challenge. Thus all new TT binding 
clones may not have to compete against the very best clones from former responses. This could partly 
explain the relatively large influx of new clones and why there are still low affinity clones in the later 
responses. The theory is supported by the work by Dal Porto et al. (9) in which they argue that affinity 
maturation during the primary GC reaction appears to be local, i.e. competition between B cells take 
place within but not between GCs. The conclusion to these observations is that each GC defines a local 
affinity optimum. Additionally, Vora & Manser have suggested that the pauciclonality of each GC 
results in antibody clones competing almost exclusively against their own hypermutated variants (42). 
Hereby, clonal selection is based on clones with better affinities than their own hypermutated “sisters” 
rather than affinities that are superior to all other antigen specific clones. This theory could explain the 
large clonal influx into hypermutated repertoires and the large span we observe in affinities. Further, it 
is consistent with the fact that we can correlate hypermutations to better off-rates for hypermutated 
variants of germline antibodies. However, the latter may suggest that affinity maturation within GCs is 
more dependent on off-rates than affinities.   
 
In summary, our previous studies have demonstrated that the genetic composition of 
tetanus specific antibody repertoires is highly diverse and similar to that of naïve B cells. Here we have 
shown that the diversity is evident after a single vaccination and does not change with many antigenic 
challenges. Also, we demonstrate that somatic hypermutations occur early after the first antigen 
encounter. As early as day 6 after the first vaccination, the level of mutations was surprisingly high 
with an average of 15 amino acid mutations per antibody. The hyperimmune repertoires, we have 
previously described, have slightly increased numbers of hypermutations compared to the primary 
repertoire and as reported earlier, they finally reach a ceiling. In our large data sets, we did not observe 
any instances of receptor editing suggesting that this is not an important mechanism for antibody 
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diversification. Further, we identified few antibodies with deletions and none with insertions – again 
indicative of a minor contribution by these processes to antibody diversification.  
The number of hypermutations for each antibody did not correlate to affinity, or on- rates 
confirming our previously reported results. However, off-rates were improved when mutations were 
introduced to germline antibodies. Based on these observations we conclude that somatic 
hypermutations are important for improvements in off-rates of germline antibodies. This is supported 
by our finding that somatic hypermutations occur very fast in the primary tetanus repertoire. 
Our findings indicate that the quality of the primary antibody repertoire against 
physiologically relevant antigens is better than predicted from hapten studies. It may therefore be of use 
in the development of future antibody therapeutics. 
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Table 1 
Results of SymplexTM repertoire cloning from 3 repertoires from each of the two hyperimmune donors 
and one primary repertoire from a tetanus naïve donor. Repertoire size was estimated by gel 
electrophoresis of a representative set of single cell RT-PCR samples (from 10-20% of the total). 
Unique V genes were identified based on the deduced amino acid sequences from DNA sequencing. 
Antibodies were assigned the same clonotype if they shared VH, JH, VK, and JK family segments, heavy 
chain CDR3 lengths and a consensus sequence in CDR3 for both heavy and light chains.  
 
Donor Boost 
no. 
Estimated 
Repertoire 
Size 
(unspecific) 
No of 
bacterial 
clones 
screened 
No. of 
TT-
positive 
clones 
No of 
sequenced 
clones 
No of 
unique VH-
VK amino 
acid 
sequences 
Estimated 
number of 
clonotypes 
TT1 V1 400 3600 338 169 120 30a 
TT1 V2 1700 2100 427 155 108 50 
TT1 V3 2400 2600 372 176 154 67 
TT2 V1 400 3400 187 102 84 42a 
TT2 V2 1600 3500 95 82 69 36 
TT2 V3 1400 3600 104 83 59 29 
TT3 V1 1400 2100 15 11 11 9 
Total  9300 20900 1538 778 605 204b 
a: The estimated numbers of clonotypes from Poulsen et al. (27) (TT1-V1 and TT2-V1) were adjusted 
from 29 and 40 to 30 and 42, respectively, due to a slightly stricter clonotype definition.   
bThe total estimated number of clonotypes is lower than the sum of numbers for all repertoires since 
many clonotypes were shared between repertoires for each donor.  
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Table 2 
Overview of 11 antibodies from a primary anti-tetanus repertoire isolated from a naïve donor after 
receiving a tetanus vaccination. Each clonotype is marked by its own color. 
 
 
 
Clone Affinity 
Total 
no. 
Of 
SHM 
HC 
SHM 
LC 
SHM VH D JH HCDR3 VK JK LCDR3 
_350j11 2,6x10-10 13 9 4 IGHV3-11*03 IGHD6-13*01 IGHJ6*02 CVRGPEDSSRWYAPSYYYYYYGMDVW IGKV1-39*01 IGKJ4*01 CQQTYSPPLTF 
_355G12 - 12 8 4 IGHV3-11*03 IGHD6-13*01 IGHJ6*02 CVRGPEDSSRWYAPSYYYYYYGMDVW IGKV1-39*01 IGKJ4*01 CQQTYSPPLTF 
_354B23 - 22 14 8 IGHV3-23*01 IGHD2-15*01 IGHJ4*02 CAKADAETCSGRRCYAFDSW IGKV3-11*01 IGKJ5*01 CQQHSNLITV 
_355J06 - 17 13 4 IGHV3-23*01 IGHD2-15*01 IGHJ4*02 CAKADAETCSGRRCYAFDSW IGKV3-11*01 IGKJ5*01 CQQHSNLITF 
_355K12 - 21 11 10 IGHV3-15*04 IGHD6-19*01 IGHJ5*02 CTHYTSGWFW IGKV3-20*01 IGKJ2*01 CQQYSTSVPYTF 
_355H12 - 18 14 4 IGHV1-69*01 IGHD2-21*02 IGHJ4*02 CARKGSGADDYFDHW IGKV3-11*01 IGKJ3*01 CQQRSSWPMITF 
_355I08 - 14 10 4 IGHV1-69*01 IGHD3-16*02 IGHJ4*02 CASRRALSTTEVADYW IGKV3-20*01 IGKJ1*01 CQQYGSSPMTF 
_355j05 - 6 5 1 IGHV3-11*03 IGHD3-10*01 IGHJ4*02 CASIGMGRGVDYW IGKV2-30*01 IGKJ1*01 CMQGTHWPWTF 
_355O23 - 13 10 3 IGHV3-33*01 IGHD2-2*01 IGHJ1*01 CARSPLVAAAVDYW IGKV3-20*01 IGKJ4*01 CQQYGSSPLTF 
_355N15 - 22 12 10 IGHV4-34*01 IGHD3-10*02 IGHJ4*02 CVRVPPIIAAADNW IGKV1-9*01 IGKJ3*01 CQHLNSYPLRFTF 
_355B16 - 9 4 5 IGHV5-51*01 IGHD3-9*01 IGHJ4*02 CIAARANHEQRYLDWFADYW IGKV1-5*03 IGKJ1*01 CQQYSFYGTF 
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Table 3  
Kinetics and affinity constants of Abs with deduced germline variable region genes and their 
hypermutated variants and the influence of hypermutations on antibody binding. 
 
 
 
 
 
 
 
 
Boost 
no. 
Clone 
On-Rate 
(M-1 s-1) 
 
Off-Rate 
(s-1) 
 
t1/2 
(min-1) 
 
Affinity 
(M) 
 
No. of 
hypermutations 
(VH + VK) 
 
- Germline VH1-69-JH6 VK1-27-JK3 3.0 x 106 3.3 x 10-4 35 1.1 x 10-10 0 + 0 
1 60D05 (VH1-69-JH6 VK1-27-JK3) 6.4 x 106 1.7 x 10-5 670 2.7 x 10-12 13 + 6 
 1 62D09 (VH1-69-JH6 VK1-27-JK3) 2.7 x 106 5.6 x 10-5 210 2.1 x 10-11 10 + 6 
 1 63B12 (VH1-69-JH6 VK1-27-JK3) 4.6 x 106 7.4 x 10-5 160 1.6 x 10-11 10 + 4 
 2 338H08 (VH1-69-JH6 VK1-27-JK3) 2.1 x 105 1.9 x 10-5 599 9.0 x 10-11 12 + 6 
2 339H12 (VH1-69-JH6 VK1-27-JK3) 6.8 x 104 6.0 x 10-5 194 8.7 x 10-10 13 + 6 
3 528H18 (VH1-69-JH6 VK1-27-JK3) 4.0 x 106 7.7 x 10-5 150 1.9 x 10-11 10 + 6 
3 528K04 (VH1-69-JH6 VK1-27-JK3) 7.0 x 105 5.1 x 10-5 227 6.7 x 10-11 9 + 5 
 
 
     
- Germline VH3-21-JH6 VK1-39-JK1 6.8 x 105 1.7 x 10-1 0.1 2.5 x 10-7 0 + 0 
1 63D10 (VH3-21-JH6 VK1-39-JK1) 1.0 x 105 4.2 x 10-4 28 4.0 x 10-9 14 + 13 
 
 
 
     
1 60A02 (VH3-21-JH3 VK1-27-JK2) 9.1 x 103 1.3 x 10-4 90 1.4 x 10-8 0 + 0 
 
 
     
2 340N16 (VH3-30-JH3 VK1-5-JK2) 1.8 x 102 3.0 x 10-5 381 1.7 x 10-7 0 + 0 
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Materials and Methods 
Donors and vaccination 
Previously, two healthy donors were boosted with the tetanus vaccine (Statens Serum Institut, 
Denmark) containing tetanus toxoid in three consecutive boosts under informed consent (26;27). Now a 
tetanus naïve donor was recruited in addition and vaccinated for the first time with the tetanus vaccine 
(Statens Serum Institut, Denmark) also under informed consent. The project was approved by the 
regional ethical committee in Copenhagen, Denmark. Blood was harvested in anticoagulant 6 days 
after vaccination.  
 
Antibody repertoires from the two hyperimmune donors 
The three consecutive tetanus specific antibody repertoires from each of the two hyperimmune donors 
were isolated, screened and characterized as described previously (26). 
 
Isolation of plasma blasts and cell sorting 
Peripheral blood mononuclear cells (PBMC) from the previously tetanus-naïve donor were purified by 
density centrifugation using Lymphoprep (Axis-Shield PoC AS) and stained with anti-CD19-FITC 
(Becton Dickinson) in MACS buffer (phosphate buffered saline (PBS), pH 7.2, 0.5% (w/v) bovine 
serum albumin (BSA), 2mM EDTA), washed and labeled with anti-FITC conjugated magnetic beads in 
order to enrich for B cells on a MACS LS column (Miltenyi Biotec) according to the manufacturer’s 
recommendations. The repertoire was sorted as previously described (27;27). Shortly, the CD19-
enriched fraction was resuspended in FACS buffer (PBS, pH 7.2, 2% fetal calf serum (FCS)) and 
incubated with anti-CD19-FITC (Becton Dickinson), anti-CD38-APC (Becton Dickinson), anti-
lambda-PE (Becton Dickinson), and anti-CD45-PerCP (Becton Dickinson) for 20 minutes at 4°C in the 
dark, washed and resuspended in FACS buffer and stained for viability with propidium iodide (PI). 
Viable cells were sorted based on the following expression profile: 
CD38high/CD19int/CD45int/lambdaneg. Single cell sorting was performed on a FACSAria cell-sorting 
system (Becton Dickinson) where single cells where sorted directly into 384 well PCR plates (Applied 
Biosystems).  
FACS analysis was performed using FACSDiva software. 97-99% purity was detected on the single 
cell sorting. 
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Plasma blasts were sorted directly into wells containing all reagents necessary for the Symplex PCR 
except for reverse transcriptase, DNA polymerase and dNTPs as described previously (27) and stored 
at -80°C for later processing. 
 
Single cell RT-PCR and PCR of antibody variable region genes 
VH and LCκ genes were amplified and linked through primer overlap extension as described previously 
(22). Briefly, VH and LCκ from each cell were amplified in a one-step RT-PCR reaction using a 
cocktail of sense primers specific for the leader regions and antisense primers to the Cγ constant 
regions for heavy chains and Cκ for the light chain. One microliter from each RT-PCR reaction was 
transferred to new plates containing reagents for a nested PCR and VH and LCκ genes were linked and 
amplified in separate PCR reactions using nested primers with overlap extensions and containing 
restriction sites at the ends of the heavy chain variable regions and the full κ light chains as previously 
described (22). 
 
Cloning and Screening 
Cloning and screening were performed as described previously (26;27). Linked antibody gene 
fragments (VH-LCκ) were pooled and cloned into expression vectors using the PCR introduced 
restriction sites as described previously (22). For the first two repertoires from each donor, linked 
antibody genes were cloned into a bacterial or mammal Fab expression vector (22;26) and the gene 
linker was replaced by a bidirectional bacterial/mammal promoter fragment (lac-tac/2xCMV) by sub-
cloning. The vectors from the naïve repertoire and the first two hyperimmune repertoires were 
transformed into bacteria (E.coli, TOP10) by electroporation and transformants were selected on 2xYT 
or LB broth agar containing 100µg/ml of carbenicillin. Single E.coli colonies were picked into 96 or 
384 well plates. Fabs were expressed directly in E.coli by induction with isopropyl-β-D-
thiogalactopyranoside (IPTG) which was added to a final concentration of 0.1 mM for screening in the 
first and second repertoires. Plasmids from clones in the third hyperimmune repertoires were 
transfected into HEK293 cells in the following manner: 1µl suspension of E.coli picked into 384 plates 
as single clones (CFU) were lysed by incubation for 15 minutes in 4M NaOH. Plasmid DNA was 
amplified using the TempliPhi Amplification kit (GE Amersham) by transferring 1µl lysed cell 
suspension to a mix of the kit enzyme and buffer and incubating at 30°C overnight and then 
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inactivating the enzyme for 10 minutes at 65°C. TempliPhi plasmids were transfected into HEK293 
cells using Optimem (Invitrogen) and 293Fectin (Invitrogen) in 384 well plates in FreeStyle HEK293 
medium (Invitrogen). The plates were incubated shaking at 37°C overnight and Tryptone N1 
(Organotechnie) was added to all wells to a final concentration of 0.4%. Plates were incubated while 
shaking another 72 hours at 37°C.  
Both bacterial and mammal clone supernatants were screened for activity against TT; the first 
repertoires were screened by ELISA and the second and third repertoire from each donor was screened 
by bead based fluorescence-linked immunosorbent assay (FLISA). All positive clones were identified 
and a number of clones were selected for sequencing (see table 1). The VH-Vκ sequences were aligned 
to group clones according to sequence homology. For each group, the V-D-J usage and location of 
somatic mutations were determined by alignment with germline sequences using the IMGT sequence 
directory (13). 
 
Fab production for kinetic measurements 
Fab fragments in E.coli were produced for SPR analysis (all clones selected for further analysis from 
the first repertoires and 6 and 4 clones from the second repertoire of donor TT1 and TT2, respectively) 
as described previously (26;27). Due to low bacterial Fab expression levels, some clone Fabs were 
expressed in HEK293 by cloning the Fab fragment into a mammal HEK293 expression vector, and 
transfecting plasmids into HEK293 cells using Optimem (Invitrogen) and 293Fectin (Invitrogen) in 
FreeStyle HEK293 medium (Invitrogen) in volumes of 30-100 ml. Cultures were incubated while 
shaking at 37°C for 6 days after which supernatants were harvested by centrifugation. Fab fragments 
were purified using Poly-prep columns (Bio-Rad) with protein L immobilized on agarose (Pierce) 
according to the manufacturer's instructions. 
The concentration of purified Fab was determined by FLISA using a purified Fab as standard. 
 
Surface plasmon resonance (SPR) 
Affinities (KD), on-rates (ka) and off-rates (kd) were determined as previously described (26) by SPR 
analysis on Biacore 2000 (GE Healthcare/Biacore, Uppsala, Sweden) or Proteon XPR36 (Bio-Rad). 
Briefly, TT was immobilized at low ligand densities on CM5 chips (Biacore) or GLC chips (Bio-Rad), 
resulting in maximum response unit (RU) values of ~100 RU or less. In most cases, this lead to proper 
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fitting of the data with monovalent 1:1 interaction kinetics. Fab fragments were diluted to 96 or 48 nM, 
and rate constants were measured by injection of at least four serial 2-fold dilutions of the antibodies at 
50µl/min. Purified Fab was diluted in running buffer (10 mM HEPES pH 7.4, 0.15 M NaCl, 3 mM 
EDTA, 0.005% surfactant P20 on Biacore 2000 and PBS pH 7.2, 0.005% Tween20 on Bio-Rad) and 
passed over the chip at 50 µl/min. 
All measurements were conducted at 25°C or 37°C. Association was measured for 5 min and 
dissociation for 20-30 min. However, for interactions with very slow off-rates (below 1x10-4 s-1), 
dissociation was measured for longer periods of time, up to 16 h, depending on the off-rate. Global 
analysis of the serially diluted analyte responses was performed with either BIAevalution or Proteon 
software 2.0.  
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The distribution of unique antibodies in different clusters for the 3 repertoires from donor TT1 (n=382) 
and TT2 (n=212). Antibodies from first repertoires (V1) are shown in blue, while second (V2) and 
third (V3) repertoire antibodies are shown in pink and green, respectively. The number of singletons in 
each repertoire is shown to the right of the dashed line. 
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29 
V and J gene segment usage of unique sequences. Distribution of heavy chain gene segment usage, VH 
(A) and JH (B), and light chain gene segment usage, VK (C) and JK (D) in unique sequences of the 
three consecutive antibody repertoires of TT1 (TT1-V1 n=120, TT1-V2 n=108, and TT1-V3 n=154, 
purple colors) and TT2 (TT2-V1 n=84, TT2-V2 n=69, and TT2-V3 n=59, green colors), and in the 
primary repertoire of TT3 (TT3-V1 n=11, yellow). The sum of all antibodies is indicated by black bars. 
White bars represent previously described naive peripheral IgM+ B cell repertoires {Brezinschek, 1997, 
J. Clin. Invest.; Foster, 1997, J. Clin. Invest.} (nVH=350, nJH=206, nVK,JK=321). 
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Figure 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Number of hypermutations on amino acid level in heavy and light chains from 11 antibodies isolated 
from a virgin donor. The mean is represented by a black bar.  
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Deletions in the tetanus repertoires. 
Positions of deleted amino acids for each clonotype are shown in dark blue for heavy chains and light 
blue for light chains. 
32 
Figure 5 
0
5
10
15
20
25
30
35
40
45
1,00E-121,00E-111,00E-101,00E-091,00E-081,00E-071,00E-06
Affinity, KD
No
.
 
o
f s
o
m
a
tic
 
hy
pe
rm
u
ta
tio
n
 
(V
H+
VK
)
TT1-A
TT1-B
TT1-C
TT2-A
TT2-B
TT2-C
TT3-A
 
0
5
10
15
20
25
30
35
40
45
1,00E+02 1,00E+03 1,00E+04 1,00E+05 1,00E+06 1,00E+07 1,00E+08
kon, M-1s-1
N
o
.
 
o
f s
o
m
a
tic
 
hy
pe
rm
u
ta
tio
n
 
(V
H
+
VK
)
TT1-A
TT1-B
TT1-C
TT2-A
TT2-B
TT2-C
TT3-A
 
A 
B 
33 
0
5
10
15
20
25
30
35
40
45
1,00E-071,00E-061,00E-051,00E-041,00E-031,00E-02
koff, s-1
N
o
.
 
o
f s
o
m
a
tic
 
hy
pe
rm
u
ta
tio
n
 
(V
H
+
VK
)
TT1-A
TT1-B
TT1-C
TT2-A
TT2-B
TT2-C
TT3-A
 
 
 
Correlation of the number of hypermutations of each antibody and its affinity (A), on-rate (B), and off-
rate (C). 
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Antibody kinetics of single antibodies from 6 large clusters where members were found in at least two 
repertoires from a donor. The color of each circle indicates the cluster number and repertoire number 
(e.g. C6-2 means cluster 6, repertoire 2). The color of the connecting lines indicates the cluster (the 
color is shared for the different repertoires within the same cluster). The number within each circle 
indicates the number of amino acid hypermutations for H+L of the antibody in question. The crossing 
grey lines indicate the affinity (KD) in nM. Clusters 1, 2, 4, 6 and 9 are from donor TT1 while cluster 7 
is from donor TT2.  
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Kinetics of antibodies in germline configuration (non-hypermutated) or their hypermutated variants. 
The color of each circle indicates the cluster and the number within each circle indicates the number of 
amino acid hypermutations for H+L of the antibody in question. The green and the blue germline 
antibody are synthesized antibodies in deduced germline configuration whereas the yellow and purple 
germline antibodies were isolated from donor TT1 (from repertoire 1 and 2, respectively). The red 
arrows indicate the change in kinetics for the hypermutated variants isolated from TT1 of two of the 
germline antibodies. We did not isolate any hypermutated variants of the two germline antibodies 
isolated directly from one of the donors.  
 
 
 
